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Resistance to every class of antibiotics has been identified clinically. The rapid development and 
spread of resistance is responsible for the diminished lifetime of many once efficacious 
therapeutics. Trimethoprim (TMP), a clinically important dihydrofolate reductase (DHFR) 
inhibitor, remains a first line treatment for Staphylococcus aureus infections but its continued 
use is threatened by the emergence of resistance. Identifying and understanding the 
mechanisms of trimethoprim resistance is crucial for the development for novel antibiotics to 
overcome the contemporary clinical resistances. Trimethoprim resistance is conferred through 
both the acquisition of mutations in the endogenous DHFR enzyme and of innately resistant 
enzymes. Guided by structure based drug design, a novel class of DHFR inhibitors, known as 
propargyl-linked antifolates (PLAs), has been developed to directly overcome trimethoprim 
resistance in Staphylococcus aureus. By doing this, we identified the contemporary 
mechanisms of antifolate resistance, developed a molecular understanding of reported and 
prospective mutational resistance mechanisms and generated a class of potent inhibitors 
against both wild type and TMPR DHFR enzymes and S. aureus strains. In addition to their 
potent activity, these inhibitors also reveal unique binding and plasticity of both the inhibitor and 
co-factor binding sites, leading to the discovery of a novel NADPH configuration. In all, these 
efforts led to a comprehensive understanding of antifolate S. aureus and the development of 
potent inhibitors that overcome these resistance mechanisms. 
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Chapter 1 
The Clinical Burden of Staphylococcus aureus 
 
Prior the introduction of penicillin in the 1940’s, infections from minor cuts and scrapes 
could lead to blood poisoning and death. In fact, mortality rates of greater than 85% for 
blood infections during that time have been reported1. Penicillin, a beta-lactam antibiotic, 
was discovered by Alexander Fleming in London in the late 1920’s and introduced to the 
clinic in the 1940’s. Its discovery is regarded as one of the most significant advances in 
medicine. As the first accessible antibiotic, penicillin reduced the amount of infection 
related deaths and played a historic role in World War II, where the number of wounded 
soldier fatalities decreased significantly1. After its mass production and wide spread use, 
penicillin resistant bacteria began presenting a significant clinical burden in the mid 
1940’s and its spread to communal settings in the 1950’s sparked the development of 
new antibiotics.  The clinical introduction of methicillin in the 1960’s reduced the burden of 
penicillin resistant bacteria, but like penicillin, resistance to methicillin developed rapidly2.  
The first methicillin-resistant S. aureus (MRSA) isolate was reported in England in 19613 
and later appearing in the US in 19684. Unlike penicillin, the development of methicillin 
resistance conferred broad resistance to the entire class of beta-lactam antibiotics2. 
 
Every year, approximately 700,000 people worldwide die of drug resistant infections5. 
According to the Antibiotic Threat Report released by the Centers for Disease Control 
released in 2013, more than 2 million Americans contract a drug resistant infection and at 
least 23,000 people die directly of the disease6. The urgent nature of drug resistance has 
prompted Presidential Priority in the 2016 Science and Technology Fiscal Budget in 
which it was declared that funding should be prioritized to the development of new 
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antibiotic resistance countermeasures including vaccines, small molecule inhibitors, 
synergists as well as implementing increased stewardship and surveillance measures7. 
The continued rise of antibiotic resistance and multi-drug resistant bacteria, a result of 
clinical and agricultural antibiotic misuse, is diminishing the efficacy of once powerful 
antibiotics. Therefore, the need to develop new, robust antibiotics is met with the need to 
understand the current state of clinical resistance and a strategy to overcome these 
resistances.  
 
1.1 The Impact of Staphylococcus aureus 
Methicillin resistant Staphylococcus aureus (MRSA), an opportunistic gram-positive 
bacterium, is the leading cause of invasive systemic infections, pneumonia as well as skin 
and soft tissue infections (SSTIs) worldwide. MRSA is the most common cause of 
healthcare-associated infections occurring during or shortly after inpatient care8. The 
Centers for Disease Control (CDC) reports over 80,000 invasive MRSA infections 
annually in the United States, more than 11,000 of these infections are fatal. The 
widespread and often critical nature of these infections prompted the CDC to classify drug 
resistant MRSA as a ‘Serious Threat’, as it poses a significant risk to public health6. As of 
2005, S. aureus accounted for 18.7% of inpatient bacterial specimens and 14.7% of 
outpatient bacterial specimens. Of those strains, 55% of ICU isolates, 59% of general 
hospital and 48% of outpatient infections were resistant to methicillin9.   
 
MRSA infections can be healthcare (HA-MRSA) or community (CA-MRSA) associated; 
CA-MRSA and HA-MRSA are genetically distinct. Community associated MRSA can 
infect healthy populations that have no defined risk factors, specifically children and 
young adults. About 90% of CA-MRSA infections are uncomplicated skin and soft tissue 
	 3 
infections (SSTIs) such as cellulitis, however due to increased virulence often affiliated 
with these strains, they are able to advance in severity to necrotizing fasciitis, necrotizing 
pneumonia and even death2,10. The ability of CA-MRSA to cause severe infections is 
highly correlated with the presence of Panton-Valentine leukocidin (PVL) genes. Panton-
Valentine leukocidin is a cytotoxin that causes leukocyte destruction, allowing for its 
evasion from immune system and allowing for infection advancement.11,12       
 
Healthcare or hospital associated MRSA infections are considered those that occur in 
response to hospitalization and are often associated with biofilm formation14. Patients 
who have undergone surgery, dialysis, require a catheter or reside in a long-term medical 
care facility are said to be predisposed to HA-MRSA; if a patient does not possess one of 
these risk factors, they are considered to have a CA-MRSA infection13. However, since 
CA-MRSA has become an epidemic within health care systems, the epidemiological 
distinction between CA-and HA-MRSA isolates becomes complicated8, 11. HA- and CA-
MRSA genotypes can be determined by identifying the staphylococcal chromosomal 
cassette mec (SCCmec), a genetic feature common to all MRSA isolates and unique to 
the epidemiological lineage of the strains12. 
 
The antibiotic combination, trimethoprim and sulfamethoxazole, is the first line therapy for 
uncomplicated MRSA infections. However, these uncomplicated MRSA infections can 
also be successfully treated with non-penicillin antibiotics including tetracyclines, 
macrolides, fluoroquinolones, aminoglycosides and linezolid. Complicated SSTIs and 
systemic infections that require hospitalization are treated with intravenous vancomycin or 
daptomycin, both glycopeptide antibiotics; with the most severe and complicated 
infections requiring combination therapies15. In addition to having a major clinical 
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presence, the ability of MRSA to rapidly develop antibiotic resistance is especially 
concerning as it has significantly limited the available treatment options; clinical 
resistance to all aforementioned antibiotics has been reported in S. aureus. 
 
1.2 The Folic Acid Cycle and Antifolates 
1.2a The Folic Acid Cycle 
Both trimethoprim and sulfamethoxazole belong to a class of antibiotics called antifolates 
as they inhibit enzymes within the folic acid cycle. Folate metabolism, via the folic acid 
cycle, is essential for the production of deoxythymidine monophosphate (dTMP), purine 
nucleotides, methionine and histidine; all of which are required for successful DNA 
replication and protein synthesis (Figure 1). During the cycle, p-amino benzoic acid and 
dihydropteroate pyrophosphate are consumed by dihydropteroate synthase for the 
generation of dihydropteroate. Dihydropteroate is then used for the synthesis of 
dihydrofolate (DHF) by reaction with dihydrofolate synthase. DHF is then reduced to 
tetrahydrofolate (THF) via the oxidation of NADPH by dihydrofolate reductase followed by 
a cyclization to N5,N10-methylene THF by a serine hydroxymethyl transferase. DHF is 
regenerated by the thymidylate synthase from N5,N10-methylene THF resulting in the 
methylation of dUMP to dTMP, a nucleotide used in DNA synthesis. Additionally, N5,N10-
methylene THF is further reduced downstream of serine hydroxymethyl transferase by 
N5,N10-methyleneTHF reductase for methionine generation and N5,N10-methylenyl THF 
reductase for both histidine and purine nucleotide synthesis (Figure 1)16. Unlike bacteria 
where DHF is synthesized de novo, eukaryotic cells rely on dietary intake as their source 
of folate and actively transport folic acid across the plasma membrane via Reduced 
Folate Transporters (RFT). Once in the cell, DHFR reduces folic acid to dihydrofolate, 
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which then undergoes a second enzymatic reduction by DHFR to THF prior to completion 
of the cycle17.  
 
 
Figure 2 Bacterial folic acid cycle; enzymes are in bold and end products (dTMP, amino 
acids and nucleotides) are boxed16. 
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1.2b Dihydrofolate Reductase 
Dihydrofolate Reductase is an essential enzyme within the folic acid cycle responsible for 
the reduction of dihydrofolate to tetrahydrofolate via the oxidation of NADPH to 
NADP+(Figure 2a). S. aureus DHFR, is 158 amino acids with a molecular weight of 17.4 
kDa. The ternary protein structure features an 8- strand beta sheet surrounded by four 
alpha helices all connected through flexible loop regions. The substrate (DHF) forms 
several ionic interactions between the pterin moiety and the side chain of Asp 27 and 
backbone carbonyl of Phe 92 as well as a hydrophobic interaction with the side chain of 
Leu 28 and the amino benzoate ring (Figure 2b). The pterin amine group forms a 
hydrogen bond with a water molecule involved in an extensive water network coordinated 
throughout the protein as well extensive van der Waals interactions with the nicotinamide 
ring. Additionally, two crucial hydrogen-bonding interactions are formed between the 
glutamate tail and guanidinium moiety of the Arg 57 (Figure 2b)18. 
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Figure 2 a) The mechanism of DHFR b) Folate and NADPH (purple) bound in the S. 
aureus DHFR (blue) active site. The amino acids and interactions made with DHF are 
highlighted (PDB ID: 3FRD). 
 
During its catalytic cycle, DHF and NADPH form a ternary structure with DHFR. Upon 
reduction of DHF to THF through the oxidation of NADPH, NADP+ is released from the 
active site leaving a binary complex of DHFR and THF. NADPH then binds the binary 
complex, releasing THF and allowing a new DHF molecule to bind, perpetuating 
catalysis19. After its release from the enzyme, THF is transformed into methylene-THF 
and continues through the folic acid cycle until it is regenerated by thymidylate synthase. 
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DHFR is the only source of THF for bacterial cells, therefore its inhibition results in 
arrested cell proliferation. As such, DHFR is a considered an essential enzyme and 
validated drug target exploited for the treatment of cancer, autoimmune disease as well 
as bacterial and parasitic infections. 
 
1.2c Clinical Antifolates 
Antifolates are inhibitors of folic acid enzymes including dihydrofolate reductase, 
thymidylate synthase (TS) and dihydropteroate synthase (DHPS). This class is clinically 
important for the treatment of cancers, infectious diseases and autoimmune disorders. 
Trimethoprim (TMP) is the only DHFR inhibitor approved for the treatment of bacterial 
infections (Figure 3). TMP is often prescribed in combination with sulfamethoxazole 
(SMX) and branded as Bactrim. Sulfamethoxazole is an antifolate targeting 
dihydropteroate synthase, an enzyme upstream from DHFR in the folic acid cycle. Both 
trimethoprim and sulfamethoxazole are bacteriostatic antibiotics, but together act 
synergistically resulting in a potent, bactericidal combination16. TMP has activity against 
gram-negative and gram-positive bacteria and TMP/SMX combination is first line 
treatment for CA-MRSA infections20-23. Trimethoprim is highly selective for susceptible, 
pathogenic DHFR over the human isoform (>8,600-fold) resulting in low-toxicity. In 
addition to its general tolerability, the combination is both orally bioavailable and available 
at minimal costs, increasing its clinical appeal23. In fact, prescriptions of TMP-SMX 
numbered more than 21 million in 2013, putting it in the group of top ten oral antibiotics 
prescribed in 201324. 
 
Unlike beta-lactam antibiotics, whose drug class is made up of many generations of 
inhibitors, no major effort to generate second-generation antifolate antibiotics has been 
	 9 
successful. Iclaprim, a TMP derivative, showed potent activity against gram-positive 
bacteria including staphylococci and streptococci and went through clinical trials for 
complicated SSTIs and hospital acquired pneumonia infections25-27. However in 2009, 
Iclaprim was denied FDA approval upon completion of Phase III trials due a lack of 
efficacy and safety, as it possessed a potent inhibitory activity of hERG channel28.  
 
Figure 3 Structures of Clinically Approved and Relevant DHFR Inhibitors 
 
In addition to its role as anti-bacterial therapeutics, DHFR has been exploited as the 
target for anti-cancer drugs, methotrexate (MTX) and pemetrexed, referred to as Classical 
Antifolates. Methotrexate is marketed for treatment of cancer, alone and in combination 
therapies, as well as for autoimmune disorders including rheumatoid arthritis, psoriasis 
and lupus. However, MTX is believed to work through different mechanisms of action for 
these non-cancer indications29. Pemetrexed is most recently approved DHFR inhibitor 
and is indicated for the treatment of non-small cell lung cancer and pleural mesothelioma 
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in combination with cisplatin30. In addition to DHFR inhibitition, pemetrexed also targets 
thymidylate synthase and GARFT, a ribonucleotide formyltransferase (Figure 3).  
  
Like dihydrofolate, these classical antifolates possess a basic head group and a 
negatively charged glutamate extension that are critical for binding of the enzyme. 
Because of the structural similarities, these compounds mimic the binding motif of the 
substrate with a basic nitrogenous headgroup that forms strong contacts with an acidic 
residue in the active site and a glutamate tail that forms extensive ionic interactions with a 
basic amino acid31-33. As substrate mimics, classical antifolates often possess very high 
affinity for DHFR enzymes, with low nano-molar to pico-molar potency towards human 
and pathogenic enzymes including E. coli and S. aureus34,35. Like folate, classical 
antifolates are actively transported into eukaryotic cells though folate transporters. As 
bacteria synthesize folate through a de novo mechanism and do not possess folate 
transport capabilities, there is no mechanism by which these classical antifolates can 
penetrate bacterial cells and therefore show poor efficacy against these species 
regardless of the high enzyme affinity29.  
 
1.3 Antibiotic Resistance in S. aureus 
Resistance to every class of antibiotics has been identified clinically. Drug resistance is 
responsible for increased morbidity, mortality and healthcare costs, estimates range from 
$20-35 billion in the US alone6. There are several major resistance mechanisms that 
affect antibiotics namely efflux of the drug from the cell, enzymatic modification of the 
drug, target mutations that reduce affinity of the drug, up-regulation of the target and 
permeability changes to the membrane. Methods in which a resistance-conferring 
enzyme is acquired by the cell, specifically an innately resistant target or a drug/ target 
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modifying enzyme, are often transferred between species on plasmid, mobile genetic 
elements, and incorporated into the chromosome via horizontal gene transfer. However, 
over-expression of the drug target or efflux pumps as well as changes in the drug target 
reducing drug affinity are a result of the accumulation of genetic mutations either in the 
gene’s promoter region or within the gene itself36.  
 
1.3a Mutational Resistance 
Point mutations in the target enzyme result in reduced affinity between the target and 
inhibitor by directly or allosterically hindering inhibitor binding. Fluoroquinolones, including 
ciprofloxacin and levofloxacin, target DNA gyrase (gyrA) and DNA topoisomerase IV (grlA 
and grlB), enzymes essential for DNA replication. The primary mechanism of resistance 
to fluroquinolones is a stepwise accumulation of mutations in these genes many of which 
are in the “quinolone resistance determining region” (QRDR) in the gyrA subunit37. 
Additionally, sulfamethoxazole resistance is conferred by the accumulation of up to 13 
mutations in folP, the gene for DHPS, resulting in high level resistance38. Importantly, the 
formation of the mutations, as with other resistance mechanisms, must confer resistance 
without sacrificing the endogenous function of the enzyme, as enzymes or cells with 
reduced fitness are less likely to survive or be pathogenic. 
 
Resistance conferred by reduced intercellular concentrations of antibiotics is achieved by 
efflux of the drug out of the cell and changes in cellular permeability reducing passive 
diffusion of the drug through the cytoplasmic membrane. In addition to mutational 
resistance, fluoroquinolones are also prone to resistance via efflux. NorA, an endogenous 
efflux system in S. aureus, can be over-expressed reducing the effective concentration 
within the cell to sub-lethal levels; inhibition of the efflux system can restore susceptibility 
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to these antibiotics. The overexpression of the efflux system is due to the accumulation of 
mutations in the gene’s promoter sequence39. 
 
1.3b Plasmid Acquired Resistance Determinants 
The ease with which bacteria transfer genetic elements from one species to another via 
plasmid genetic elements is responsible to the wide spread distribution of highly resistant 
genes. Once acquired by the cell, the genes encoded within genetic elements can be 
integrated into the chromosomal DNA through the process of horizontal gene transfer, 
although some plasmids contain mechanisms that allow gene expression without 
genomic incorporation. This mechanism of genetic material transfer is responsible for the 
introduction of innately resistant, drug modifying and enzyme modifying enzymes31.  
 
Resistance to methicillin and other beta-lactams in MRSA is conferred by the presence of 
a penicillin-resistant penicillin binding protein (PBP2a), encoded by the mecA gene. β-
lactam antibiotics target the transpeptidase domain of endogenous penicillin binding 
proteins (PBPs) involved in bacterial cell wall synthesis. PBPs are essential to bacterial 
survival and the maintenance of cell wall integrity by acting as transpeptidases, cross-
linking adjacent glycan strands in the cell membrane. PBP inhibition, via acylation by the 
β-lactam ring, halts cell wall synthesis while peptidoglycan autolysis continues and 
creates a compromised cell wall. The cells succumb to osmotic pressure, resulting in cell 
death40.  PBP2a has low affinity for beta-lactam antibiotics allowing for uninterrupted 
transpeptidase activity in the presence of high beta-lactam concentrations. The mecA 
gene found on the SCCmec genetic element, is common in all MRSA strains and is 
required for its ‘Methicillin resistant’ designation41. The acquisition of innately resistant 
target enzymes is also responsible for antifolate resistance (Chapter 1.3c).   
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Additional beta-lactam resistance in S. aureus and other bacterial species is 
accomplished by the acquisition of β -lactamase enzymes. β-lactams bind β-lactamases 
and the nucleophilic active site acylates the β-lactam ring via a ring opening reaction. 
Once acylated, an active site water molecule hydrolyzes the acyl bond and the cleaved, 
deactivated β-lactam antibiotic is released from the active site 
 which deactivates the antibiotics by cleaving the lactam ring through an acylation 
mechanism, releasing an inactive form of the drug42. Similarly, plasmid-acquired enzymes 
can deactivate both macrolides and aminoglycosides.  For example, bifunctional 
aminoglycoside deactivating enzymes, such as AAC(6’)-APH(2”), have both acetyl 
transferase and phosphotransferase activity and have broad specificity towards the entire 
class of aminoglycosides43.  These enzymes add acetyl and phosphate groups to specific 
alcohol substituents, reducing the affinity to its target, the 30S Ribosomal subunit. 
Similarly, mph isoforms phosphorylate a narrow spectrum of macrolid antibiotics such as 
erythromycin, which also targets the ribosome44.  
 
In addition to modification of macrolides by phosphorylation, erm enzymes, most 
commonly ermA, ermB, ermC, act as rRNA ribosomal methylases. These genes 
methylate the 23S ribosomal macrolide binding site, reducing the affinity between the 
inhibitor and binding site without sacrificing ribosomal function. The erm genes are 
inducible and affect a broader spectrum of macrolide antibiotics than the macrolide 
phosphorylase enzymes including erythromycin, azithromycin and clindamycin. These 
genes are also more common than the macrolide modifying enzymes in the clinic45. 
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Resistance can also be conferred by biological changes to the target. For example, 
resistance to vancomycin, a first line antibiotic for complicated CA-MRSA and HA-MRSA, 
is conferred by changes in the cytoplasmic membrane. Vancomycin and other 
glycopepetides such as daptomycin bind the carboxy terminal of the D-Ala-D-Ala 
disaccharide penyapeptide cell wall precursor during peptidoglycan synthesis, blocking 
access for the transpeptidases required for cell wall generation. Resistance to 
vancomycin is conferred by the acquisition of a cluster of van genes that produce D-Ala-
D-Lac disaccharides that are incorporated into the cell wall instead of D-Ala-D-Ala, 
drastically reducing the affinity of vancomycin46. While still rare, vancomycin-intermediate 
and vancomycin-resistant MRSA pose potentially devastating clinical consequences, as 
the treatment options for these strains are already very limited.  
 
1.3c Antifolate Resistance 
TMP/SMX resistance in S. aureus began to arise in the 1980s following its clinical 
introduction in 196847-49. In the 1990s, two TMPR mechanisms were identified as 
conferring clinical TMP resistance: point mutations in the endogenous DHFR gene, dfrB, 
and the acquisition of an innately resistant DHFR enzyme. A panel of point mutations, in 
both the allosteric and active sites of the enzyme, resulted in moderate to high-level 
resistance depending on the identity of the mutation. Noteworthy in this group was a Phe 
to Tyr mutation at the 98th position that was isolated both alone and in combination with 
other minor, allosteric mutations. Alone, the F98Y mutation conferred up to 400-fold loss 
of affinity between TMP and the enzyme but the presence of H149R or H30N mutations 
contributed to even greater losses in activity. An interesting compensatory relationship 
between the two mutations suggested that the accumulation of the second mutation 
increased the fitness of the enzymes in addition to increasing its resistance48.  
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Figure 4 The chemical structures of trimethoprim and sulfamethoxazole. 
 
In addition to point mutations within the target, a horizontally transferred, plasmid-
encoded resistant DHFR enzyme also appeared. The translated protein of the dfrA gene, 
often called S1 (but will be called DfrA here for clarity), was observed to confer high levels 
of TMP resistance at the enzyme level47. DfrA has three mutations in comparison to the 
TMP-sensitive S. epidermidis DHFR: V31I, G43A and F98Y; where F98Y is the major 
resistance determinant. The exact role of the F98Y mutation in TMP resistance is 
unknown, however studies suggest that it disrupts or destabilizes the binding of NADPH 
reducing its synergy with TMP, which is crucial for its potent activity47. More recently, two 
additional plasmid acquired TMPR genes, dfrG and dfrK, have been identified. Both of 
these genes, which are genetically similar, confer high levels of TMP resistance and 
appear to be highly mobile as they have also been isolated in many Staphylococci, 
Streptococci and Enterococci species50. Not only has no recent survey of TMPR MRSA 
isolates from US hospitals identified common molecular mechanisms of resistance, but 
the contribution of dfrG and dfrK was highly negated as clinically relevant despite 
reports51. Resistance for both pemetrexed and methotrexate has also been reported as a 
response to their use as anti-cancer agents. For pemetrexed, up-regulation of both 
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thymidylate synthase and dihydrofolate reductase have been reported52,53. Much more is 
known about methotrexate resistance, including decreases in active drug transport due to 
changes in the reduced folate carrier (RFC), efflux out of the cell, and up-regulation of 
DHFR29.  
 
1.4 Small Molecule Therapeutics to Overcome Drug Resistance 
Exploiting new antimicrobial targets would temporarily reduce the clinical burden of drug 
resistant bacteria. However, no major classes of antibiotics have been discovered since 
the late 1980’s, despite the introduction of linezolid and daptomycin in the early 2000’s54. 
Efforts to overcome clinical antibiotic resistance are crucial for the continued, efficacious 
treatment of these infections. These efforts include the development of next generation 
inhibitors that are able to directly target the resistance mechanism and that are less 
susceptible to developing resistance. In order to accomplish this, a comprehensive 
understanding of the current and potential molecular mechanisms of resistance, through 
structural models and biochemical evaluations, is applied to the iterative process of 
development and evaluation.  
 
Of the common mechanisms of resistance, only efflux, enzymatic modification and target 
mutations can be modeled using protein crystallography. Efforts to utilize crystal 
structures of efflux pump systems aim to elucidate the structural basis of substrate 
specificity, knowledge of this can lead to the design on inhibitors that are less susceptible 
efflux mediated resistance. Perhaps the two most successful examples of drug design to 
overcome resistances is the development of fluoroquinolones to overcome mutational 
resistance and β -lactam antibiotics that evade deactivation by β -lactamases. 
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1.4a Modification of the drug: β -lactamase enzymes 
β-lactam antibiotics, including penicillins, cephalosporins and carbapenems (Figure 2a), 
have a broad spectrum of activity and are often used as a staple of therapy in clinically 
relevant infections caused by both Gram-positive and Gram-negative bacteria. 
Resistance to this class of antibiotics, primarily through drug modification via β-
lactamases, has become a major barrier to effective treatment40. 
 
 
Figure 2: a. Beta-lactam antibiotic structures and imipenem, the first clinically available 
carbapenem antibiotic. Crystal structures of imipenem bound to b) TEM-1 (PDB: 1BT5, 
magenta) and c) AmpC (PDB: 1LL5, blue) beta-lactamases. 
  
There are four different classes of β-lactamases based on structural homology. Classes 
A, C and D β-lactamases employ a nucleophilic serine to acylate the β-lactam bond while 
Class B uses a Zn2+ ion in the active site55.  As β-lactamases have a high degree of 
structural homology to the PBPs, β-lactam antibiotics exhibit high affinity for these 
enzymes. Extended-spectrum β-lactamases (ESBLs), mainly from Class A, arose from 
early β-lactam use and are active in certain Gram-negative bacteria. ESBLs inactivate 
cephalosporin antibiotics that are typically resistant to acylation via β-lactamases.   
 
Among the β-lactam antibiotics that are not susceptible to deactivation by serine β-
lactamases is a class of antibiotics called carbapenems55. Structurally, carbapenems 
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have a similar 4-5 fused ring scaffold as penicillins differing by carbon substitution at the 
C1 position and a double bond at the C2-C3 position of the pyrroline ring (Figure 2). Of the 
clinically relevant β-lactams, carbapenems have the greatest potency and broadest 
spectrum of activity towards Gram-negative and Gram-positive bacteria56. Carbapenems 
act as β-lactamase inhibitors and are thus inherently resistant to deactivation by β-
lactamases. Imipenem, the first clinically available carbapenem, binds the β-lactamase 
active site with high affinity and like other β-lactam antibiotics becomes acylated. 
However, owing to a slow rate of hydrolysis, imipenem acts more as an inhibitor than a 
substrate. A crystal structure of imipenem bound to TEM-1, a Class A β-lactamase (PDB: 
1BT5) and AmpC, a Class C β-lactamase (PDB:1LL5) captures the acyl intermediate that 
is key to its action as a β-lactamase inhibitor (Figure 2).  The structures show the 6α-1R-
hydroxyethyl substitutions on the β-lactam ring cause the ligand to adopt an unexpected, 
strained conformation once bound to the enzyme. This strained conformation displaces 
the hydrolytic water in the active site, protecting it from deacylation55-57.  
 
Discovery of newer generation carbapenems is critical in order to overcome emerging 
resistance by Class B β-lactamases and the metabolic instability of imipenem. Imipenem 
is susceptible to elimination via dehydropeptidase-1 (DHP-1) found in the renal tubules, 
requiring the co-administration of a DHP-1 inhibitor to improve stability.  Doripenem, a 
later generation carbapenem, corrects for imipenem’s metabolic instability, increases its 
Gram-negative bacterial activity and has reduced β-lactamase susceptibility56. In addition 
to overcoming metabolism by DHP-1, attempts have been made to overcome resistance 
to Class B, metallo-β-lactamases. This has proven to be difficult, although strides have 
been made using the carbapenem transition state as a basis for novel beta-lactamase 
inhibitors. Additionally, crystal structures of metallo-β-lactamases, such as the recently 
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published New Delhi metallo-β-lactamase, will aid the design of inhibitors. Other 
motivating factors for new carbapenem discovery include overcoming lowered PBP 
affinity due to point mutations, resistance due to efflux, and issues overcoming poor 
cellular penetration57. 
 
1.4b Modification of the Target: Binding Site Mutations 
Mutations in the target protein that reduce the affinity between the drug and protein may 
arise by selection in the presence of drug pressure. The mutations may occur in the first 
shell of residues that contact the drug and eliminate key contacts or may arise in the 
outer shell and affect the conformation or dynamics of the drug-binding site. If mutations 
in the drug target is a mechanism by which resistance arises for a given drug, it is 
possible to determine the structures of both the wild type and mutated (resistant) proteins 
in order to understand the basis of resistance and allows for a modeling approach to 
predicting and overcoming the loss of interactions. 
 
Bacterial topoisomerases, including DNA gyrase (topoisomerase II) and DNA 
topoisomerase IV, are the target of quinolone antibiotics and are essential for replication. 
The topoisomerases have formed a successful platform for drug discovery for the past 
several decades, beginning with the discovery of the Gram-negative antibacterial activity 
of nalidixic acid37. Over the years, there have been several generations of quinolone 
antibiotics, with notable examples including ciprofloxacin, levofloxacin and moxifloxacin58. 
Each generation of quinolones has expanded the spectrum of coverage of these 
compounds to include Gram-negative and -positive bacteria, Pseudomonas and 
Mycobacterium tuberculosis58.  The primary mechanism of resistance to fluroquinolones 
in S. aureus is a stepwise accumulation of mutations in grlA, grlB and gyrA. High levels of 
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resistance are often achieved through mutations in the target combined with up regulation 
of efflux pump activity, for example norA in S. aureus. Crystal structures of Acinetobacter 
baumanii 59 or Streptococcus pneumonia60 topoisomerase IV bound to DNA and 
moxifloxacin have revealed many of the details of the mechanisms of topoisomerases, 
the mode of inhibition of the quinolone antibiotics and the structural basis of quinolone 
resistance.  
 
 
Figure 3. a) Chemical structures of moxifloxacin and GSK299423 b) The crystal structure 
of gyrase (purple) bound to DNA (backbone shown in orange) and two copies of 
GSK299423 (cyan) from PDB ID: 2XCS61. The figure shows a superposition of 
moxifloxacin (green) from PDB ID: 3FOF60. Typical resistance mutations are shown in 
magenta. 
 
In response to the observed resistance to quinolones, several groups have worked to 
design more effective molecules that are active against the resistant strains. For example, 
scientists at Glaxo Smith Kline designed compound GSK299423 to act via a mechanism 
distinct from the quinolones based on stabilization of a pre-cleavage enzyme-DNA 
complex61. Structures of GSK299423 show that the compound occupies a novel non-
catalytic binding pocket between the two GyrA subunits, which is adjacent to but not 
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overlapping with the ciprofloxacin site. As such, the affinity of the compound is not 
affected by the existing resistance mutations. In fact, GSK299423 shows potent activity 
against several bacterial strains, both wild-type and fluoroquinolone-resistant.  
 
1.5 Conclusions 
Staphylococcus aureus and its notorious ability to evolve and evade antibiotic pressure 
by the development of antibiotic resistance presents a major clinical burden. With the rise 
of community acquired MRSA strains and the continual decrease in therapies, MRSA has 
resulted in increased mortality, morbidity and costs associated with the onset of 
infections. Antifolates are crucial for the efficacious treatment of these infections, 
specifically the combination of TMP/SMX. However, its continued use is threatened by the 
development of diverse resistance mechanisms.  
 
In this work, we present the development of a novel class of antifolates to overcome 
trimethoprim resistance; predicting, inducing and identifying the molecular mechanisms of 
resistance to the experimental and clinical antifolates. Understanding the interactions 
between the drug and target, through resistance, not only allows for the rational 
development of potent inhibitors against the resistance determinants but inhibitors that 
are also less susceptible to resistance. In doing this, we have identified two major lead 
scaffolds that show superior activity against TMPR enzymes derived from the iterative 
process of structure based drug design.  
 
 
 
 
	 22 
1.6 References 
1.  Lowy, F. Antimicrobial Resistance: The Example of Staphylococcus Aureus. J. 
Clin. Invest. 2003, 111 (9), 1265–1273. 
2.  Chambers, H. F.; Deleo, F. R. Waves of Resistance: Staphylococcus Aureus in 
the Antibiotic Era. Nat. Rev. Microbiol. 2010, 7 (9), 629–641. 
3.  Jevons, M. P. ‘Celbenin’-resistant Staphylococci Br. Med. J. 1961, 1, 124–125. 
4.  Barrett, F.; McGehee, R.; and Finland, M. Methicillin-Resistant Staphylococcus 
aureus at Boston City Hospital-Bacteriological and Epidemiologic Observations. New 
Engl. J. Med. 1968, 279, 441–448. 
5.  O’Neill, J. Tackling Drug-Resistant Infections Globally: Final Report and 
Recommendations. Review on Antimicrobial Resistance. 2016. 
6.  Centers for Disease Control, US Department of Health and Human Services, 
Antibiotic Resistance Threats in the United States, 2013. 
7.  Deese, B.; Holdren, J. Memorandum for the Heads of Executive Departments and 
Agencies. Science and Technology Priorities for the FY 2016 Budget. United States 
Office of Science and Technology Policy. 2014. 
8.  Lodise Jr., T. P.; McKinnon, P. S. Burden of Methicillin-Resistant Staphylococcus 
Aureus: Focus on Clinical and Economic Outcomes. Pharmacotherapy 2007, 27, 1001–
1012. 
9. Styers, D.; Sheehan, D. J.; Hogan, P.; Sahm, D. F. Laboratory-Based Surveillance 
of Current Antimicrobial Resistance Patterns and Trends among Staphylococcus Aureus: 
2005 Status in the United States. Ann. Clin. Microbiol. Antimicrob. 2006, 5, 1-9. 
10.  Kluytmans-Vandenbergh, M. F. Q.; Kluytmans, J. W. Community-Acquired 
Methicillin-Resistant Staphylococcus Aureus: Current Perspectives. Clin microbiol nfect 
2006, 12, 9–15. 
11.   Lina, G.; Piémont, Y.; Godail-Gamot, F.; Bes, M.; Peter, M. O.; Gauduchon, V.; 
Vandenesch, F.; Etienne, J. Involvement of Panton-Valentine Leukocidin-Producing 
Staphylococcus Aureus in Primary Skin Infections and Pneumonia. Clin. Infect. Dis. 1999, 
29 (5), 1128–1132. 
12. Watkins, R. R.; David, M. Z.; Salata, R. Current Concepts on the Virulence 
Mechanisms of Meticillin-Resistant Staphylococcus Aureus. J. Med. Microbiol. 2012, 61, 
1179–1193. 
13.  Bush, K.; Leal, J.; Fathima, S.; Li, V.; Vickers, D.; Chui, L.; Louie, M.; Taylor, G.; 
Henderson, E. The Molecular Epidemiology of Incident Methicillin-Resistant 
Staphylococcus Aureus Cases among Hospitalized Patients in Alberta, Canada: A 
Retrospective Cohort Study. Antimicrob. Resist. Infect. Control. 2015, 4, 35. 
14. Singh, R.; Ray, P.; Das, A.; Sharma, M. Penetration of Antibiotics through 
Staphylococcus Aureus and Staphylococcus Epidermidis Biofilms. J. Antimicrob. 
Chemother. 2010, 65, 1955–1958. 
15.  Damberger, D. M.; Boyd, S. E. Management of Staphylococcus aureus Infections. 
Am. Fam. Physician. 2005, 72, 2474-2481. 
	 23 
16. Zhou, W.; Scocchera, E. W.; Wright, D. L.; Anderson, A. C. Antifolates as Effective 
Antimicrobial Agents: New Generations of Trimethoprim Analogs. Med. Chem . Comm. 
2013, 4, 908. 
17. Human DHFR  
18. Frey, K. M.; Lombardo, M. N.; Wright, D. L.; Anderson, A. C. Towards the 
Understanding of Resistance Mechanisms in Clinically Isolated Trimethoprim-Resistant, 
Methicillin-Resistant Staphylococcus Aureus Dihydrofolate Reductase. J. Struct. Biol. 
2010, 170 (1), 93–97. 
19.  Osborne, M. J.; Schnell, J.; Benkovic, S. J.; Dyson, H. J.; Wright, P. E. Backbone 
Dynamics in Dihydrofolate Reductase Complexes: Role of Loop Flexibility in the Catalytic 
Mechanism. Biochemistry 2001, 40, 9846–9859. 
20.  Frei, C. R.; Miller, M. L.; Lewis, J. S.; Lawson, K. a; Hunter, J. M.; Oramasionwu, 
C. U.; Talbert, R. L. Trimethoprim-Sulfamethoxazole or Clindamycin for Community-
Associated MRSA (CA-MRSA) Skin Infections. J. Am. Board Fam. Med. 2010, 23 (6), 
714–719. 
21.  Gorwitz, R. J.; Jernigan, D. B.; Powers, J. H.; Jernigan, J. A. Participants in the 
CDC-convened experts’ meeting on management of MRSA in the community: Summary 
of an experts meeting convened by the Centers for Disease Control and Prevention 2006. 
22.  Nathwani, D.; Morgan, M.; Masterton, R. G.; Dryden, M.; Cookson, B. D.; French, 
G.; Lewis, D. Guidelines for UK Practice for the Diagnosis and Management of Methicillin-
Resistant Staphylococcus Aureus (MRSA) Infections Presenting in the Community. J. 
Antimicrob. Chemother. 2008, 61 (5), 976–994. 
23. Liu, C.; Bayer, A.; Cosgrove, S. E.; Daum, R. S.; Fridkin, S. K.; Gorwitz, R. J.; 
Kaplan, S. L.; Karchmer, A. W.; Levine, D. P.; Murray, B. E.; et al. Clinical Practice 
Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-
Resistant Staphylococcus Aureus Infections in Adults and Children. Clin. Infect. Dis. 
2011, 52 (3), 18-55. 
24.  Center for Disease Control and Prevention. Centers for Disease Control and 
Prevention Outpatient antibiotic prescriptions — United States 2013. 
25.   Hawser, S.; Lociuro, S.; Islam, K. Dihydrofolate Reductase Inhibitors as 
Antibacterial Agents. Biochem. Pharmacol. 2006, 71, 941–948. 
26.   Schneider, P.; Hawser, S.; Islam, K. Iclaprim, a Novel Diaminopyrimidine with 
Potent Activity on Trimethoprim Sensitive and Resistant Bacteria. Bioorganic Med. Chem. 
Lett. 2003, 13, 4217–4221. 
27.  Sincak, C.; Schmidt, J. Iclaprim, a novel diaminopyrimidine for the treatment of 
resistant gram-positive infections. Ann Pharmacother. 2009, 43 ,1107–1114. 
28. Viswanathan, K.; Frey, K. M.; Scocchera, E. W.; Martin, B. D.; Swain, P. W.; 
Alverson, J. B.; Priestley, N. D.; Anderson, A. C.; Wright, D. L. Toward New Therapeutics 
for Skin and Soft Tissue Infections: Propargyl-Linked Antifolates Are Potent Inhibitors of 
MRSA and Streptococcus Pyogenes. PLoS One 2012, 7 (2), 1–9. 
	 24 
29.  Walling, J. From methotrexate to pemetrexed and beyond. A review of the 
pharmacodynamics and clinical properties of antifolates. Investigational New Drugs. 
2006, 24, 33-77. 
30.  Chattopadhyay, S.; Moran, R.; Goldman, I. Pemetrexed: biochemical and cellular 
pharmacology, mechanisms and clinical applications. Mol. Cancer Ther. 2007, 6, 404-17. 
31.  Bennett, B.; Wan, Q.; Ahmad, M.; Langan, P.; Dealwis, C. X-ray structure of the 
ternary MTX.NADPH complex of the anthrax dihydrofolate reductase: a pharmacophore 
for dual-site inhibitor design. J. Struct. Biol. 2009, 166, 162−171.  
32.  Sawaya, M.; Kraut, J. Loop and subdomain movements in the mechanism of 
Escherichia coli dihydrofolate reductase: crystallographic evidence. Biochemistry 1997, 
36, 586−603.  
33.  Li, R.; Sirawaraporn, R.; Chitnumsub, P.; Sirawaraporn, W.; Wooden, J.; 
Athappilly, F.; Turley, S.; Hol, W. Three-dimensional structure of M. tuberculosis 
dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. J. 
Mol. Biol. 2000, 295, 307−323. 
34.  Burchall, J.; Hitchings, G. Inhibitor Binding Analysis of Dihydrofolate Reductases 
from Various Species. Mol. Pharmacol. 1965, 1, 126−136.  
35.  Kopytek, S.; Dyer, J.; Knapp, G.; Hu, J. Resistance to methotrexate due to 
AcrAB-dependent export from Escherichia coli. Antimicrob. Agents Chemother. 2000, 44, 
3210−3212. 
40.   E, Aires J.; Nikaido, H. AcrB multidrug efflux pump of Escherichia coli: composite 
substrate-binding cavity of exceptional flexibility generates its extremely wide substrate 
specificity. J. Bacteriol. 2003, 185, 5657–5664.  
42.  Opperman, T.; Kwasny, S.; Kim, H. S. Characterization of a novel pyranopyridine 
inhibitor of the AcrAB efflux pump of Escherichia coli. Antimicrob. Agents Chemother. 
2014, 58 (2), 722–733.  
43.   Daigle, D. M.; Hughes, D. W.; Wright, G. D. Prodigious Substrate Specificity of 
AAC(6’)-APH(2’’), an Aminoglycoside Antibiotic Resistance Determinant in Enterococci 
and Staphylococci. Chem. Biol. 1999, 6 (2), 99–110. 
44.   Leclercq, R. Mechanisms of Resistance to Macrolides and Lincosamides: Nature 
of the Resistance Elements and Their Clinical Implications. Clin.Infect.Dis. 2002, 34 (1), 
482–492. 
45.  Sutcliffe, J.; Grebe, T.; Tait-Kamradt, A.; Wondrack, L. Detection of Erythromycin 
Resistant Determinants by PCR. Antimicrob Agents Chemother 1996, 40 (11), 2562–
2566. 
46.  Weigel, L. M.; Clewell, D. B.; Gill, S. R.; Clark, N. C.; McDougal, L. K.; Flannagan, 
S. E.; Kolonay, J. F.; Shetty, J.; Killgore, G. E.; Tenover, F. C. Genetic Analysis of a High-
Level Vancomycin-Resistant Isolate of Staphylococcus Aureus. Science 2003, 302 
(2003), 1569–1571. 
47.   Dale, G. E.; Broger, C.; Hartman, P. G.; Langen, H.; Page, M. G. P.; Then, R. L.; 
Stuber, D. Characterization of the Gene for the Chromosomal Dihydrofolate Reductase 
	 25 
(DHFR) of Staphylococcus Epidermidis ATCC 14990: The Origin of the Trimethoprim-
Resistant S1 DHFR from Staphylococcus Aureus? J. Bacteriol. 1995, 177, 2965–2970. 
48.   Dale, G. E.; Broger, C.; D’Arcy, a; Hartman, P. G.; DeHoogt, R.; Jolidon, S.; 
Kompis, I.; Labhardt, a M.; Langen, H.; Locher, H.; et al. A Single Amino Acid Substitution 
in Staphylococcus Aureus Dihydrofolate Reductase Determines Trimethoprim 
Resistance. J. Mol. Biol. 1997, 266, 23–30. 
49.  Houvinen, P.; Sundstrom, L.; Swedberg, G.; Skold, O. Trimethoprim and 
Sulfamethoxazole Resistance.  Antimicrob. Agents Chemother. 1995, 39, 279. 
50.   Bergmann, R.; Van Der Linden, M.; Chhatwal, G. S.; Nitsche-Schmitz, D. P. 
Factors That Cause Trimethoprim Resistance in Streptococcus Pyogenes. Antimicrob. 
Agents Chemother. 2014, 58 (4), 2281–2288. 
51.   Nurjadi, D.; Olalekan, A. O.; Layer, F.; Shittu, A. O.; Alabi, A.; Ghebremedhin, B.; 
Schaumburg, F.; Hofmann-Eifler, J.; Van Genderen, P. J. J.; Caumes, E.; et al. 
Emergence of Trimethoprim Resistance Gene dfrG in Staphylococcus Aureus Causing 
Human Infection and Colonization in Sub-Saharan Africa and Its Import to Europe. J. 
Antimicrob. Chemother. 2014, 69 (9), 2361–2368. 
52.  Zhao, R.; Goldman, I. D. Resistance to Antifolates. Oncogene 2003, 22, 7431–
7457 
53.  Sigmond, J.; Backus, H.; Wouters D. et. al. Induction of resistance to the 
mutitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is 
associated with thymidylate synthase overexpression. 2003, 66, 431-438. 
54. Silver, L. L. Challenges of Antibacterial Discovery. Clin. Microbiol. Rev. 2011, 24 
(1), 71–109. 
55.  Papp-Wallace, K.; Endimiani, A.; Taracila, M.; Bonomo, R. Carbapenems: past, 
present and future. Antimicrob. Agents Chemother. 2011, 55, 4943–4960. 
56.   Beadle B, Shoichet B. Structural basis for imipenem inhibition of class C β-
lactamases. Antimicrob. Agents Chemother. 2002, 46, 3978–3980.  
57.  Maveyraud. L.; Mourey, L.; Korta, L.; et al. Structural basis for clinical longevity of 
carbapenem antibiotics in the face of challenge by the common class A β-lactamases 
from the antibiotic-resistant bacteria. J. Amer. Chem. Soc. 1988,120, 9748–9752.  
58.  Pommier, Y.; Le, E.; Zhang, H.; Marchand, C. DNA topoisomerases and their 
poisoning by anticancer and antibacterial drugs. Chem. Biol. 2010, 17, 421–433. 
59.  Wohlkonig, A.; Chan, P.; Fosberry, A.; et al. Structural basis of quinolone inhibition 
of type IIA topoisomerases and target-mediated resistance. Nat. Struc. Mol. Biol. 2010 
17, 1152–1153. 
60.  Laponogov, I.; Sohi, M.; Veselkov, D.; et al. Structural insight into the quinolone- 
DNA cleavage complex of type IIA topoisomerases. Nat. Struc. Mol. Biol. 2009, 16, 667–
669. 
61.  Bax, B.; Chan, P.; Eggleston, D.; et al. Type IIA topoisomerase inhibition by a 
new class of antibacterial agents. Nature 2010, 466, 935–940. 
 
 
	 26 
Chapter 2 
Development of Propargyl-linked Antifolates as Potent Antimicrobial Agents 
 
2.1 Evolution of Propargyl-linked Antifolates from Trimethoprim  
Antifolates are important agents for continued anti-cancer and anti-microbial treatments. 
Trimethoprim is a well-tolerated, inexpensive antibiotic with a broad activity against gram-
positive, gram-negative and parasitic diseases. However, the development of resistance 
and prevalence of innately resistant pathogens limits the use of this therapeutic. Efforts to 
develop a new class of antifolates against these clinically important and resistant disease 
states attempt to combat these problems. The development of this class of antifolates 
employed the iterative process of structure based drug design, in which high resolution X-
ray structures of the protein:inhibitor complex are used to guide inhibitor design. Rational 
modifications to the inhibitor scaffold, based on the interpretation of the crystal structures, 
are tested in-vitro to validate or reject the design principle1. Ultimately, this method should 
result in the development of selective, potent inhibitors optimized against its target.  
 
Crystal structures of trimethoprim in complex with Cryptosporidium hominis (C. hominis) 
dihydrofolate reductase (Ch DHFR) revealed that the inhibitor’s poor fit into the active site 
is responsible for its innate resistance. Evaluation of the Ch DHFR active site revealed a 
narrow hydrophobic ‘tunnel’ leading to an unoccupied substrate-binding pocket. 
Therefore, a series of TMP-like antifolates were developed to expand the distance 
between the diaminopyrimide and trimethoxybenzyl rings and extend the inhibitor further 
into the active site to accumulate hydrophobic interactions2.  
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Modifications to the TMP structure and extension of the single methyl linkage include an 
acetylene linker (Figure 1, Scaffold A) and ethylene linker including the cis- and trans- 
isomers as well as its saturated alkane counterparts (Scaffold B). However, the only TMP 
derivative that gained activity against these parasitic DHFR enzymes contained a rigid 
acetylene linker connected to the trimethoxybenzyl ring by a propargylic carbon (PLA 
Scaffold)3. This scaffold, named for its propargyl linker, was further modified with alkyl 
substitutions on the diaminopyrimidine ring and propargylic position resulting in a series 
compounds with nanomolar activity against the enzyme. 
 
Figure 1 TMP Derivatives Optimizing Linker Identities 
 
Cryptosporidium hominis (C. hominis) is an opportunistic parasite that was a major cause 
of morbidity in immunocompromised patients, specifically those with HIV. However, as 
HIV diagnostics and therapies improved, the clinical impact of C. hominis decreased4 and 
the focus of the development of Ch DHFR inhibitors shifted to gram-negative and gram-
positive bacteria as well as pathogenic fungal and mycobacterium species.  
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The first generation PLAs were assessed against Bacillus anthracis, an innately TMPR 
gram-positive bacteria that was feared as a tool of bioterrorism5. Crystal structures of the 
PLAs in the Bacillus anthracis dihydrofolate reductase (Ba DHFR) active site shows the 
acetylene fitting through the narrow hydrophobic tunnel made of Phe 96 and placing the 
trimethoxybenzyl ring in the hydrophobic, substrate binding pocket, as designed. 
Additional analysis of the structures indicated that further alkyl substitutions at the C6 
position on the diaminopyrimidine ring, specifically an ethyl substituent; exploits 
interactions with an active site valine (Val 32) and leucine (Leu 29) residue. This work 
concluded that increased potency and selectivity over human DHFR can be achieved by 
adding bulky substitutions at the meta-position of the trimethoxybenzyl ring to increase 
contacts within the substrate binding site6. This revelation lead to the development of the 
second generation of propargyl-linked antifolates that feature an ethyl substituted 
diaminopyrimidine linked to the meta-substituted biaryl system by an acetylene linker 
(Figure B). The proximal B-ring and distal C-rings can be substituted with both 
heterocycles or aromatic rings as well as small alkyl or polar substituents, allowing for 
further optimization and establishment of a structure activity relationship.  
 
Figure 2 Second Generation PLA Scaffold 
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The second generation of propargyl-linked antifolates explored different C-ring 
substituents. Inhibitors with a distal benzyl or dimethyl benzyl were evaluated against 
wild-type S. aureus DHFR (DfrB) and a quality control S. aureus strain (ATCC 43300). 
The series of compounds with these hydrophobic C-rings exhibited very potent (3-80 nM) 
enzymatic potency and MICs below 100 ng/mL7. Crystal structures of this series validate 
the design principles of building these compounds into the substrate-binding pocket. The 
structure showed the standard polar interactions between the active site and 
diaminopyrimidine ring as well as hydrophobic interactions with Val 31 and stacking 
interactions between the acetylene linker and Phe 92 side chain.  The biaryl system 
picked up extensive side chain Leu 20, Leu 28, Ile 50 and Leu 54 contributing to the 
formation of stable, inhibitory complex with the distal ring pointed toward the solvent 
exposed pocket of the enzyme. Unfortunately, this class of compounds displayed poor 
solubility and potent activity against human DHFR and resulted in minimal selectivity with 
over 70% of the inhibitors having a human/ S. aureus selectivity ratio of <10 7. 
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Figure 3 Crystal structure of a distal dimethylbenzyl substituted biaryl PLA bound to S. 
aureus DHFR (3F0S) highlighting the extensive network of hydrophobic interactions 
between the inhibitor and active site. 
 
Replacement of the benzyl and substituted benzyl rings with heterocycles, namely 4-
pyridine, increased the selectivity, potency and solubility of the class (Section 2.2). The 
biaryl compounds showed increased potency against a panel of gram-positive bacteria, 
including Staphylococcus aureus and Streptococcus pyogenes7 as well as gram-negative 
bacteria8 and fungal species Candida albicans and Candida glabrada9,10. This class of 
compounds was also used as probes to explore the importance of stereochemistry at the 
propargylic position (Section 2.3). A third, and current, generation of PLAs were further 
optimized by the addition of a para-carboxylate meant to form ionic interactions with polar 
amino acids in the distal region of the substrate-binding site, this class of compounds is 
described in Section 2.4.  
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2.2 Pyridine PLAs as a Promising Lead Scaffold 
The meta-pyridine biaryl PLA scaffold was the first promising lead series within the class 
against S. aureus DHFR. The evolution of the propargyl linked antifolates from single aryl 
trimethoprim derivatives to hydrophobic, bulky meta-biphenyl compounds illustrates how 
this class of compounds can be optimized as potent DHFR inhibitors. The further 
incorporations of C-ring heteroatoms to the biaryl 
scaffold increased potency, solubility and selectivity. 
Identifying 4-pyridyl PLAs as a second-generation 
lead scaffold provides an opportunity for continued 
development and optimization by exploring various RP 
and B-ring substitutions (Figure 4)7. The second-
generation pyridine class of PLAs can be divided into three major scaffolds: mono-
methoxy substituted, di-methoxy substituted and a rigid dioxolane, fused ring scaffold.  
 
2.2a Methoxy-substituted PLAs 
Compounds with single substitutions at the R1 and R2 positions were synthesized with 
and without alkyl substitutions at the propargyl position (RP), evaluated for both cellular 
and enzymatic activity, establishing a structure activity relationship. The R1 substituted 
compounds show a 32-fold difference in cellular activity when comparing the propargyl 
hydrogen (UCP1021) and the propargyl methyl (UCP1040) with MICs of 0.0195 µg/mL 
and 0.625 µg/mL but show very similar enzymatic activity with IC50 values of 21nM and 
30nM, respectively (Figure 5). The addition of the propargylic methyl creates a single 
stereocenter in the inhibitor, which could account for the loss off activity seen with 
UCP1040, as single enantiomer inhibitors are known to display differential activity against 
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Figure 4 Pyridine PLA Scaffold  
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its enzymatic target11. The importance of the stereochemistry at this position was 
explored and discussed in Chapter 2.3.	 
 
Figure 5 Methoxy-substituted PLAs with Cellular and Enzymatic Activities 
 
Moving the methoxy from the R1 to the R2 position only resulted in minimal losses in 
cellular activity, with MICs increasing from 0.0195 to 0.0781µg/mL with a RP hydrogen 
substitution (UCP1015). However incorporation of a methyl at this position, in 
combination with the R2-methoxy (UCP1006), results in no MIC shift when compared to 
UCP1015, however it gains 8–fold activity over its R1-methoxy equivalent. Similarly, the 
IC50 values for these compounds are almost indistinguishable at 19nM and 12nM for 
UCP1006 and UCP1015 (Figure 5)7. 
 
Previously published crystal structures indicate an extensive network of hydrophobic 
interactions between the pyridine PLA and the DHFR active site, in addition to the 
hydrogen bonding interactions of the diaminopyrimidine moiety to an active site water, 
side chain of Asp 27 and backbone carbonyls of Leu 5 and Phe 92. The aromatic Phe 92 
side chain makes additional stacking interactions with the acetylene linker and the side 
chains Leu 28 and Val 31 make additional hydrophobic interactions with the C6-ethyl on 
the diaminopyrimidine. Ile 50 and Leu 54 side chains make extensive interactions with the 
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biaryl system whose pyridine ring is oriented towards the solvent exposed area of the 
active site. Finally, the propargyl methyl appears to make hydrophobic interactions with 
the nicotinamide ring of NADPH (Figure 6). 
 
 
Figure 6 DfrB (purple) complexed with NADPH and UCP1006 (blue) highlighting the 
hydrogen bonding and hydrophobic interactions between the inhibitor and active site, 
PDB ID: 3SGY.  
 
2.2b Dimethoxy and Dioxolane Substituted PLAs 
Single methoxy B-ring substitutions on the pyridine scaffold afford potent activity against 
wild-type MRSA (ATCC 43300) and DHFR enzyme (DfrB). Trimethoprim contains three 
methoxy B-ring substituents proximal to the hydrophobic active site, accumulating weak 
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interactions that result in potent, broad-spectrum activity. Increasing and exploiting these 
hydrophobic interactions can further optimize the pyridine PLAs and increase potency 
against the DHFR targets. To probe this hypothesis, a series of pyridine PLAs with 
dimethoxy substituents (R1/R3 and R2/ R3 substituted) pyridine PLAs were synthesized 
and evaluated. The series of compounds also features compounds with a benzodioxolane 
fused ring system at the R1/R2 and R2/R3 positions revealing a SAR between dioxolane 
positions as well as propargyl substitutions. 
 
Pyridine PLAs with methoxy substituents at the R1/R3 and R2/R3 were synthesized and 
evaluated, the latter scaffold with and without substitutions at the RP position. With RP 
hydrogens, moving the second methoxy from the R1 (UCP1033) to R2 (UCP1039) 
positions resulted in a 16-fold increase in both cellular and enzymatic activity with MICs of 
0.3125 µg/mL to 0.0195 µg/mL and IC50 values of 202 nM and 14 nM, respectively (Figure 
7). The addition of the propargylic methyl to UPC1039 (UCP1082) resulted in an increase 
in MIC to 0.3125 ug/mL, mimicking the MIC of the R1/R3 substituted and potentially 
indicating that substitutions at the RP and R1 positions have similar effects in substrate 
binding (Figure 7).  
 
Figure 7 Dimethoxy-substituted PLAs with Cellular and Enzymatic Activities 
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This series was pursued further by constraining the dimethoxy substitutions via a 
dioxolane ring resulting in a fused B-ring system that has reduced flexibility in the active 
site. Even though substitutions at the R1 positions were not optimal for the dimethoxy 
series, a single R1/R2 benzodioxone compound with an RP methyl was evaluated. This 
compound exhibited poor cellular and enzymatic activity with an MIC of 0.625 µg/mL and 
an IC50 of 4.2 µM. Shifting the dioxolane ring to the R2/R3 positions (UCP1038) reduced 
the MIC to 0.0781 µg/mL and IC50 value to 17nM. Furthermore, removal of the RP-methyl 
raised the MIC to 0.3125 µg/mL but left the IC50 unaffected while the introduction of two 
RP-methyl substituents further increased the MIC to 0.625 µg/mL (UCP1072, Figure 8). 
 
Figure 8 Dioxolane-substituted PLAs with Cellular and Enzymatic Activities 
 
Because dioxolane rings are a known metabolic liability, as the acetal can form 
covalent bonds to the heme of CYP enzymes a RP methyl, R2/R3 dioxolane with 
deuterium at this position was synthesized (UCP1070)12. When trying to avoid metabolic 
or other pharmacokinetic liabilities, deuterium, which mimics hydrogen in size and 
chemical properties, can substitute hydrogen atoms and mitigate these reactivities13. The 
addition of the deuterium to the dioxolane ring resulted in no loss of activity when 
compared to its hydrogenated counterpart (UCP1038).  
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Figure 9 The crystal structure of a) DfrB:NADPH:UCP1070 (blue) and b) 
DfrB:NADPH:UCP1070 (blue) superimposed with DfrB:NADPH:UCP10067 (purple). The 
amino acids that form interactions with specific binding modes are the same color as the 
corresponding inhibitor.  
 
A 1.47Å crystal structure of UCP1070 complexed with DfrB reveals two distinct 
conformations of NADPH and binding positions of the biaryl system. The two binding 
modes could be a result of the capture of the single enantiomers within the racemic mix, 
where as one inhibitors binds in the same orientation observed in Figure 6 and the other 
occupies a more solvent exposed binding pocket of the active site (Figure 10b). The 
structure reveals distinct hydrophobic interactions between the two binding modes where 
Ile 50 maintains contact with both but one inhibitor position forms interactions with Leu 54 
(blue) and the other picks up interactions with Leu 20, located on a flexible loop region of 
the active site (pink, Figure 9). The additional interactions made between dioxolane ring 
and Leu 20 and Ile 50 side chains may contribute to the superior potency of the dioxolane 
and dimethoxy-substituted compounds, validating this attempt to further optimize the 
class of PLAs. The relevance and implications of the variable and novel NADPH 
configurations seen in Figure 9 are discussed in depth in Chapter 2.5.  
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2.3 Enantiopure Propargyl-linked Antifolates 
Some of the most potent PLAs that have been evaluated against DHFRs of pathogenic 
bacteria feature a methyl substitution at the propargyl position resulting in a single 
stereogenic center6-10. Previous structural studies with a series of PLAs show that these 
branched substituents are proximal to the cofactor-binding site and may provide 
compensatory interactions with NADPH as well as providing conformational control of the 
biaryl ring system14,15. Therefore, investigating the role of the stereogencicity of the 
propargyl center in governing the inhibitors activity becomes priority. Probing the role of 
the configuration at the single stereocenter in these inhibitors required the preparation of 
a series of non-racemic, branched PLA inhibitors. These inhibitors possess potent 
enzyme inhibition (IC50 values <50nM), antibacterial effects (most MICS <1µg/mL) and 
form stable ternary complexes with the cofactor and enzyme. Individual crystal structures 
of a pair of enantiomers in S. aurues DHFR reveal that a single change in configuration of 
the stereo-center drove both the binding orientation of the biaryl systems as well as the 
selection of an alternative NADPH cofactor16.  
 
2.3a Biochemical and Microbiological Evaluation of Enantiomers 
The series of enantiopure inhibitors indicates that the compounds maintain strong 
inhibition of wild-type S. aureus DHFR (DfrB) with the majority of inhibitors having IC50 
values less than 50nM (Table 1). The compounds also display significant antibacterial 
activity against a quality control strain of MRSA (ATCC 43300) with the most active 
enantiomers showing an 8-fold increase in activity over trimethoprim. In contrast to TMP, 
the PLAs were designed to form alternative and additional contacts with residues in the 
active site by the biaryl domain and branched at the propargylic position to become less 
dependent on synergy with the cofactor. Interestingly, varying degrees of antibacterial 
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activity were observed within the pairs of enantiomers. For example, the MICs of the R- 
and S- R1 methoxy substituted inhibitors (UCP1061 and UCP1062) differed 8-fold with 
values of 0.3125 µg/mL and 0.0391 µg/mL, respectively. Similarly, the R- and S-R2 
methoxy inhibitors (UCP1064 and UCP1063) have MIC values of 1.25 µg/mL and 0.078 
µg/mL, a 16-fold difference in antibacterial activity. Conversely, the R3 methoxy 
(UCP1096/UCP1097), dioxolane (UCP1098/UCP1099) and R2 ,R3-dimethoxy (UCP1079/ 
UCP1080) substituted compounds only had a 2- or 4-fold discrepancy in MIC values 
(Figure 10, Table 1).   
 
Figure 10 Structures of Enantiopure PLA compounds  
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Table 1 Biological activity of Enantiopure PLA compounds 
Inhibitor 
Sa MIC 
(μg/mL) 
DfrB IC50 a 
(nM) 
DfrB IC50 b 
(nM) 
NADPH Rate 
(μM/min) 
Thy+ Sa MIC 
(μg/mL) 
UCP1061 (R) 0.3125 15.0 + 0.7 69 + 5 -0.919 5 
UCP1062 (S) 0.0391 18+ 2 155 + 5 -0.965 5 
UCP1063 (S) 0.0781 11 + 0.7 37 + 5 -0.454 5 
UCP1064 (R) 1.25 19 + 1 464 + 27 -4.571 10 
UCP1079 (R) 1.25 46 + 4 26 + 3 -0.850 10 
UCP1080 (S) 2.5 74 + 6 98 + 8 -2.712 >20 
UCP1096 (R) 1.25 202 + 20 458 + 37 -19.944 10 
UCP1097 (S) 0.3125 35 + 6 211 + 12 -0.428 10 
UCP1098 (R) 0.3125 46 + 6 78 + 4 -1.241 5 
UCP1099 (S) 0.0781 35 + 2 45 + 6 -0.359 10 
TMP 0.3125 23 + 3 77+4 -0.505 >20 
a Measured with 5 minutes pre-incubation of enzyme and inhibitor 
bMeasured with no pre-incubation of enzyme and inhibitor  
 
 
As antibacterial activity is highly dependent on the degree and persistence of the 
blockade of the essential targeted pathway, we investigated the target inhibition profile of 
the enantiomers with DHFR. By comparing enzyme inhibition values using the standard 
incubation of enzyme and inhibitor (5 min)7 with those that did not have the pre-incubation 
step, we attempted to detect differences in the capacity for the enantiomers to quickly for 
a stabled, inhibited complex. The results show an increase in the observed IC50 values 
with the magnitude of increase depending on the specific pairs. For example, the 
dioxolane derivatives (UCP1098/ UCP1099) display on marginal increases in IC50 value 
while the R2-methoxy derivative (UCP1063) shows a more substantial increase in 
observed IC50 (24.4-fold) as well as a more significant difference between the two 
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enantiomers (3.4 vs. 24.4-fold). Overall these experiments suggest that some inhibitors 
require the pre-incubation step in order to form a high affinity complex. 
 
Rates of dissociation of the complexes were also determined for five pairs of 
enantiomers. Dissociation, in which the inhibitors and the enzyme were incubated with 
the enzyme for 18-24 hours prior to activation with the substrate, was determined to 
further understand the stability of the tertiary complex17. The enzymatic reaction, 
measured by the rate of oxidation of NADPH, was monitored over an hour period and the 
differential rate of dissolution of the complex was determined for each enantiomer pair. 
Overall, the target inhibition profile experiments show that inhibitors, UCP1063, 
UCP1079, UCP1080, UCP1098 and UCP1099 appear to form an inhibited complex 
quickly. Furthermore, several inhibitors including UCP1061, UCP1062, UCP1063, 
UCP1079, UCP1097 and UCP1099 have a relatively show rate of dissociation of this 
complex (Table 1 and Figure 11). As effective antibacterial agents must quickly form a 
long-lasting and effective inhibitory complex with the target, these results are promising, 
especially for UCP1063 and UCP1099, as these compounds possess both of these 
characteristics.  
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Figure 11 Dissociation of the inhibitory complex (DfrB:NADPH:PLA) over a 60 minutes 
reaction period following 18 hours of incubation. Differences of dissociation rates indicate 
the differences in stability of the complex attributing to antimicrobial effects.  
 
The potential of the enantiomers to possess differential affinity to an unknown second 
target, resulting to increased antibacterial activity, was probed by end-product rescue 
experiments. As the PLAs are inhibitors of the folic acid biosynthetic pathway, which is 
primarily responsible for the production of deoxythymidine monophosphate, rescue 
experiments were conducted to measure MIC values in the presence of excess thymidine 
(Thy+)18. With 10 μg/mL thymidine, MIC values rose to 5-10 μg/mL indicating on-target 
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activity (Table 1). Thy+ MICs that increase less than 8-fold indicates inhibitory activity 
against a target outside of the folic acid cycle. It is not believed that differences in 
enantiomer activity are due to preferential permeability or efflux, as the physiochemical 
properties of the enantiomers are identical16. 
 
2.3b Structural Studies of an Enantio-pure Pair of Inhibitors 
Crystal structures of DfrB complexed with UCP1061 and UCP1062 reveal unexpected 
and significant differences in the binding mode of the two enantiomers with the enzyme. 
After collection of diffraction data (2.69Å and 2.16Å, respectively) the structures were 
determined by molecular replacement with probe molecule PDB ID 3F0Q10. The structure 
of DfrB:NADPH:UCP1062 is identical to the previously reported structure of S. aureus 
DHFR crystallized with its racemic counter part, UCP1006 (Figure 6)7, suggesting that the 
ternary complex with UCP1062 is more thermodynamically stable complex relative to that 
formed with UCP1061. In the structure of DfrB:NADPH:UCP1062, the enzyme binds the 
extended, β-form of NADPH with a number of key van der Waals contacts between the 
inhibitor and the nicotinamide ring of the cofactor involving each of the four carbons of the 
propargyl linker. In addition to the expected interactions between the diaminopyrimidine 
and residues Asp 27, Val 31 and Leu 28 there are contacted between Leu 28, Ile 50, met 
42 and Leu 54 and the hydrophobic pyridine C-ring favors a coplanar arrangement with 
its joined B-ring (Figure12).  
 
The structure of DfrB:NADPH:UCP1061 reveals a major change in both biphenyl binding 
mode and NADPH cofactor binding where the nicotinamide and ribose rings are 
displaced approximately 3.2Å relative to the standard β-NADPH anomer, a result of the 
puckering of the internal phosphates. In this alternative NADPH structure, as seen in the 
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DfrB:NADPH:UCP1070 structure (Figure 9), the caboxamide forms three water-mediated 
hydrogen bonds to the protein rather than the direct hydrogen bonding interactions with 
Ala 7 (Figure 12b). Despite this displacement, the pyrophosphate tail and adenine 
nucleotide are ultimately placed in the identical binding positions14,15. The significance and 
impact this alternative NADPH is discussed in-depth in Section 2.5.  
 
Figure 12 Crystal structures of wild-type S. aureus DHFR (DfrB) bound to cofactor and 
inhibitors: a) compound UCP1062 (teal) and β-NADPH (salmon) or b) compounds 1061 
(purple) and α-NADPH NADPH (orange). Panel C shows a superposition of the two 
structures. 
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Aside from NADPH, Ile 50 undergoes a second significant conformation change in order 
to accommodate the differing enatiomeric preference. Both a 1.5Å displacement of the 
protein backbone and a change of the side chain rotamer of Ile 50 are necessary to 
accommodate the R-configuration of UCP1061. Therefore, when a racemic mixture of the 
ligand is present, the protein would need to undergo a significant conformation change to 
binding the opposite enantiomer. 
 
Evaluation of 5 pairs of enantiopure PLAs in the effort to further optimize the scaffold 
towards efficacious inhibition of S. aureus emphasizes the importance of substitutions, 
specifically the stereochemistry of substitutions at this propargylic position. Biochemical, 
microbiological and structural analysis indicates differences in binding orientations, 
cofactor recruitment, and the stability of the inhibitory complex; each contributing to 
differing antibacterial activities between enantiomer pairs. This work highlights the 
importance of pursuing enantiomerically pure inhibitors as we continue to modify and 
optimize the series. 
 
2.4 Charged Propargyl-linked Antifolates  
Classical antifolates, such as methotrexate and pemetrexed, mimic substrate structure 
and exhibit sub-nanomolar affinity for eukaryotic and prokaryotic DHFR enzymes. 
However, these compounds lack bacterial efficacy due to insufficient permeability into the 
cell, a result of its highly charged nature20-22. These classical antifolates, marketed as 
potent chemotherapeutic, are actively transported into eukaryotic cells through folic acid 
transporters, but because bacterial cells produce folic acid de novo, they do not possess 
the mechanisms required for uptake. Methotrexate’s high affinity for the enzyme is 
credited to the ionic interactions formed between the enzyme and the glutamate tail of the 
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compounds23 (Figure 13). Similarly, the superior activity of the pyridine PLAs over TMP is 
attributed the increase of interactions between the inhibitor and enzyme. However, 
building onto the PLA scaffold by the addition of a C-ring carboxylate to mimic that of 
methotrexate and folic acid to pick up ionic interactions with an active site argenine 
residue and further optimize the inhibitors.  
 
Figure 13 SaDHFR complexed with β-NADPH and a) folate (blue, PDB:3FRD) and 
UCP1061 (magenta) a pyridine substituted and b) UCP1191(light blue) a carboxylate 
substituted PLA. The ionic interaction acquired through the addition of the C-ring 
carboxylate is highlighted in panel B. 
 
In addition to the acquisition of a hydrogen bonding interaction between the inhibitor and 
the protein, the introduction of charged character to the PLAs is expected to increase 
permeability of the compounds into gram-negative bacteria, namely Escherichia coli and 
Klebsiella pneumonia. The absence of PLA activity against these pathogenic strains is 
attributed to the lack of passive diffusion through the thick peptidoglycan outer membrane 
of these pathogenic species8. Fluoroquinolones, specifically ciprofloxacin, and 
tetracyclines have potent activity against these gram-negative bacteria, their ability to 
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penetrate the membranes and accumulate in the cell is attributed to the zwitterion 
character of a single carboxylic acid23. In order to explore these hypotheses, we 
developed a series of compounds that features a phenyl C-ring with carboxylic acid 
substitution and varying B-ring and propargylic substitutions (Figure 14). While the 
addition of zwitterionic character did not increase activity in gram-negative species, with 
the most potent compounds having a MIC of 10 µg/mL24, ventures to improve the protein-
inhibitor interactions were successful. 
 
2.4a Biological Evaluation of COOH-PLAs against S. aureus 
UCP1106, a para- carboxylate substituted PLA with an R1-methoxy, was the first 
compound of the series to be evaluated revealing very promising cellular and enzymatic 
activity in wild-type S. aureus. The role of the carboxylate placement was explored and 
optimized within the series, by synthesizing and evaluating the ortho- (UCP1133) and 
meta- (UCP1124) substituted analogs (Figure 14, Table 2). Migration of the carboxylate 
from the para- position to both the meta- and ortho- positions resulted in significant, 5- 
and 12- fold decrease in cellular activity, with a rise in MIC from 0.0195 µg/mL to 0.625 
µg/mL and >20 µg/mL, respectively.  
 
Figure 14 Structures of PLAs to determine COOH placement SAR 
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The series of p-carboxylate compounds was further expanded with various B-ring and 
propargylic substitutions. Moving the methoxy from the R1 (UCP1106) to the R2  
(UCP1175) position resulted in a three-fold increase in enzymatic activity against 
SaDHFR, from 32 to 11 nM, respectively. This modification also resulted in a 2-fold 
decrease in MIC from 0.0195 to 0.0098 µg/mL. Meanwhile, the placement of the methoxy 
group had little effect on activity against HuDHFR (Table 2)24, 25.  
 
Evaluation of enatiopure PLAs is crucial for the continued optimization of the series of 
COOH-PLAs, as the methyl configuration is important not only for its noncovalent 
interactions but also for directing the binding position of the biaryl system16. The S-
enantiomer of UCP1106 (UCP1164) exhibits no significant change in IC50, unlike the R-
enantiomer (UCP1163) that has a 7-fold loss in enzymatic activity and 16-fold loss in 
cellular activity with MICs of 0.625 µg/mL. The R2- methoxy enantiomers, inhibitors 
UCP1172 (R) and UCP1173 (S), maintain similar activity as their hydrogen-substituted 
counterpart (UCP1175), with MICs of 0.0098 µg/mL and IC50 values of 8.9 nM, 14 nM and 
11 nM, respectively. Similarly, UCP1205 and UCP1206 and the racemate UCP1191 with  
a constrained dioxolane ring at the R2 and R3 positions are nearly distinguishable by 
activites with MICs of 0.0098 µg/mL and IC50 values of 18nM,17nM and 10nM, 
respectively (Figure 15, Table 2).  
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Figure 15 Structures of the Evaluated PLA Compounds  
Table 2 Cellular and Ezymatic Evaluation of COOH-PLAs  
Inhibitor S. aureus 
 MIC (µg/mL) 
SaDHFR IC50 
(nM) 
Hu DHFR 
IC50 (μM) 
UCP1106 0.0195 32 + 0.001 870 + 30 
UCP1124 >20 359 + 0.03 10,800 + 200 
UCP1133 0.625 157 + 0.008 1,580 + 60 
UCP1163 0.625 37 + 2 1,630 + 90 
UCP1164 0.0391 216 + 20 1,960 + 0.05 
UCP1172 0.0098 9  + 0.7 1,020 + 0.06 
UCP1173 0.0098 14 + 1 1,700 + 100 
UCP1175 0.0098 11.0 + 0.6 690 + 40 
UCP1191 0.0098 10.0 + 0.2 ND 
UCP1205 0.0098 18 + 3 ND 
UCP1206 0.0098 17 + 2 ND 
TMP 0.3125 23 + 3 198.2 + 0.1 
MTX >40 ND ND 
 
p-COOH PLAs exhibits potent cellular and enzymatic activity against S. aureus MICs 
values ranging from 0.0098-0.625 µg/mL (Table 2). Furthermore, inhibitors UCP1175, 
UCP1172 and UCP1173 were shown to be bactericidal with minimum bactericidal 
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concentrations (MBC) less than four times the MIC24,26. While this class of compounds 
does not overcome barriers in gram-negative activity, as they were designed to, the 
compounds are promising candidates for development against gram-positive species.  
   
2.4b Structural Analysis of Charged PLAs in S. aureus DHFR 
In order to understand the mechanisms of action and validate design principles, the X-ray 
crystal structures of S. aureus DHFR bound to a panel of COOH-PLAs were determined. 
Crystals of SaDHFR complexed with NADPH and inhibitors UCP1106, UCP1175 and 
UCP1191 produced diffraction amplitudes to 2.24 Å, 1.81 Å and 1.88Å, respectively. All 
structures were solved using molecular replacement using: PDB 3F0Q19 as a model. All 
structures feature the COOH-PLA bound with full or partial occupancy of β-NADPH and 
its alternative α-anomer in its cyclized, ring-closed tautomer. In all structures, the 
diaminopyrimidine of the antifolate forms conserved hydrogen bonds with Asp 27 and 
backbone carbonyl oxygen atoms from Leu 5 and Phe 92 (Figure 16). The propargyl 
linker and benzodioxalane B-ring form hydrophobic interactions with Phe 92, Thr 46, Leu 
28, Val 31 and Ile 50. The phenyl C-ring is positioned well to form hydrophobic 
interactions with Leu 54, Val 31 and Leu 28. 
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Figure 16 Active site views of a) UCP1106 and b) UCP1175 highlighting water network 
formed between the inhibitor and enzyme and comparisons of c) the binding position of 
the hydrogen substituted PLAs and d) the contrasting NADPH conformations 
 
The UCP1106 complex shows the coordination of a water molecule between the 
carboxylic acid (2.1Å) and the side chain of Arg 57 (2.8Å)  (Figure 16a). Conversely, the 
structure with compound UCP1175 exhibits an extensive water network involving at least 
four water molecules, coordinated between the carboxylic acid and both amino groups on 
Arg 57 as well as the carbonyl oxygen of Leu 28.  The water network expands to include 
additional hydrogen bonding interactions with the side chains of Asn 56 and Thr 36 
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(Figure 16b). The binding modes of the inhibitor represent significant differences in the 
crystal structures with inhibitors UCP1106, UCP1175 and UCP1191. The methoxy 
substitution in the R1 position of compound UCP1106 shifts the biaryl system 1.2 Å 
toward the solvent exposed surface, which is likely responsible for differences in the 
observed water networks between compounds UCP1106 and UCP1175 (Figure 16c).   
 
Crystal structures of UCP1191, reveals a potential basis for the increased cellular and 
enzymatic potency of propargylic substituted PLA-COOH compounds. Importantly, the 
carboxylate moiety forms one direct ionic bond to Arg 57 and one water-mediated 
hydrogen bond to Arg 57 and Lys 32 (Figure 17), as opposed to the water network 
formed with between the carboxylate and Arg 57 in both UCP1106 and UCP1175 
structures. This direct interaction is believed to occur in all of the propargyl substituted 
PLA-COOHs, explaining the increased activities of UCP1172, UCP1173, UCP1205 and 
UCP1206. Conversely, the R1-methoxy substitution of UCP1163 and UCP1164 is 
believed to dictate its binding location, where substitutions of the propargylic position are 
not likely push the biphenyl system closer to Arg 57.  
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Figure 17 Binding of UCP1191 in the active site highlighting the a) water mediated 
interaction with Arg 57 and b) direct hydrogen bonding interactions. 
 
Both UCP1106 and UCP1175 structures feature the cyclized α-anomer of NADPH in the 
cofactor-binding site. The structure with DfrB:NADPH:UCP1106 shows 40% occupancy 
and that with DfrB:NADPH:UCP1175 shows 100% occupancy of the tricyclic α-NADPH 
anomer. DfrB:NADPH:UCP1191 contains 100% occupation of the extended β-NADPH 
cofactor. This switch in NADPH identity, discussed in Section 2.5, is believed to be a 
result of the binding position of the acetylene linker, dictated the various propargylic and 
B-/ C-ring substitutions.  
 
Allowing the incorporation of negatively charged functionality to the PLA scaffold and the 
addition of key contacts with the enzyme afforded some of the most potent and selective 
activity seen within the class of antifolates. Structural studies reveal how the incorporation 
of a carboxylate moiety can mimic one of the key interactions common to classical 
antifolates. Specifically, it was demonstrated that modifications to B-ring and propargylic 
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substitutions allow for the optimization of inhibitor binding. Optimization within this series 
of compounds resulted in the displacement of a water network and the formation a strong, 
direct ionic interaction with the side chain of Arg 57. As Arg 57 is conserved in pathogenic 
DHFR enzymes, specifically TMPS and TMPR S. aureus associated enzymes; it is likely 
that the interactions between these PLAs with this residue will also be conserved; this 
point is an important distinction that will be highlighted in Chapters 4 and 5.  
 
2.5 Role of NADPH in PLA Binding and Activity 
Crystallographic studies of propargyl-linked antifolates with S. aureus DHFR revealed an 
unexpected, novel NADPH configuration. This phenomenon was first observed in a series 
of wild-type and mutant crystal structures with a panel of first generation PLAs14,15. 
Initially, this alternative NADPH was believed to be β-NADPH bound in a novel 
conformation, however further analysis has revealed that the change is actually a 
consequence of a switch in configuration at the anomeric carbon of the nicotinamide 
ribose to produce the α-form. NADPH is known to exist in equilibrium between the two 
anomers, with a distribution of approximately 1.5 % α- and 98.5% β-form27. The β- to α- 
anomerization requires a reversible ring opening, ring-closing mechanism (Figure 18). 
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Figure 18 The mechanism of the reversible, acid catalyzed β- to α-NADPH 
anomerization followed by the irreversible tautamerization. 
 
 Upon additional scrutiny of the crystal structures and their electron density maps, it was 
discovered that the α-NAPDH anomer actually exists in its cyclized, closed tautomer state 
(Figure 18, 19). This additional step results in the formation of a covalent bond (Figure 
18) that requires the precursory β- to α- anomerization to occur in order for the 
nicotinamide and ribose alcohol to be on the same plane for reaction28,29. However, 
biochemical evaluations show that tNADPH is neither an active cofactor nor an inhibitor of 
DHFR, as enzymatic assays with the purified tricyclic NADPH have an IC50 of 111 +6 uM. 
While the source of the tricyclic NADPH is unknown, it is believed that the protein 
facilitates and stabilizes the condensed α-NADPH configuration, which is believed to be a 
transition state for the transformation of tricyclic-NADPH29. 
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Figure 19 Difference density (dark blue) in the structure of DfrB:NADPH:UCP1061 
indicates that alpha NADPH anomer (purple) exists in the closed ring tautomer state 
(magenta). Moving the ribose alcohol to fit the difference density resulted in the ring 
closure, capturing the rigid NADPH tautomer. 
 
In the structures featuring the tNADPH, the nicotinamide ring is displaced 2.5Å for amine 
and 4.5Å for the carboxyl atom compared to its β-NADPH counterpart. The displaced 
nicotinamide ring coordinates three water molecules between the amide and the 
backbone of Phe 92, Ile 14 and Ala 7, whereas the nicotinamide amide of β-NADPH 
forms direct hydrogen bonding interactions with Ala 7 (Figure 20). Additionally, the 
alternative anomer displaces a water molecule coordinated between the nicotinamide 
phosphate of β-NADPH and the sidechain of Asn 18, which becomes occupied by the 
ribose moiety of α-NADPH stabilizing the condensed NADPH conformation. Cyclization 
results in the slight displacement of a water coordinated between the ribose and side 
chains of Asn 18 and Asp 120, however the displaced ribose gains a direct interaction 
with Asn 18 (Figure 21).   
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Figure 20 The interactions of the nicotinamide rings of both beta- and tricyclic-NADPH 
with DfrB active site. The beta-NADPH (blue) forms two direct hydrogen bonding 
interactions with Ala 7 and the tricyclic-NADPH (purple) coordinates three water 
molecules between Ala 7, Phe 92 and Ile 14 (not shown). 
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Figure 21 The interactions between a) beta-NADPH (green) and b) tricyclic-NADPH 
(purple) ribose and ribose phosphate and DfrB. The waters and hydrogen bonding 
interactions associated with the extended B-NADPH are shown in green and those 
associated with tricyclic NADPH are shown in black. Panel C shows the superposition of 
the two structures, highlighting the significant structural changes that the protein must 
undergo to accommodate the two NADPH anomers. 
 
 
The transformation from the extended β-NADPH to the condensed alpha and tNADPH 
conformation is possible by the flexibility and plasticity of the internal NADPH phosphates. 
These phosphates reorient to form a hydrogen-bonding interaction with Gln 95 backbone 
instead of a 2.6Å hydrogen bond with a water networked between the sidechain of Asn 18 
and an Asp 120 coordinated water of β-NADPH. This reorientation maintains a 2.6Å 
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hydrogen bonding interaction with Thr 46 and Thr 96, although the latter interacts with the 
phosphate through a different plane (Figure 22). 
 
 
Figure 22 The interaction of the internal phosphates of beta- (green) and tricyclic- 
(purple) NADPH, the bonding interactions are shown in green and black, respectively. 
The binding interaction between the pterin ring and the protein are conserved in both 
beta- and tricyclic NADPH 
 
Biochemical (Section 2.3, Figure 11) and structural analysis indicate that both tricyclic 
and beta-NADPH can form stable ternary structures with the DfrB and inhibitors, 
specifically UCP1061 and UCP1062. Interestingly, a crystal structure of UCP1006, the 
racemic mix of UCP1061 and UCP1062, exclusively selects beta-NADPH and its 
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corresponding enantiomer, potentially indicating preference for the beta-anomer complex. 
While the exact mechanism by which the alternate cofactor is recruited to the 
protein:inhibitor complex is still unknown, the binding of the inhibitor, influenced by both 
mutations in DfrB and the structure of the inhibitor of itself, appear to influence this 
selection. For example, UCP1061 and UCP1062 differ by a single stereogenic center and 
recruit 100% occupancy of the tricyclic-NADPH and beta-NADPH, respectively. In the 
structure with UCP1061, where α-NADPH is primarily stabilized by van der Waals 
interactions by the projection of the methyl group inhibitor into a pocket formed by Phe 92 
and Thr 46. However, one of the water molecules coordinated between the NADPH and 
protein forms a hydrogen bond with the Phe 92 backbone, which forms extensive 
hydrophobic interactions with the acetylene linker (Figure 23).   
 
In addition to the stereogenic steering of the biaryl system, a 1.5Å displacement of the 
acetylene linker is observed, resulting from the position of the RP methyl (Figure 23) with 
the inhibitor whose linker binds nearer to the NADPH biding site UCP1061), correlates to 
the tricyclic NADPH. This shift in the acetylene linker was also observed with the panel of 
COOH-PLA’s whose binding position was attributed to the coordination of waters, or 
direct hydrogen bonding interaction with Arg 57 (Section 2.4). While it is possible that the 
binding position of the acetylene linker is an artifact of the identity of the NADPH present, 
the potent activity and assumed potent binding of the PLAs is assumed to be preferential 
to that of NADPH. 
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Figure 23 The binding of the PLAs, directed by a single stereogenic center, appears to 
influence the recruitment of the NADPH anomers. The distance between the proparyglic 
carbon atoms of UCP1061 (purple) and UCP1062 (green) is 1.5Å.  
 
2.6 Conclusions 
The development of a novel class of antifolates, guided by the acquisition of high-
resolution crystal structures, has resulted in a class of compounds with potent enzymatic 
and cellular activity against S. aureus DHFR. These inhibitors, evolving from 
trimethoprim, retain the 2,4-diaminopyrimidine and linked various benzyl and biaryl 
system through a propargylic acetylene linker. By evaluating the aryl identities of the 
distal and proximal rings on the biaryl system as well as substituents on these rings and 
the propargylic methyl, we can elucidate a structure-activity relationship for scaffold 
optimization. 
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The first identified classes of lead PLA compounds against S. aureus featuring a distal-
pyridine ring were optimized from a series of TMP derivatives and hydrophobic biaryl 
compounds. Not only did the pyridine compounds show an increase in cellular and 
enzymatic activity, the increased solubility gained by the polar character of the pyridine 
was crucial for continued lead development. B-rings and RP substitutions further 
optimized the class and highlighted the important role that the propargylic methyl, the sole 
chiral center of the inhibitor, plays in the activity of the PLAs, therefore a panel of 
enatiomerically pure PLAs were developed and analyzed. 
 
Biological and structural studies of these enantio-pure compounds show that the 
configuration of this chiral center provides essential conformational control of the biaryl 
moiety as well as increases functionality proximal to the cofactor. A noteworthy 
observation is that two enantiomers, containing only a single stereogenic center, drove a 
unique change in the adjacent NADPH binding site, leading to the binding of a modified, 
minor component of the natural cofactor. Continued modifications to the scaffold to try 
and gain ionic interaction with an active site arginine and mimic the binding of the natural 
substrate resulted in the generation of inhibitors further optimized against their target.   By 
understanding the functionality of the stereogenic center and the importance of the 
carboxylate substitution on the distal benzyl ring, compounds that contain both of these 
attributes display a 32-fold increase in cellular potency over TMP as well as show good 
drug-like properties such as solubility and selectivity.  
 
Finally, crystal structures of DfrB bound to cofactor and inhibitor revealed a novel 
configuration of NADPH. While the potential relationship between inhibitors and NADPH 
remains convoluted, the plasticity of the active site to accommodate this novel binding 
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conformation reveals a previously unknown plasticity.  Additionally, the ability of the 
enzyme, inhibitor and tricyclic-NADPH to form a stable inhibitory complex with diminished 
interactions between the nicotinamide ring and acetylene linker 
 
2.7 Acknowledgments 
I would like to acknowledge Eric Scocchera (COOH-PLAs), Dr. Naren G-Dayanadan 
(dioxolanes and pyridines) and Dr. Santosh Keshipeddy (enantiomers) for the synthesis 
of the PLA compounds presented here as well as Dr. Kathleen Frey for the early pyridine 
compound data and Dr. Janet Paulsen and Behnoush Haijan for the expression and 
purification of the human DHFR. I would like to thank Dr. Bruce Donald, Dr. Eric May and 
their students Dr. Pablo Gainza and Jason Pattis for their discussions of NADPH. Finally,  
I would like to acknowledge the beamline staff at Stanford Synchrotron Radiation 
Lightsource (SSRL) and Brookhaven National Lab (BNL) for their assistance with 
crystallography data collection.  
 
 
 
 
 
 
 
 
 
 
 
	 63 
2.8 References 
1. Bolstad, D. B.; Bolstad, E. S. D.; Frey, K. M.; Wright, D. L.; Anderson, A. C. 
Structure-Based Approach to the Development of Potent and Selective Inhibitors of 
Dihydrofolate Reductase from Cryptosporidium Structure-Based Approach to the 
Development of Potent and Selective Inhibitors of Dihydrofolate Reductase from 
Cryptosporidium. J. Med. Chem. 2008, 6839–685. 
2. Anderson, A. C. Two Crystal Structures of Dihydrofolate Reductase-Thymidylate 
Synthase from Cryptosporidium Hominis Reveal Protein-Ligand Interactions Including a 
Structural Basis for Observed Antifolate Resistance. Acta Crystallogr. Sect. F Struct. Biol. 
Cryst. Commun. 2005, 61 (3), 258–262.  
3. Pelphrey, P. M.; Popov, V. M.; Joska, T. M.; Beierlein, J. M.; Bolstad, E. S. D.; 
Fillingham, Y. a.; Wright, D. L.; Anderson, A. C. Highly Efficient Ligands for Dihydrofolate 
Reductase from Cryptosporidium Hominis and Toxoplasma Gondii Inspired by Structural 
Analysis. J. Med. Chem. 2007, 50, 940–950. 
4. Checkley, W.; White, A. C.; Jaganath, D.; Arrowood, M. J.; Chalmers, R. M.; 
Chen, X. M.; Fayer, R.; Griffiths, J. K.; Guerrant, R. L.; Hedstrom, L.; et al. A Review of 
the Global Burden, Novel Diagnostics, Therapeutics, and Vaccine Targets for 
Cryptosporidium. Lancet Infect. Dis. 2015, 15 (1), 85–94. 
5. Toole, T. O.; Henderson, D. a; Bartlett, J. G.; Ascher, M. S.; Eitzen, E.; 
Friedlander, A. M.; Gerberding, J.; Hauer, J.; Hughes, J.; Mcdade, J.; et al. Updated 
Recommendations for Management. JAMA, J. Am. Med. Assoc. 2002, 287 (17), 2236–
2253. 
6. Beierlein, J. M.; Frey, K. M.; Bolstad, D. B.; Pelphrey, P. M.; Joska, T. M.; Smith, 
A. E.; Priestley, N. D.; Wright, D. L.; Anderson, A. C. Synthetic and Crystallographic 
Studies of a New Inhibitor Series Targeting Bacillus Anthracis Dihydrofolate Reductase. J. 
Med. Chem. 2008, 51 (23), 7532–7540. 
7. Viswanathan, K.; Frey, K. M.; Scocchera, E. W.; Martin, B. D.; Swain, P. W.; 
Alverson, J. B.; Priestley, N. D.; Anderson, A. C.; Wright, D. L. Toward New Therapeutics 
for Skin and Soft Tissue Infections: Propargyl-Linked Antifolates Are Potent Inhibitors of 
MRSA and Streptococcus Pyogenes. PLoS One 2012, 7 (2), 1–9. 
8. Lamb, K. M.; Lombardo, M. N.; Alverson, J.; Priestley, N. D.; Wright, D. L.; 
Anderson, A. C. Crystal Structures of Klebsiella Pneumoniae Dihydrofolate Reductase 
Bound to Propargyl-Linked Antifolates Reveal Features for Potency and Selectivity. 
Antimicrob. Agents Chemother. 2014, 58 (12), 7484–7491. 
9. Paulsen, J. L.; Liu, J.; Bolstad, D. B.; Smith, A. E.; Priestley, N. D.; Wright, D. L.; 
Anderson, A. C. In Vitro Biological Activity and Structural Analysis of 2,4-Diamino-5-(2-
Arylpropargyl)pyrimidine Inhibitors of Candida Albicans. Bioorganic Med. Chem. 2009, 17 
(14), 4866–4872. 
10. G-Dayanandan, N.; Paulsen, J. L.; Viswanathan, K.; Keshipeddy, S.; Lombardo, 
M. N.; Zhou, W.; Lamb, K. M.; Sochia, a E.; Alverson, J. B.; Priestley, N. D.; et al. 
Propargyl-Linked Antifolates Are Dual Inhibitors of Candida Albicans and Candida 
Glabrata. J. Med. Chem. 2014, 57 (6), 2643–2656. 
	 64 
11. Chen, F.; Larsen, M. B.; Sánchez, C.; Wiborg, O. The S-Enantiomer of R,S-
Citalopram, Increases Inhibitor Binding to the Human Serotonin Transporter by an 
Allosteric Mechanism. Comparison with Other Serotonin Transporter Inhibitors. Eur. 
Neuropsychopharmacol. 2005, 15, 193–198. 
12. Orr, S. T. M.; Ripp, S. L.; Ballard, T. E.; Henderson, J. L.; Scott, D. O.; Obach, R. 
S.; Sun, H.; Kalgutkar, A. S. Mechanism-Based Inactivation (MBI) of Cytochrome P450 
Enzymes: Structure-Activity Relationships and Discovery Strategies to Mitigate Drug-Drug 
Interaction Risks. J. Med. Chem. 2012, 55 (11), 4896–4933. 
13. Gant, T. G. Using Deuterium in Drug Discovery: Leaving the Label in the Drug. J. 
Med. Chem. 2014, 57 (9), 3595–3611. 
14. Frey, K. M.; Liu, J.; Lombardo, M. N.; Bolstad, D. B.; Wright, D. L.; Anderson, A. 
C. Crystal Structures of Wild-Type and Mutant Methicillin-Resistant Staphylococcus 
Aureus Dihydrofolate Reductase Reveal an Alternate Conformation of NADPH That May 
Be Linked to Trimethoprim Resistance. J. Mol. Biol. 2009, 387 (5), 1298–1308. 
15. Frey, K. M.; Lombardo, M. N.; Wright, D. L.; Anderson, A. C. Towards the 
Understanding of Resistance Mechanisms in Clinically Isolated Trimethoprim-Resistant, 
Methicillin-Resistant Staphylococcus Aureus Dihydrofolate Reductase. J. Struct. Biol. 
2010, 170 (1), 93–97. 
16. Keshipeddy, S.; Reeve, S. M.; Anderson, A. C.; Wright, D. L. Non-Racemic 
Antifolates Stereo-Selectively Recruit Alternate Cofactors and Overcome Resistance in S. 
Aureus. J. Am. Chem. Soc. 2015. 
17. Copeland, R. A.; Pompliano, D. L.; Meek, T. D. Drug – Target Residence Time 
and Its Implications for Lead Optimization. Nature Drug Disc 2006, 5, 730-740. 
18. Koch, A. E.; Burchall, J. J. Reversal of the Antimicrobial Activity of Trimethoprim 
by Thymidine in Commercially Prepared Media. Appl. Environ. Microbiol. 1971, 22 (5), 
812–817. 
19. Frey, K. M.; Georgiev, I.; Donald, B. R.; Anderson, A. C. Predicting Resistance 
Mutations Using Protein Design Algorithms. Proc. Natl. Acad. Sci. U. S. A. 2010, 107 
(31), 13707–13712. 
20. Burchall, J.; Hitchings, G. Inhibitor Binding Analysis of Dihydrofolate Reductases 
from Various Species. Mol. Pharmacol. 1965, 1, 126−136.  
21. Kopytek, S.; Dyer, J.; Knapp, G.; Hu, J. Resistance to methotrexate due to AcrAB-
dependent export from Escherichia coli. Antimicrob. Agents Chemother. 2000, 44, 
3210−3212. 
22. Kruszewska, H.; Zareba, T.; Tyski, S. Antimicrobial activity of selected non-
antibiotics - activity of methotrexate against Staphylococcus aureus strains. Acta Polym. 
Pharm. 2000, 57S, 117−119.  
23. O’Shea, R.; Moser, H. Physicochemical properties of antibacterial compounds: 
implications for drug discovery. J. Med. Chem. 2008, 51, 2871−2878.  
24. Scocchera, E.; Reeve, S. M.; Keshipeddy, S.; Lombardo, M. N.; Hajian, B.; 
Sochia, A. E.; Alverson, J. B.; Priestley, N. D.; Anderson, A. C.; Wright, D. L. Charged 
	 65 
Nonclassical Antifolates with Activity Against Gram-Positive and Gram-Negative 
Pathogens. ACS Med. Chem. Lett. 2016, 7, 692-696. 
25. Lamb, K.; G-Dayanandan, N.; Wright, D.; Anderson, A. Elucidating Features That 
Drive the Design of Selective Antifolates Using Crystal Structures of Human Dihydrofolate 
Reductase. Biochemistry 2013, 52, 7318–7326. 
26. Pankey, G.; Sabath, L. Clinical Relevance of Bacteriostatic versus Bactericidal 
Mechanisms of Action its the Treatment of Gram-Positive Bacterial Infections. Clin. Infect. 
Dis. 2004, 38, 864−870. 
27. Oppenheimer, N. J.; Arnold, L. J.; Kaplan, N. O. A Structure of Pyridine 
Nucleotides in Solution. Proc. Nat. Acad. Sci. USA 1971, 68, 3200-3205 
28. Oppenheimer, N. J.; Kaplan, N. O. Structure of the Primary Acid Rearrangement 
Product of Reduced Nicotinamide Adenine Dinucleotide (NADH). Biochemistry 1974, 13 
(23), 4675–4685. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 66 
Chapter 3 
Protein Design Algorithms Predict Viable Resistance to a Lead PLA 
 
3.1 Computer Algorithms to Predict Drug Resistance 
Mutational resistance is a common mechanism conferring resistance observed in nearly 
every class of antibiotics as well as chemotherapeutics and antivirals. Being able to 
predict mutations in-silico and understand the specific mechanisms in which a target can 
mutate and confer resistance would allow for the development of more successful and 
robust therapeutics. Advancements in computational biology have fostered the 
development of algorithms capable of producing these outcomes. Minimally, a successful 
algorithm would predict resistance mutations that maintain enzyme function while 
reducing inhibitor affinity. However, a more powerful algorithm would also predict 
mutations that maintain the fitness of the pathogen and are therefore likely to be selected 
in vitro or in vivo. Predicting “fit” mutations is a significant challenge because the variables 
that contribute to fitness in an organism are complex and often unknown.  Additionally, a 
successful algorithm would predict novel mutations that are responsive to novel 
compounds. A prospective strategy such as this would be especially effective in the 
discovery of therapeutics for which it is difficult to generate resistant cells in vitro. 
 
Previous attempts to predict mutational drug resistance have been reported. One study 
optimized molecular dynamics and thermodynamic integration calculations to reproduce 
experimentally derived data and therefore computationally predict the effects of mutations 
at two well characterized amino acids on the binding of a small molecule inhibitor to the 
P38α MAP kinase1. Others, focused heavily on HIV proteases, validate combinations of 
various computational methods by correlating their results to obtained in-vitro mutant or 
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clinical data for approved therapeutics. As these studies are retrospective analyses, often 
of known mutations that arise under pressure from known drugs, they do not address the 
problem of prospectively predicting a fit mutation2-4.  
 
3.2 Prediction of resistance mutations by K* in OSPREY 
In this chapter, we report the application of the structure-based protein design algorithm, 
K* in OSPREY, to identify prospective single nucleotide polymorphisms (SNP) that confer 
resistance to UCP1006, Figure 1, a lead PLA. In previous work5, the structure-based K* 
algorithm in the OSPREY protein design suite6,7 was used to predict double mutations in  
S. aureus DHFR that confer resistance to the older generation PLA. Of the top 10 
predicted mutations, all of them contained mutations at Phe 92 and the top 7 contained 
mutations at Val 31, with Val31Tyr prevailing; the remaining three mutations occurred at 
Ile 50. A detailed biochemical and structural analysis of the top three mutations 
(V31Y/F92I, V31Y/F92V and V31Y/F92S) validated K*’s ability to accurately the effect of 
mutations on enzyme fitness and inhibition. 
 
Bacterial DHFR, specifically S. aureus, is an ideal model system for these predictions as 
the development of a single amino acid mutation results in trimethoprim resistance; 
higher levels of resistance are conferred by the accumulation of a second mutation8. As 
we continue to develop PLAs that overcome the molecular mechanisms of resistance to 
TMP9, it would be useful to predict mutations that may arise for this new class of 
antifolates. Using ratios of positive design scores that predict binding of the substrate, 
dihydrofolate, and negative design scores that predict binding of the inhibitor, 
OSPREY/K* identified catalytically competent resistance mutations6,7.  
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The protein design algorithm, K* in OSPREY6, was used to identify mutations 
characterized by single nucleotide polymorphisms (SNPs) that maintain binding to the 
substrate, dihydrofolate, while conferring resistance to the UCP1006 (Figure 1). Nine 
active site residues (Leu 5, Val 6, Leu 20, Leu 28, Val 31, Thr 46, Ile 50, Leu 54 and Phe 
92) were allowed to either maintain their wild type identity or to mutate to a restricted 
group of residues that involve only a single nucleotide polymorphism (Table 1). 
 
K* searches were performed on both the substrate (DHFR:NADPH:dihydrofolate) and 
inhibitor (DHFR:NADPH:UCP1006) ternary complexes. K* scores approximate the 
binding affinity (Ka) and are computed as a ratio of Boltzmann-weighted partition functions 
for rotamer-based conformational ensembles of the bound protein:inhibitor complex, free 
protein and free ligand. Since higher K* scores 
predict greater affinity, the ideal mutation would 
have a high score for DHF and a low or zero 
score for UCP1006. The wild-type sequence was 
ranked 18th with a design ratio of 1.95 x 106 
(Table 1). Mutants that had both (I) higher 
ranking than the wild-type and (II) a good predicted binding affinity to DHF (i.e., positive 
design score) were considered as resistant mutants. Four mutations (V31L, V31I, L5I, 
L5V) exhibiting high ratios for the scores representing positive (binding to DHF) and 
negative design (binding to inhibitor) are shown in Table 2. 
 
 
 
 
N
N
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Figure 1 Structure of UCP1006 
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Table 1 K* Rankings by Positive/Negative Design Ratio 
K* Rank 
Single 
Nucleotide 
Mutation 
Substrate Positive 
design K* Score 
Negative design 
K* Score 
Ratio: positive / 
negative design 
1 V31L 2.16E+41 3.04E+19 7.11E+21 
2 V31I 4.87E+36 8.18E+14 5.95E+21 
3 L5I 6.06E+39 3.54E+24 1.71E+15 
4 L5V 4.01E+44 3.44E+30 1.16E+14 
5 L54R 6.31E+43 1.60E+30 3.94E+13 
6 L20F 6.06E+20 1.75E+07 3.46E+13 
7 V31D 1.54E+41 5.65E+32 2.72E+08 
8 L5Q 2.84E+44 1.20E+36 2.36E+08 
9 V31A 7.32E+40 7.86E+33 9.31E+06 
10 V6G 3.92E+42 4.27E+35 9.18E+06 
11 I50L 5.18E+38 5.69E+31 9.10E+06 
12 F92S 2.09E+43 2.52E+36 8.32E+06 
13 L54Q 2.62E+42 3.21E+35 8.14E+06 
14 V31G 2.64E+40 3.38E+33 7.80E+06 
15 T46A 2.88E+42 5.27E+35 5.46E+06 
16 V61 1.10E+43 4.01E+36 2.75E+06 
17 L28M 3.27E+42 1.58E+36 2.07E+06 
18 WT 7.16E+42 3.66E+36 1.96E+06 
19 T46S 4.93E+42 3.46E+36 1.42E+06 
20 L28F 2.25E+42 1.73E+36 1.30E+06 
21 L28W 1.29E+43 1.01E+37 1.28E+06 
22 L20S 3.57E+41 2.95E+35 1.21E+06 
23 L20I 3.04E+42 2.94E+35 1.03E+06 
24 L20V 7.43E+41 7.40E+35 1.01E+06 
25 V6A 4.71E+42 6.07E+36 7.76E+05 
26 L54V 1.46E+41 2.68E+35 5.44E+05 
27 L28S 1.34E+41 3.74E+35 3.59E+05 
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28 V6D 1.18E+43 6.05E+37 1.95E+05 
29 V6L 7.26E+42 6.47E+37 1.12E+05 
30 F92V 8.18E+40 2.80E+36 2.29E+04 
31 I50V 2.49E+42 1.74E+38 1.43E+04 
32 L28V 3.19E+39 2.37E+35 1.35E+04 
33 F92I 8.91E+40 8.48E+36 1.05E+04 
34 F92C 1.02E+40 5.37E+36 1.90E+03 
35 I50S 3.07E+41 2.37E+38 1.30E+03 
36 I50T 1.11E+42 9.85E+38 1.13E+03 
37 I50N 6.81E+41 1.53E+39 4.46E+02 
38 I50M 1.00E+40 7.50E+37 1.33E+02 
39 F92L 4.02E+37 4.20E+36 9.59E+00 
40 L5R 4.21E+34 4.27E+35 9.88E-02 
41 T46I 5.05E+36 2.25E+42 2.25E-06 
42 V6F 0.00E+00 2.94E+36 0.00E+00 
43 V31F 0.00E+00 8.69E-11 0.00E+00 
44 T46R 0.00E+00 0.00E+00 0.00E+00 
45 T56K 0.00E+00 1.14E+14 0.00E+00 
46 F92Y 0.00E+00 3.10E+32 0.00E+00 
47 I50F 0.00E+00 3.37E+35 0.00E+00 
 
3.3 Biochemical and Structural Evaluation of K* Predicted Mutants 
To validate the positive and negative design results from K*, site-directed 
mutagenesis was used to create the top four ranked mutant DHFR enzymes: Sa(V31L), 
Sa(V31I), Sa(L5I), and Sa(L5V). Michaelis-Menten kinetics (Table 2) reveal that the 
enzymes maintain their catalytically competency with only minor losses in kcat/KM. The 
activity of the mutant enzymes validates the success of the positive design component of 
the computational search, meanwhile drastically decreased activity of the inhibitor against 
the mutant enzyme validates the negative design component. Resistance, measured by 
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loss in Ki, ranged from 2-fold to 58-fold, with the top-ranked mutants (V31L and V31I) 
conferring the greatest level of resistance. In fact, K* accurately ranked the mutations as 
their experimental ratio of inhibition constants correlates with their K* design ratio. 
 
Table 2 Characterization of wild-type and mutant enzymes 
Enzyme K* Ratio Rank K* design ratio kcat/KM 
Fold Lossb 
(Kimut/Kiwt) 
UCP1006 
Sa (wt) 18 1.96 E+06 6.1 ± 0.3 n/a 
Sa (V31L) 1 7.11 E+21 1.60 ± 0.06 58 
Sa (V31I) 2 5.95 E+21 1.74 ± 0.07 36 
Sa (L5I) 3 1.71 E+15 2.24  ± 0.1 4.4 
Sa (L5V) 4 1.16 E+14 1.8  ± 0.1 1.9 
 
 
The lowest energy conformations of the top-ranked mutations, SaV31L and SaV31I, were 
compared to the crystal structure of wild-type SaDHFR:NADPH:UCP1006 to understand 
the basis of the resistance prediction9. Carbons Cδ1 and Cδ2 in Leu 31 are predicted to 
displace Phe 92, most likely to avoid steric hindrance with the phenyl side chain (Figures 
2 and 3). In addition, these carbons are observed to sterically interfere with the pyrimidine 
ring, displacing it from its corresponding position in the wild-type structure. Both of these 
steric interactions are expected to significantly weaken inhibitor binding. 
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Figure 2 Comparison of the structures of wild-type SaDHFR bound to NADPH and 
UCP1006 (PDB ID: 3SGY, blue) with the K*-predicted lowest-energy structure of 
SaDHFR (V31L) (yellow). All residues allowed to be flexible and to mutate during the K* 
prediction are shown in yellow stick form. The cofactor, NADPH, is shown in green. 
 
 
Figure 3 Computationally-predicted effect of the V31L mutation on inhibitor binding.   A) 
the wild-type S. aureus DHFR:inhibitor complex  (shown in blue) and B) the 
computationally predicted model of the mutant V31L in complex with the inhibitor (in 
which the mutant is shown in magenta and the complex is shown in blue).  In addition to 
V31 and the inhibitor, F92 is also shown in a stick model, while the remainder of the 
protein is shown in ribbon form.   
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3.4 Selection of UCP1006R Mutants  
3.4a Microbiological Evaluation of Generated Mutants 
In order to show the application of these predictions to a living pathogen, UCP1006R 
MRSA strains were generated and selected by the bacteria under pressure from 
UCP1006 and probed for mutations in the endogenous DHFR (dfrB). A first round of 
selection revealed a single F98Y mutation. F98Y (a TTT to TAT transversion mutation), a 
mutation that has been clinically identified as a mechanism that S. aureus DHFR confers 
resistance to TMP, has a resistance frequency of 1.21 x 10-12. The F98Y strain was then 
exposed to a second round of mutant selection experiments. Five of the generated nine 
colonies of surviving bacteria yielded the computationally predicted V31L mutation (a GTT 
to CTT transversion mutation). An overall frequency of 7.56 x 10-24 reflects the step-wise 
mechanisms in which the mutations developed. One of the nine colonies yielded V31G 
(14th in the ranked list, with a 10-fold increase in the K* ratio over the wildtype) and the 
remaining three colonies possessed only F98Y. Both the single F98Y and double 
V31L/F98Y mutant strains were characterized to evaluate antimicrobial susceptibility and 
relative fitness. Trimethoprim, whose resistance profile includes the F98Y mutation, was 
included as a reference (Table 3). A comprehensive evaluation of all mutant strains 
generated in these and additional selection experiments are characterized in Chapter 4. 
 
Table 3 Characterization of Strain Susceptibility and Fitness 
Strain 
MIC UCP1006 
(µg/mL)(fold loss) 
MIC TMP (µg/mL) 
(fold loss) 
Relative 
Fitness 
Doubling Time 
(min) 
Wild-type 0.0781 0.3123 1 22.5 
F98Y 2.5 (32) 10 (32) 0.98 23.2 
V31L, F98Y 20 (256) 40 (128) 0.86 25.4 
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UCP1006 and TMP have MIC values of 2.5 µg/mL and 10 µg/mL for the F98Y strain, 
respectively, representing a 32-fold loss when compared with the wild-type ATCC 43300 
strain. The addition of the V31L mutation confers an additional 8-fold loss for UCP1006 
and 4-fold loss for TMP, resulting in total 256- and 128-fold losses, respectively. As 
observed previously, the Sa(F98Y) DHFR mutation does not reduce the fitness of the 
strain10,11. The presence of the V31L/F98Y mutation reported here results in minimal (14 
%) loss of fitness, as measured by a pair-wise fitness assay. Log-phase cell growth was 
minimally affected by the presence of the single F98Y or double V31L/F98Y mutation with 
doubling times at 22.5 minutes for the wild-type strain and 23.2 and 25.4 minutes for the 
mutants, respectively. 
 
3.4b Biochemical Evaluation of Generated Mutants 
In order to understand why the V31L mutation arises only in the background of the F98Y 
mutation, we examined detailed inhibition and kinetic data for the enzymes. Here, we also 
included the F98Y mutation and data for trimethoprim as a comparator. The Sa(F98Y) 
mutation has more pronounced effects on trimethoprim, resulting in 38- and 5-fold losses 
in Ki against trimethoprim and UCP1006, respectively. However, the Sa(V31L) mutation 
affects UCP1006 more significantly, resulting in 15- and 60-fold losses in Ki against 
trimethoprim and UCP1006 (Table 4). The Sa(V31L,F98Y) double mutant clearly confers 
much greater resistance with a 148-fold loss in Ki for trimethoprim and an 189-fold loss in 
Ki for UCP1006. 
 
Michaelis-Menten constants, determined for each of the enzymes (Table 4), reveals a 
compensatory relationship between the mutations. The KM value for DHF is reduced from 
the wild-type value (17.5 μM) by 2-fold for Sa(F98Y)DHFR to 8.4 μM while the same 
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value for Sa(V31L) DHFR is increased by 2.4-fold to 42.9 μM. In combination, the 
Sa(V31L/F98Y) DHFR restores the KM for DHF to 4.1 μM.  Interestingly, the KM value for 
NADPH for Sa(F98Y) increases to 56.8 μM from the wild-type value of 32.6 μM and the 
KM value for NADPH in Sa(V31L) decreases to 15.6 μM. The double mutant maintains the 
decreased KM of Sa(V31L) and has an overall lower KM relative to wild-type at 22.3 μM. 
Taken together, the data show that while F98Y and V31L negatively affect NADPH and 
DHF, respectively, the two mutations in combination restore the KM values to wild-type 
levels. Additionally, the kcat/KM value for the double mutant is increased to 10.9 μM-1. 
 
Table 4: Characterization of MRSA Generated Mutant Enzymes 
 
DHFR 
TMP 
Ki, nM 
UCP1006 
Ki, nM 
DHF 
KM, μM 
NADPH 
KM, μM 
kcat kcat/KM 
WT 3.5 ± 0.5 2.8 ± 0.2 17.5 ± 2 32.6 ± 4 106.9 ± 2 6.1 ± 0.3 
F98Y 131 ± 4 13 ± 1 8.4 ± 0.7 56.8 ± 5 44.7 ± 0.4 5.33 ± 0.08 
V31L 54 ± 2 170 ± 20 42.9 ± 3 15.6 ± 3 68.8 ± 2 1.60 ± 0.06 
V31L, F98Y 520 ± 30 530 ± 30 4.1 ± 0.8 22.3 ± 2 44.8 ± 2 10.9 ± 0.8 
 
 
3.5 Structural Analysis of Sa (V31L, F98Y) DHFR 
The data in Tables 2 and 4 indicate that the mutations have a direct influence on 
substrate and cofactor binding as well as inhibitor potency. In order to understand the 
structural effects of the mutations, we determined a crystal structure of the double mutant 
enzyme.  Crystals of Sa (V31L, F98Y) DHFR produced diffraction amplitudes to 2.1 Å 
when co-crystallized with NADPH and a propargyl-linked antifolate that is structurally 
similar to UCP1006. The structure was solved using Fourier methods based on the model 
of the single mutant Sa(F98Y) bound to NADPH and a propargyl-linked antifolate (PDB 
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ID:3F0U)12.  The Sa(V31L, F98Y) structure features the standard extended form of 
NADPH but lacks the PLA present during co-crystallization. 
 
Comparisons of the Sa (V31L, F98Y) structure with the structure of wild-type enzyme 
bound to UCP1006 reveal a structural basis of resistance indicated by significant 
conformational changes induced by the presence of the two mutations. The most 
significant amino acid reorientations are observed between Phe 92, Val 31 and the 
binding site of the diaminopyrimidine moiety of UCP1006. The major change centers on 
Leu 31 that projects 2.0 Å further into the active site than the wild-type Val 31 residue, 
resulting in a corresponding 2.3 Å shift in Phe 92 into the active site and 1.4 Å shift of the 
backbone carbonyl (Figure 2a).  This new Phe 92 orientation restricts the side chain from 
adopting the position needed for ligand binding and disrupts stabilizing hydrophobic 
interactions with the acetylene linker.  The shift of the Phe 92 carbonyl also results in the 
loss of a hydrogen bond to the 4-amino group of the pyrimidine. Additionally, Leu 31 is 
2.2 Å from the 6-ethyl substituent of the diaminopyrimidine, indicating potential repulsive 
steric interactions. 
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Figure 4 Crystal structures of the wild-type and mutant enzymes show conformational 
changes at Phe 92 and His 30. a) Superposition of the structures of 
Sa(wt):NADPH:UCP1006 from PDB ID: 3SGY (blue) with Sa(V31L,F98Y):NADPH 
(magenta) 
 
 
Figure 4 Crystal structures of the wild-type and mutant enzymes show conformational 
changes at Phe 92 and His 30. b) Superposition of the structures of 
Sa(wt):NADPH:UCP1006 from PDB ID 3SGY (blue) with Sa(F98Y):NADPH (yellow) and 
Sa(V31L/F98Y):NADPH (magenta). 
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Furthermore, the B-helix, adjacent to the active site and possessing critical amino acids 
for ligand binding, shifts 0.4 Å away from the active site. Distances between the ligand 
and amino acids Asn 25, Asp 27, His 30 and Leu 34 are increased by 0.4 Å, 
concomitantly reducing hydrogen bonding and van der Waals interactions essential for 
stability and ligand binding. Moreover, the shift in the B-helix results in a 1.1 Å shift in the 
imidazole ring of His 30. The shifted His 30 side chain extends the binding site, allowing 
for a glycerol molecule to displace a water molecule that typically provides stabilizing 
hydrogen bonds between the pyrimidine amino group of UCP1006 and the His 30 
imidazole (Figure 5).  A similar disruption of the water network has been previously 
shown in a crystal structure of the clinically observed resistance mutant Sa (H30N, F98Y) 
with NADPH and a propargyl-linked antifolate13. In combination, the observations for Phe 
92, Leu 31 and the B-helix explain the lower affinity of UCP1006 for the mutant enzyme. 
 
The Sa(V31L, F98Y) enzyme maintains catalytic competency. Comparisons of the 
Sa(V31L/F98Y) structure with wild-type Sa/NADPH/DHF (PDB ID: 3FRD)14 indicates that 
a shift in the Phe 92 peptide carbonyl would have little or no effect on DHF binding or 
turnover since there are no direct interactions between the two groups. Any minor steric 
interactions between Phe 92 and the pterin ring of DHF may be compensated by the 
additional interactions in the glutamate tail that remain undisturbed. 
 
In order to verify which structural effects result from the presence of the mutations and 
which result from enzyme lacking a bound ligand, we determined the structure of 
Sa(F98Y)DHFR bound only to NADPH. Comparisons of the structures of binary 
Sa(F98Y):NADPH, Sa(F98Y/V31L):NADPH and ternary Sa:NADPH:UCP1006 indicate 
that the reorientations of Phe 92 and His 30 are due to the presence of the mutations. 
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Like the Sa(F98Y/V31L):NADPH structure, the Sa(F98Y):NADPH structure features the 
same 0.4 Å shift of the B-helix away from the active site. However, the conformation of 
Phe 92 in the Sa(F98Y/V31L)  structure appears to be influenced by the V31L mutation 
as the conformation of this residue in the Sa(F98Y) structure is approximately 0.5 Å 
closer to that observed in the ternary structure.  Similarly, the V31L mutation influences 
the conformation of His 30 as a comparison of the Sa(F98Y):NADPH and ternary 
(Sa:NADPH:UCP1006) structures shows that the His 30 conformation is the same (Figure 
2b). 
 
Figure 5 A molecule of glycerol is observed to bind in the active site of the structure of 
Sa(F98Y/V31L):NADPH. The Sa(F98Y/V31L) structure is shown in magenta, the 3SGY 
structure (Sa(wt):NADPH:1) structure is shown in blue for reference. The molecule of 
glycerol replaces the 2-amino group and a water molecule found in the wild-type 
structure. 
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Comparisons of the crystal structure of Sa(F98Y/V31L):NADPH with the lowest energy 
predicted structure of the K*-predicted single V31L mutant (Figure 1) shows a 
conservation of the effect of the V31L mutation on Phe 92.  The predicted structure also 
indicates a steric interaction between Leu 31 and the C6-ethyl substituent of the 
pyrimidine ring of UCP1006, which compliments the crystallographic results. Incidentally, 
when K* was previously used to predict resistance mutations with another propargyl-
linked antifolate that maintains the same atoms as UCP1006 other than possessing a 
methyl instead of an ethyl group at the C6 position of the pyrimidine ring, the Val 31 
mutants ranked lower than the Leu 5 mutations. These results further validate that the 
steric interaction between Leu 31 and the ethyl group specifically contribute to resistance. 
 
3.6 Conclusions 
In summary, the K* algorithm in OSPREY was successfully used to predict unique single 
amino acid mutations in the active site of S. aureus DHFR that confer resistance to 
UCP1006. Four of the predicted mutant enzymes were created and shown to be 
catalytically competent and resistant to UCP1006, with the top-ranked mutant having a 
58-fold reduction in inhibitor potency. Excitingly, the computational predictions were 
shown to not only be biochemically validated, but also selected in the bacteria under 
antibiotic pressure as the top-ranked mutation, V31L, was selected in the background of 
an F98Y mutation, which has been clinically observed. Exploration of the enzymatic 
fitness of this novel double mutant revealed a compensatory relationship between the 
single F98Y and V31L mutations that results in a doubly mutated enzyme with fitness 
comparable to the wild-type enzyme. Consideration of the cellular fitness revealed that 
the double mutant strain only suffered a slight loss in fitness over both the progenitor 
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strain and the previously characterized F98Y strain. Crystal structures of the double 
mutant enzyme revealed the structural basis of compound resistance. 
 
The mutation V31L emerged as the top-ranked SNP that maintained dihydrofolate binding 
while conferring inhibitor resistance by perturbing Phe 92 and sterically interfering with 
the C6-ethyl group of the pyrimidine ring. Interestingly, there is a strong correlation 
between the current results and those obtained in the first application of K* to identify 
double mutants of SaDHFR that confer resistance. In the previous study5, the seven top-
ranked mutations were variants of Val 31 and Phe 92; a crystal structure of the 
V31Y/F92I mutant enzyme shows that the F92I mutation reduces van der Waals 
interactions and the V31Y mutation introduces destabilizing steric bulk.  Overall, it is 
striking that the same structural effect is selected with both applications of K* whether it is 
applied to identify double or SNP mutations. 
 
Having validated the mutational prediction capabilities of K*/OSPREY via bacterial 
selection of the predicted mutants, the algorithm could potentially be applied to many 
different research areas. Specifically, the computational prediction of drug-resistance 
mutations could be valuable in cases where it is more difficult to raise mutant strains or 
cell lines in vitro, such as with viruses or cancer cell lines. Overall, the extension of the 
computational prediction of drug resistance to observations of biologically relevant 
mutants provides new opportunities in drug discovery, especially for those targets that are 
most affected by mutational resistance. 
 
 
 
	 82 
3.7 Acknowledgements 
The K* algorithm in the OSPREY Protein Design Suite was developed by Dr. Bruce 
Donald and experiments were run by his students Pablo Gainza and Dr. Ivelin Georgiev. 
The initial single mutant enzyme construction, characterization and F98Y, 
V31L:NADPH:UCP1006 crystal growth was done by Dr. Kathleen Frey. I would also like 
to acknowledge the staff at beamline X4A of the National Synchrotron Light Source at 
Brookhaven National Laboratory for their assistance with X-ray data collection.  
 
3.8 References 
1. Zhu, S.; Travis, S.; Elcock, A. Accurate Calculation of Mutational Effects on the 
Thermodyamics of Inhibitor Binding to p38α MAP Kinase: A combined 
computational and experimental study. J. Chem. Theory Comput. 2009, 9, 3151-
3164. 
2. Ishikita, H.;  Warshel, A. Predicting Drug-Resistant Mutations of HIV Protease. 
Angew. Chem. Int. Ed. 2008, 47, 697-700. 
3. Hao, G.-F.; Yang, G.-F.; Zhan, C.-G. Computational mutation scanning and drug 
resistance mechanisms of HIV-1 protease inhibitors. J. Phys. Chem. B 2010,114, 
9663-9676. 
4. Safi, M.;  Lilien, R. Efficient a Priori Identification of Drug Resistant Mutations 
Using Dead-End Elimination and MM-PBSA. J. Chem. Inf. Model. 2012, 52, 1529-
1541.  
5. Frey, K.; Georgiev, I.; Donald, B.; Anderson, A. Predicting resistance mutations 
using protein design algorithms. Proc. Natl. Acad. Sci. 2010, 107, 13707-13712. 
6. Gainza, P. et al. OSPREY: Protein Design with Ensembles, Flexibility, and 
Provable Algorithms. Meth. Enz. 2013, 523, 87-107. 
7. Chen, C.; Georgiev, I.; Anderson, A; Donald, B. Computational Structure-Based 
Redesign of Enzyme Activity. Proc. Natl. Acad. Sci. 2009,106, 3764-3769. 
8. Dale, G. et al. A single amino acid substitution in Staphylococcus aureus 
dihydrofolate reductase determines trimethoprim resistance. J. Mol. Biol. 1997, 
266, 23-30. 
9. Viswanathan, K. et al. Toward new Therapeutics for Skin and Soft Tissue 
Infections: Propargyl-linked Antifolates Are Potent Inhibitors of MRSA and 
Streptococcus pyogenes. PLoS ONE 2012, 7, e29434. 
10. Frey, K.; Viswanathan, K.; Wright, D.; Anderson, A. Prospectively screening novel 
antibacterial inhibitors of dihydrofolate reductase for mutational resistance. 
Antimicrob. Agents and Chemother. 2012, 56, 3556-3562. 
	 83 
11. Vickers, A.; Potter, N; Fishwick, C.; Chopra, I; O'Neill. A. Analysis of mutational 
resistance to trimethoprim in Staphylococcus aureus by genetic and structural 
modelling techniques. J. Antimicrob. Chemother. 2009, 63, 1112-1117. 
12. Frey, K. et al. Crystal Structures of Wild-type and Mutant Methicillin-resistant 
Staphylococcus aureus Dihydrofolate Reductase Reveal an Alternative 
Conformation of NADPH that may be linked to Trimethoprim Resistance. J. Mol. 
Biol. 2009, 387, 1298-1308. 
13. Frey, K.; Lombardo, M.; Wright, D.; Anderson, A. Towards the Understanding of 
Resistance Mechanisms in Clinically Isolated Trimethoprim-resistant, Methicillin-
resistant Staphylococcus aureus Dihydrofolate Reductase. J. Struc. Biol. 2010, 
170, 93-97. 
14. Oefner, C. et al. Increased hydrophobic interactions of iclaprim with 
Staphylococcus aureus dihydrofolate reductase are responsible for the increase in 
affinity and antibacterial activity. J. Antimicrob. Chemother. 2009, 63, 687-698. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 84 
Chapter 4 
Understanding and Overcoming Mutational Resistance to Trimethoprim with Charged 
Antifolates 
 
4.1 Understanding Mutational Resistance in S. aureus 
The accumulation of amino acid mutations in the active site of the drug target is a 
common mechanism of antibiotic resistance implicated in the loss of clinical efficacy to 
antifolates, including TMP1 and SMX2, as well as fluoroquinolones3. Sulfamethoxazole 
resistance is conferred by the accumulation of up to thirteen mutations in the 
dihydropteroate synthase (DHPS) whereas a variety of mutations across the DNA gyrase 
A (gyrA) and topoisomerase A and B (grlA and grlB) results in resistance to 
fluoroquinolones2,3. The first description of mutations in the endogenous DHFR (dfrB) 
reported four sets of mutations that determined clinical TMP resistance across Europe,  
the UK and South America4. The group of mutations includes F98Y, the combinations of 
F98Y with H30N or H149R and a L20V, N59I and F98Y triple mutant. The single F98Y 
mutation resulted in a 64-fold loss in cellular potency whereas the double and triple 
mutants resulted in a 254-fold loss of activity. Structural studies indicate that the presence 
of the Tyr 98 disrupts the Phe 92 binding resulting in the loss of a hydrogen bonding 
interaction between the Phe 92 backbone carbonyl and the 4-amino group of the 
diaminopyrimidine. The formation of an interior hydrogen bond between the Tyr 98 phenol 
and the Leu5 backbone carbonyl, further reducing the hydrogen bonding interactions 
between TMP and the active site, was observed4. 
 
 Additional studies indicate that the presence of the F98Y mutation disrupts cofactor 
binding and diminishes the crucial synergy between TMP and NADPH, which in turn 
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confers resistance5. More in-depth crystallographic studies looking to overcome F98Y 
mutation with early generation of PLAs indicates that an alternative NADPH conformation 
correlates with decreased activity against this enzyme6. While the exact mechanism by 
which Tyr 98 confers resistance remains convoluted, its impact on clinical antifolate 
resistance remains of the utmost importance. Furthermore, comprehensive biochemical 
and structural analysis of the clinically isolated TMPR double mutant, Sa (H30N, F98Y) 
DHFR indicates that the double mutant doesn’t only confer high levels of TMP resistance, 
but that the accumulation of mutations does not compromise enzymatic efficiency. Crystal 
structures of this enzyme bound to a first generation PLA showed that the loss of a water 
mediated hydrogen bond between His30 and Thr111 is responsible for the loss of TMP 
efficacy7. Compounding this observation with previously understood effects of the Phe98 
mutation on NADPH and inhibitor binding allows for a complete understanding of 
mutational resistance and allows for the development of more robust inhibitors. 
 
In vitro generation of resistance is achieved by extended exposure of large 
concentrations (1011 to 1012 CFU/mL) of bacterial culture to high concentrations (6x MIC) 
of inhibitor. Upon exposure to inhibitor, the resistant bacteria are revealed and can grow 
unharmed under the antibiotic pressure. It is unclear whether these revealed mutant 
strains are generated directly in response to antibiotic pressure from a stress response or 
if these resistant bacteria pre-exist in small quantities and are revealed upon the death of 
the susceptible population. The first report of the prospective analysis of mutational 
resistance to early generation PLAs in S. aureus yielded the selection of F98Y, F98I and 
H30N single mutants at a very low (10-10) mutational frequency. It was also observed that 
the series of PLAs exhibited superior potency over TMP against these enzymes and 
showed lower mutation prevention concentrations (MPCs). This indicates that the class of 
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antifolates can compensate for the resistance effect of the mutations, are potentially less 
susceptible to mutational resistance and are promising candidates to overcome clinical 
resistances. 
 
4.2 Generation and characterization of UCP1006R MRSA strains  
To further characterize the resistance profile of the propargyl-linked antifolates, strains 
containing point mutations in the dfrB, generated by extended UCP1006 exposure, were 
selected and analyzed by microbiological, biochemical and structural mechanisms. For 
single-step mutant selection, the ATCC quality control strain 43300 was subjected to 
UCP1006 at 6x MIC yielded three clinically observed mutations: F98Y, H30N and H149R 
as well as three novel mutations: F151S, F151C and D142Y. A second round of 
resistance selection using UCP1006 and progenitor strains possessing F98Y or H149R 
yielded a series of both novel and clinically relevant double mutants (Table 1). As strains 
containing H30N/F98Y and F98Y/H149R mutants have been isolated clinically after 
exposure to TMP1, we chose to fully characterize the fitness of these mutant enzymes 
and bacteria, including their single mutant (F98Y, H30N, H149R) counterparts (Table 1) 
at a biochemical, structural and cellular level. 
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Table 1 Mutant Strain Selection using UCP1006  
Mutant 
Progenitor 
Strain 
Single Nucleotide 
Polymorphism 
Seq. 
Frequency (%) 
Overall 
Freq 
Doubling 
time (min) 
F98Y WT TTT to TAT 2/19 (10.5) 3.11x10-11 34.53 
H149R WT CAT to CGT 7/19 (36) 1.07x10-10 38.34 
H30N WT CAT to AAT 3/19 (15.8) 4.68x10-11 36.62 
F151S WT TTT to TCT 3/19 (15.8) 4.68x10-11 ND 
F151C WT TTT to TGT 2/19 (10.5) 3.11x10-11 ND 
D142Y WT CAT to TAT 1/19 (5.3) 1.57x10-11 ND 
H30N/V70L WT GTA to TTA 1/19 (5.3) 1.57x10-11 ND 
F98Y, H149R H149R TAT to TTT 1/1 (100) 1.23x10-11 30.89 
H30N, F98Y F98Y CAT to CGT 2/16 (12.5) 8.20x10-12 35.06 
F98Y, F151S F98Y TTT to TCT 1/16 (6.25) 4.10x10-12 ND 
F98Y, F151C F98Y TTT to TGT 1/16 (6.25) 4.10x10-12 ND 
V31G, F98Y F98Y GTT to GGT 6/16 (37.5) 2.46x10-11 ND 
V31L, F98Y F98Y GTT to CTT 5/16 (31.3) 2.05x10-11 25.4 
V31G, F98Y, 
V112D 
F98Y 
(V31G) GTT to GGT 
(V112D) GTT to GAT 
1/16 (6.25) 4.10x10-12 ND 
 
 
Overall mutation frequencies for each strain exposed to UCP1006 were calculated based 
on the inoculum and average number of colonies appearing on the 6x MIC experimental 
plates. Resistance to UCP1006 with S. aureus is generated at a very low frequency of 
2.96 x 10-10. Overall mutation frequencies are even lower to progenitor strains possessing 
F98Y and H149R, with rates of 6.56 x 10-11 and 3.75 x 10-11, respectively. Specific 
mutational frequencies were then calculated based on the number of sequenced colonies 
with a particular mutation. If the generation of double mutants occurs in a step-wise 
fashion, the combined frequency of resistance could be as low as 10-21.  Evaluation of 
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bacterial fitness, measured by doubling time, shows that the majority of the mutant strains 
exhibit only minor losses in growth time (1.08-1.2 x doubling time of wild-type), with the 
exception of Sa(F98Y/H149R), which preserved or slightly improved doubling time (Table 
1). Overall, these studies show that the accumulation of the mutations retains cellular 
fitness of the strains. 
 
4.3 Generation and Evaluation of UCP1006R Enzymes 
The recombinant mutant DHFR enzymes were created by site-directed mutagenesis of 
the wild-type enzyme and purified using affinity chromatography. Michaelis-Menten 
kinetics were measured for each enzyme using 12.5-100 µM NADPH and 12.5-100 µM 
DHF (Table 2)9. Overall, the enzymes, with the exception of Sa(H149R), have kcat/KM 
values within approximately 2-fold of the wild-type value. Sa(H149R) has a significantly 
reduced kcat/KM value (6-fold reduction), which is a consequence of higher KM values for 
both DHF and NADPH. Interestingly, the double mutant Sa(F98Y/H149R) compensates 
for the low efficiency of the single Sa(H149R) mutant as the Sa(F98Y/H149R) enzyme 
restores the KM value for DHF and NADPH to nearly wild-type values. Similarly, the single 
H30N mutation suffers a significant decrease in NADPH KM (31.21 to 79.89 µM); this KM 
value is restored to a value near wild-type in the double Sa(H30N/F98Y) mutant. This 
compensatory relationship was observed in the analysis of F98Y, V31L enzymes 
generated after the K* prediction, however here, the single mutants are also fit9.   
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Table 2 Mutant Enzyme Characterization 
 
 
KM (DHF) 
(μM) 
Vmax (DHF) 
KM (NADPH) 
(μM) 
kcat DHF 
(s-1) 
kcat/KM 
DHF 
WT 17.5 62.93 31.21 41.13 2.4 
F98Y 8.38 68.38 57.08 44.76 5.3 
H30N 24.49 45.76 79.89 29.91 1.2 
H30N, F98Y 11.24 39.98 51.17 26.1 2.3 
H149R 63.54 42.44 303.4 27.74 0.4 
F98Y, H149R 5.24 44.98 45.08 29.40 5.6 
 
 
4.4 Propargyl-linked Antifolates Overcome Mutational Resistance 
Understanding mutational resistance to UCP1006 is critical for guiding the development 
of a newer generation of robust PLAs that overcome the effects of the point mutations. By 
examining previously identified structure-activity relationships6, 8, 10 and testing several 
compounds likely to inhibit the single mutant enzymes, we initially identified a series of 
pyridine lead compounds, UCP1006, UCP1038, UCP1039 and UCP1040, with potent 
MICs against the single mutant strains and enzymes. The incorporation of the knowledge 
that enantio-specific methyl substitutions at the propargyl position can steer the biaryl 
system and result in a further optimized interaction with the enzyme led to the evaluation 
of UCP1062, UCP1063 and UCP109912. These enatio-pure PLAs further increased the 
activity against single mutant strains and enzymes and showed the first hints of activity 
against the double mutant strains.  Finally, incorporation of the carboxylate C-ring 
substitution on ring to the initial set of promising compounds lead to a series of 
compounds potent enzymatic and cellular activity across all single and double mutant 
species11 (Figure 1, Tables 3 and 4).   
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All of the compounds exhibit good potency (Ki values less than 16 nM, against the single 
mutant enzymes Sa (F98Y) and Sa(H30N) with only minor losses relative to wild-type 
(Table 4). UCP1038 lost the greatest affinity for the Sa(H30N) enzyme with a 12.6-fold 
loss. Activity against the single mutant Sa(H149R) was more compromised, where TMP 
loses activity against the Sa(H149R) mutant by 69-fold. The PLAs possess a range of 
affinity for this enzyme, ranging from UCP1173 with a Ki value of 153 nM to UCP1038 
with a Ki value of 1362 nM. UCP1039 with unconstrained 3’ and 4’ methoxy groups 
maintained reasonable affinity with a Ki of119 nM when compared to compound 
UCP1038, showing that flexibility, in addition to the propargylic subsitutions, may be 
critical for affinity to the mutant enzymes. In general, the dioxalane compounds 
(UCP1038 and UCP1099) as well as compounds UCP1040, 1062 and 1063 lose 
significant affinity for the Sa (F98Y, H30N) double mutant enzyme (180 to 300-fold loss), 
TMP losses 130-fold loss of activity against this enzyme. Inhibition of Sa (F98Y, H149R) 
remains a struggle for the pyridine substituted PLA series. 
 
The PLA-COOH class of compounds was designed to form ionic interactions with a 
conserved arginine to provide compensatory interactions in these mutant enzymes. 
These COOH substituted compounds, with the exception of UCP1106, show much 
greater affinity for the double mutant Sa (F98Y, H30N) enzyme with Ki values ranging 
from 19-45 nM. With Ki values of 107-2059 nM against the double mutant Sa (F98Y, 
H149R) enzyme pyridine compounds as well as UCP1106 and TMP maintain challenge. 
However, UCP1172 and UCP1173 show significant inhibition for this enzyme, with Ki 
values of 69 and 55 nM, respectively. Again, it appears that the presence of the ionized 
carboxylates may provide critical additional interactions to compensate for reduced 
contacts elsewhere in the complex.  
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Figure 1. Structure of Trimethoprim and PLAs  
Table 3 Ki (nM) of PLAs against WT and mutant enzymes 
Compound Sa(WT) Sa(F98Y) Sa(H30N) Sa(H149R) Sa(H30N, 
F98Y) 
Sa(F98Y, 
H149R) 
TMP 3.4+0.3 14.68+0.08 6.9+0.2 240+10 595+5 1729+40 
UCP1006 2.8+0.3 13.1+0.7 12.9+1 681+27 191+10 2059+200 
UCP1038 2.5+0.1 3.0+0.4 33.2+1 1363+38 485+40 779+25 
UCP1039 2.1+0.1 12.1+0.6 4.5+0.4 119+7 449+40 107+9 
UCP1040 4.51+0.09 19.7+1 5.9+0.9 1563+34 820+80 878+30 
UCP1062 2.6+0.3 8.6+0.4 16.7+0.6 1154+19 801+51 894+84 
UCP1063 1.6+0.1 16.7+1 16.5+1 269+20 417+30 422+14 
UCP1099 5.2+0.3 13.6+0.8 8.9+0.6 174+4 345+10 289+20 
UCP1106 4.8+0.1 11.7+0.5 3.9+0.4 130+3 158+4 142+2 
UCP1164 5.5+0.1 11.8+0.7 3.8+0.6 862+39 36+3 295+9 
UCP1175 1.64+0.09 11.3+0.7 3.36+0.06 323+23 45+3 184+5 
UCP1172 1.3+0.1 7.9+0.2 3.5+0.6 111+7 19+1 69+2 
UCP1173 2.1+0.1 5.57+0.08 3.3+0.2 153+11 16.6+0.3 55+1 
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The compounds were also tested for inhibition of the growth of wild-type and mutant 
(Sa(F98Y), Sa(H30N), Sa(H149R), Sa(H30N, F98Y) and Sa(F98Y/H149R)) strains of S. 
aureus (Table 3). The antibacterial activity of TMP was clearly crippled by even the single 
mutations and reached a 50-100 µg/mL MIC value against the double mutant strains. The 
pyridine PLAs as well as UCP1106 and UCP1164 were more potent against the wild-type 
strain than TMP and many were more potent against the single mutants (MIC values 
between 0.078 and 5 µg/mL). However, these compounds also suffered significant losses 
against the strains with double mutations in DHFR. PLAs UCP1172, 1173 and 1175 have 
superior activity against the wild-type strain as well as strains with both single and double 
mutants. Notably, the MIC value for UCP1173 against either of the double mutant strains 
is only 4-fold higher than the MIC value of TMP for wild-type S. aureus. On-target activity 
of the PLAs was verified end-product rescue MICs, in which the folic acid cycle is 
bypassed by the increased concentration thymidine concentration in the growth media 
(Thy+)11,12. All compounds, with the exception of UCP1038, UCP1062 UCP1063 and 
UCP1099 have Thy+ MICs of >40 µg/mL, where UCP1038, UCP1062 and UCP1063 have 
Thy+ MICs of 5 µg/mL and UCP1099 had an MIC of 10 µg/mL. These MIC values rise by 
64x – 4081x, validating that the compounds inhibit DHFR. 
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Table 4 Minimum Inhibitory Concentrations (µg/mL) 
Compound 
ATCC 
43300 
Sa(F98Y) Sa(H30N) Sa(H149R) 
Sa(H30N, 
F98Y) 
Sa(F98Y,
H149R) 
TMP 0.3125 10 2.5 2.5 50 100 
UCP1006 0.0781 2.5 2.5 2.5 20 80 
UCP1038 0.0781 1.25 5 5 40 40 
UCP1039 0.0195 0.625 0.625 0.625 20 40 
UCP1040 0.625 2.5 2.5 2.5 20 40 
UCP1062 0.0391 0.625 0.625 0.625 40 20 
UCP1063 0.0195 1.25 0.625 1.25 10 20 
UCP1099 0.0195 1.25 2.5 2.5 20 20 
UCP1106 0.0195 0.1563 0.1563 0.1564 6.25 >50 
UCP1164 0.0391 0.1563 0.1563 0.0781 >40 >40 
UCP1175 0.0195 0.1563 0.1563 0. 1563 5 10 
UCP1172 0.0098 0.0781 0.0781 0.0391 1.25 2.5 
UCP1173 0.0098 0.0781 0.0781 0.0781 1.25 1.25 
  
 
4.5 Structural Analysis of Mutant Enzymes and UCP1106 
A series of crystal structures with the wild-type and mutant enzymes elucidates the 
structural changes caused by the selected mutations. Mutants Sa (F98Y), Sa (H30N) and 
Sa (H30N, F98Y) DHFR were co-crystallized with NADPH and UCP1106; the structure of 
the wild type Sa DHFR complex with NADPH and UCP1106 has been previously 
described (PDB: 5HF0; Figure 1)11.  The structures of the wild-type and Sa (H30N) 
enzymes feature mixed occupancy of tricyclic- and β-NADPH in the cofactor binding site 
(Figure 2), similar to previous observations6, 10.  
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Figure 2 View of wild-type SaDHFR (purple) bound to β-NADPH (salmon), α-NADPH 
(yellow) and UCP1106 (green). 
 
The structural basis of antifolate resistance in these F98Y mutant enzymes appears to 
involve the loss of a critical hydrogen bond between the carbonyl backbone of Phe 92 
and the conserved 4-amino group of the inhibitor. Comparisons between structures of 
wild-type SaDHFR and those with the F98Y mutant enzymes show that the F98Y 
mutation induces a rotation of the Phe 92 backbone carbonyl by 1.1 Å, which disrupts the 
hydrogen bond between the carbonyl oxygen and the N4-amino group of the 
diaminopyrimidine ring (Figure 3). The hydrogen bond between the Phe 92 carbonyl and 
the 4-amino group in the wild-type enzyme is 2.9 Å; in the mutated structure it is 3.9 Å. 
There is a new hydrogen bond between Tyr 98 and the 4-amino group, but with reduced 
strength (3.4 Å). Loss of this conserved hydrogen bond to Phe 92 would represent a 
significant loss in affinity. 
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Figure 3 The shift in the position of the carbonyl of Phe 92 in the F98Y mutant (cyan) 
eliminates a hydrogen bond to the 4-amino group of the inhibitor. The black bar 
represents the 1.1 Å shift. The water molecule bound to the nicotinamide ring of α-
NADPH and Phe 92 is shown. 
 
The presence of the Asn 30 mutation results in the re-organization of a water network 
between the active site residues and the inhibitor, effectively eliminating a hydrogen bond 
between the pyrimidine ring and protein. In the structure with wild-type SaDHFR, a critical 
water molecule bound to the N2-amino group of the diaminopyrimidine (2.9 Å; cyan in 
Figure 1c) is involved in a water network with the backbone carbonyl of Tyr 109 (2.8 Å) 
and the imidazole side chain of His 30, effectively tying the diaminopyrimidine to two 
protein residues (Figure 4). In fact, the distance of this water molecule bound to His 30 is 
quite conserved, having an average value of 2.9 Å over several SaDHFR:PLA crystal 
structures.  In the structures with the Asn 30 mutation, the water molecule (magenta in 
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Figure 4) more closely coordinates with the mutated Asn residue instead of the inhibitor, 
reducing the effective hydrogen bonding interactions of the inhibitor. Measurements of the 
distance of the water molecule to the 2-amino group show that the bonds are 3.4 Å and 
3.5 Å in the SaH30N and Sa(F98Y/H30N) structures, respectively; these distances are 
too far to create effective hydrogen bonds. This disruption of the water network linking the 
inhibitor to the active site residues is similar to that reported in our earlier structure7.  
 
Figure 4 Two water molecules (blue and red) tie the pyrimidine ring to His 30 (wt) and Tyr 
109. The H30N mutation (magenta) pulls one of the water molecules (magenta) 1 Å away 
from the 2-amino group, eliminating the hydrogen bond. 
 
 
The double mutant enzyme, F98Y/H30N shows both the shifted carbonyl for Phe 92 as 
well as the altered water network at Asn 30, greatly decreasing the hydrogen bonding 
interactions of the 2- and 4-amino groups of the pyrimidine ring. There is a prominent 
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functional synergy between these two mutations. Not only does the second mutation 
further weaken inhibitor binding by disrupting contacts at the pyrimidine ring, but also 
restores the catalytic activity of the enzyme to near wild-type values (Table 2).  The two 
cooperative effects provide a powerful mechanism for the organism to become drug 
resistant.  
 
In general, the PLAs show significantly increased potency for the mutant enzymes 
relative to TMP. One reason for this increased potency is the coordination of a water 
molecule, observed in both the F98Y and F98Y/H30N structures, between the 
carboxylate group on UCP1106 and Arg 57 (2.5 Å) (Figure 5).  The extra hydrogen bonds 
created by the coordinated water molecule and Arg 57 compensate for interactions lost 
by the pyrimidine ring. The presence of the tricyclic a-NADPH anomer indicates a 
potentical beneficial relationship between PLA activity and novel anomer. The displaced 
nicotinamide of tNADPH coordinates a water molecule (2.4 Å) that stabilizes the carbonyl 
of Phe 92 (3 Å), preserving the hydrogen bonding interactions between Phe 92 and the 
inhibitor (Figure 3). β-NADPH does not coordinate this water molecule, does not stabilize 
the Phe 92 carbonyl and effectively allows the loss of the hydrogen bond.  
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Figure 5 A water molecule forms hydrogen bonds between the carboxylate and Arg 57 	
4.6 Conclusions 
Through generation, selection and analysis of UCP1006R S. aureus mutants, the 
biochemical and molecular mechanisms of resistance via point mutations can be 
evaluated. By focusing on a panel of strains containing dfrB mutations that have clinically 
identified as TMP resistance determinants, discovery efforts can be focused on 
overcoming modifications that the enzyme has known to accommodate with minimal 
fitness losses. Overall, the mutation frequency for the PLAs is very low with frequencies 
between 10-10 and 10-11.  A series of fitness experiments show that the mutant enzymes 
and strains, especially double mutants, are as fit as wild-type. Evaluation of TMP and a 
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series of twelve PLAs shows that the PLAs are generally much more potent than TMP 
against both the mutant enzymes and strains. Specifically, the PLAs possessing a 
carboxylate moiety exhibited good potency against the difficult double mutant enzymes 
and strains.  
 
Crystal structures of UCP1106 bound to NADPH and SaDHFR, Sa (F98Y), Sa (H30N) 
and Sa (F98Y/H30N) show that the mutations specifically diminish the binding of the 2- 
and 4-amino groups on the pyrimidine ring through nuanced changes in the water 
networks. The carboxylate moiety forms hydrogen bonds, water mediated in the case of 
UCP1106, with an active site arginine, compensating for some of the lost pyrimidine 
interactions and restoring affinity to the mutant enzymes. Overall, the PLA-COOH 
compounds appear to be excellent lead compounds that maintain potency for wild-type 
enzymes and strains while overcoming resistance features in mutant enzymes and 
strains, further indicating that optimization of this class of compounds can overcome 
future enzymatic modifications.  
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Chapter 5 
Understanding and Overcoming Clinical Trimethoprim Resistance 
 
5.1 Clinical Trimethoprim/Sulfamethoxazole Resistance 
Resistance to trimethoprim began developing over a decade after its introduction to the 
clinic in 19621,2. A single TMPR S. aureus strain from Switzerland revealed the first clinical 
TMPR determinant, an innately resistant plasmid-acquired DHFR enzyme.  The gene, 
dfrA, located on a mobile genetic element, encodes a highly resistant DHFR enzyme 
commonly referred to as S1 DHFR (here referred to as DfrA).  DfrA is believed to 
originate from Staphylococcus epidermidis, as it contains three mutations: V31L, G43A 
and F98Y when compared to its TMPS endogenous DHFR2. DfrA and DfrB share an 80% 
sequence similarity. In 1997, point mutations in the endogenous DHFR (DfrB), (including 
F98Y as well as H30N, F98Y and F98Y, H149R), discussed extensively in Chapter 5 
were identified as clinical TMPR determinants3. 
 
More recently, two additional TMPR dfr isoforms were identified in S. aureus clinical 
isolates.  The first gene, dfrG, encoding an innately resistant DHFR enzyme (DfrG), was 
initially identified in Thailand4 followed by reports of its wide spread throughout sub-
Sahara Africa5. This latter study monitored the import of the gene to Europe through 
people traveling from Africa. Finally, DfrK, encoded by the gene dfrK, were detected in 
farmers and children living near rural, highly agricultural regions in Ireland6. DfrK, which 
shares a 90% sequence identity with DfrG, had been widely reported in pathogenic 
strains of porcine and livestock S. aureus, prior to its identification in human pathogens7,8. 
DfrG and DfrK only share a 38% sequence identity to DfrA and 40% to DfrB. Like dfrA, 
dfrK and dfrG are located on highly mobile genetic elements and incorporated into the 
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chromosomes via horizontal gene transfer. Despite knowledge of the existence of the 
plasmid-encoded resistance elements dfrG and dfrK, their importance in clinical strains of 
MRSA and MSS Awas not thought to be significant. Therfore, antifolate development was 
more targeted toward the accumulation of resistant  mutants of the chromosomal gene. 
 
Recent surveillance reports indicate a regional variance in resistance rates for TMP, 
whereas US hospitals report rates of 2-3% for TMP/SMX9, European travel clinics report 
rates of up to 50% for TMP and 19% for TMP/SMX5. There has be no recent survey of the 
molecular mechanism of resistance to TMP or TMP/SMX in United States hospitals. Until 
this point, we have been pursuing the design of inhibitors that overcome mutational 
resistance with the intentions of creating broad activity against current, clinically relevant 
TMPR strains. Initial success of the class of carboxylate PLAs against series the TMPR 
mutant enzymes and strains, specifically ones containing F98Y, validates these design 
efforts. As antibiotic resistance is constantly evolving, it is crucial to identify the 
contemporary mechanisms of resistance in order to further develop potent lead 
compounds. Presented in this chapter is the investigation into the molecular mechanisms 
of TMP resistance in S. aureus isolates from Connecticut hospitals and efforts to identify 
inhibitors that directly inhibit the predominating mechanisms of resistance.  
 
5.2 Characterization of TMPR Clinical Isolates 
Over a two-year period, more than 30 TMPR S. aureus isolates were obtained from the 
clinical microbiology laboratories at UConn Health/John Dempsey Hospital (UCH) and 
Hartford Hospital (HH). These strains were isolated in the course of routine clinical care 
and originally submitted for routine susceptibility testing. The strains were collected from 
different patients, were isolated from a variety of sources including blood, skin and soft 
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tissue (SSTI), sputum (lung) and the sinus cavity and feature diverse antibiotic resistance 
genotypes. The blood sample was derived from a hospitalized patient; the other isolates 
were outpatient derived. TMP/SMX resistance rates at UCH and HH are reported at <1 % 
and 2% for MSSA and 2-3% and 5% for MRSA isolates, respectively.  
 
The first obtained clinical isolates, UCH MRSA 1-10, revealed high levels (MIC > 
1mg/mL) of TMP resistance (Table 1). Initial investigations into the TMPR mechanisms 
indicated that all strains contained a WT, TMPS endogenous DHFR (dfrB) and the lack of 
the well-characterized dfrA gene was confirmed by PCR. In order to explore further, we 
initially conducted whole genome sequencing on a single strain, UCH MRSA 1. Genomic 
analysis revealed the presence of a second, chromosomally incorporated DHFR enzyme 
encoded by the gene, dfrG that had been integrated into the chromosome. To our 
knowledge, this is the first report of dfrG in North America. We then used PCR to evaluate 
the remaining strains for their dfrB sequences and the presence of dfrG as well as two 
other plasmid-encoded genes, dfrA and dfrK, known to occur in S. aureus2,6,11. 
Surprisingly, we found that all of the clinical isolates carried one of the plasmid-encoded 
genes, with dfrG predominating in 78% of strains. We also identified, for the first time in 
the United States, the presence of the dfrK gene. dfrA appeared in the remaining strains. 
Given the limited number of strains and hospitals represented here, the occurrence of 
these diverse, previously unreported resistance elements are striking. 
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Table 1 Characterization of All TMPR Clinical MRSA Isolates 
Strain Source dfrB TMPR 
element 
Strain Source dfrB TMPR 
element 
UCH 1 Blood WT dfrG UCH124 Urine WT dfrG 
UCH 2 Sputum WT dfrG UCH 126 Wound WT dfrG 
UCH 5 Sputum WT dfrG UCH127 SSTI WT dfrG* 
UCH 6 Urine WT dfrG UCH128 SSTI WT dfrG 
UCH 7 Sputum WT dfrG UCH129 Wound WT dfrG 
UCH 8 Sputum WT dfrG UCH130 SSTI WT dfrG 
UCH 9 Feces WT dfrG UCH131 Urine WT dfrG 
UCH 10 Sputum WT dfrG UCH132 Blood WT dfrG 
UCH115 SSTI WT dfrA HH553 Sputum WT dfrA 
UCH116 SSTI WT dfrA HH601 Blood WT dfrG 
UCH117 Urine WT dfrG HH714 SSTI WT dfrG 
UCH118 SSTI WT dfrA HH1144 SSTI WT dfrA 
UCH119 SSTI WT dfrG HH1155 Sputum WT dfrG 
UCH120 Trachea WT dfrG HH1184 Sputum WT dfrK 
UCH121 Sputum WT dfrG HH1251 SSTI WT dfrA 
UCH123 Wound WT dfrG MSSA 1 Sinus WT dfrG 
* Strain is SMXS, which presents as BactrimS clinically 
 
A panel of eight strains, based on their antibiotic phenotypes, was selected for a more in-
depth microbiological, biochemical and genetic analysis. Seven of the selected strains 
were classified as MRSA and one additional was MSSA; the methicillin resistance 
classifications were based on clinically determined susceptibilities. All three of the 
innately resistant DHFRs are represented in the panel of isolates (Table 2, Figure 1). The 
fitness of the strains, as measured by doubling time, doesn’t appear to be any affected by 
harboring these extra genes as the doubling times were generally shorter than the ATCC 
43300 strain (Table 2). 
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Figure 1 Composite gel showing PCR products depicting the presence of dfrG, dfrA, dfrK 
and dfrB in the UCH and HH strains.  
 
While each of the strains is highly resistant to TMP, they have variable 
susceptibilities SMX, with MIC values between 250 and >1,000 µg/mL or 15-500 µg/mL, 
respectively. UCH MRSA 127, which contains dfrG but is SMX susceptible presents 
clinically as BactrimS with the MIC at the clinical breakpoint. This point can convolute the 
surveillance TMPR statistics in clinical labs that only screen for Bactrim resistance. In 
addition to TMP and SMX, strains show varying resistance profiles to a wide range of 
commonly used antibiotics including erythromycin, fluoroquinolones, aminoglycosides 
and tetracycline (Table 3). 
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Table 2 Characterization of Select TMPR Clinical Isolates 
Strain 
Designation 
Infection 
Source 
TMP 
Resistant 
Gene 
dfrB 
TMP 
MIC 
(μg/mL) 
SMX MIC 
(μg/mL) 
Doubling 
Time (min) 
UCH 1 Blood dfrG WT >1,000 >500 40.33 
UCH 115 SSTI dfrA WT 250 500 35.19 
UCH 121 Sputum dfrG WT >1,000 >500 28.17 
UCH 127 SSTI dfrG WT >1000 15.625 38.61 
HH 714 SSTI dfrG WT >1000 >500 27.39 
HH 1144 SSTI dfrA WT 250 >500 32.54 
HH 1184 Sputum dfrK WT >1000 >500 29.38 
UCH MSSA 1 Sinus Cavity dfrG WT >1000 >500 36.49 
Sa43300 ATCC None WT 0.3125 10 38.16 
 
 
To better understand the possible relationships between these strains, the genetic 
diversity was determined through sequencing and typing of the spaA gene12. The analysis 
showed that five of the strains (UCH MRSA115, UCH MRSA121, UCH MSSA1, HH 
MRSA714 and HH MRSA1144), including strains from both hospitals and the MSSA 
strain, were clonally indistinguishable. However, UCH MRSA127, HH MRSA1184 and 
UCH MRSA1 are clonally distinct isolates. Importantly, within the group of five clonal 
isolates, dfrA and dfrG are represented and dfrK is found the distinct yet related strain, 
HH MRSA 1184, Figure 2. The appearance of the different dfr isoforms within the closely 
related cluster as well as more genetically distinct strains suggests that they are on 
potentially highly mobile resistance elements.   
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Figure 2 Clonal characterization of S. aureus strains by spaA sequencing 
 
5.3 Clinical Isolates Exhibit a Range of Antibiotic Susceptibilities 
The phenotypes to commonly prescribed non-TMP antibiotics were determined for the 
panel of isolates revealing diverse variability in susceptibilities. All strains were 
susceptible to vancomycin, linezolid, rifampin and daptomycin and have varied 
susceptibilities to sulfamethoxazole, erythromycin, clindamycin, tetracycline, gentamicin 
and a variety of fluoroquinolones, based on breakpoint MICs (Table 3).  To better 
understand the diversity of the isolates, the remaining seven genomes were sequenced 
and the molecular mechanisms of resistances were identified. The only resistance 
mechanism that mirrors the clonality pattern is found with sulfamethoxazole; the group of 
five clonal strains contained five previously reported folP mutations (F17L, T28S, T59S, 
L64M, E205K) conferring high-level SMX resistance. Whereas, UCH 1 contains thirteen 
folP mutations (F17L, V30I, T31N, M37I, I58V, T59S, V60L, L64M, I110M, V117I, V126I, 
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E208K, F226L) and HH1184 contains nine (V30I, I58V, T59S,V60L, L64M, I100M, V117I, 
V126I, F226L)13. 
 
Table 3 Antibiotic Susceptibility Profiles of Clinical MRSA Isolates (μg/mL) 
Strain Erythromycin Clindamycin Tetracycline Gentamicin Levofloxicin 
UCH 1 >4 (R) <0.12 (S) <2 (S) <2 (S) 64 (R) 
UCH 115 <0.25 (S) <0.12 (S) >16 (R) >16 (R) >64 (R) 
UCH 121 >4 (R) 0.25 (S) <2 (S) <2 (S) >64 (R) 
UCH 127 >4 (R) <0.12 (S) <2 (S) <2 (S) 8 (R) 
HH 714 2 (R) <0.12 (S) <2 (S) <2 (S) >64 (R) 
HH 1144 >4 (R) >2 (R) >16 (R) >16 (R) 8 (R) 
HH 1184 >4 (R) 0.25 (S) <2 (S) <2 (S) 0.25 (S) 
UCH MSSA 1 >4 (R) >2 (R) <2 (S) <2 (S) 8 (R) 
 
TetM, a ribosome protection protein, is identified as the tetracycline resistance 
determinant observed in UCH115 and HH114414. Gentamicin resistance in UCH115 and 
HH1144 is conferred by a plasmid borne AAC(6’)-APH(2”) aminoglycoside resistance  
enzyme15.  Tetracycline and aminoglycoside resistance was only identified in strains 
containing dfrA, however these strains differ both in fluoroquinolone resistance 
mechanisms and macrolide susceptibility. mphC, a 2’-phosphotransferase which directly 
inactivates the macrolides via phosphorylation determines selective macrolide resistance 
(erythromycin) in UCH MRSA121, UCH MRSA127 and HH MRSA1184, all clonally 
distinct isolates20,21. mphC is not commonly reported to confer macrolide resistance in 
human S. aureus isolates, instead it is more frequently reported in agricultural studies22.  
ermC, a 23s rRNA methyl transferase, found in UCH MRSA 1, HH MRSA 1144 and UCH 
MSSA 1 confers resistance to both macrolides and lincosamines (clindamycin)23. 
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Resistance to fluoroquinolone in all strains except HH MRSA1184 is conferred through a 
variety of mutations in the quinolone resistance-determining regions (QRDRs) of DNA 
gyrase subunit A (gyrA) and topoisomerase IV, subunits A and B (grlA and grlB).  The 
combinations of mutations vary from single gyrA mutations to the accumulation of four 
mutations between gyrA, grlA, and grlB were observed16,17. NorA efflux activity in 
fluoroquinolone resistance was determined by MIC in the presence of reserpine, a NorA 
inhibitor. Minimal shifts in MIC for levofloxacin and up to 8-fold decrease in ciprofloxacin 
MIC indicate that NorA has minimal influence on fluoroquinolone resistance (Table 4)18,19. 
 
Table 4 Minimum Inhibitory Concentrations with 20 µg/mL Reserpine (µg/mL) 
 Minimum Inhibitory 
Concentration 
Minimum Inhibitory Concentration  
20 µg/mL Reserpine 
Strain Levofloxacin Ciprofloxacin Levofloxacin Ciprofloxacin 
UCH 1 64 >64 64 (1) 32 (>2) 
UCH 115 >64 >64 >64 (>1) 32 (>2) 
UCH 121 >64 64 >64 (>1) 32 (2) 
UCH 127 8 32 4 (2) 8 (4) 
HH 714 >64 64 >64 (>1) 32 (2) 
HH 1144 8 64 8 (1) 16 (4) 
HH 1184 0.25 1 <0.125 (>2) <0.125 (>4) 
UCH MSSA 1 8 64 8 (1) 32 (2) 
Fold increases in MIC noted in parenthases 
 
HH MRSA 1184 is the only strain to contain the Panton-Valenitine leukocidin, a virulence 
factor that produces a cytocoxin associated with tissue necrosis and leukocyte damage24. 
All strains clinically classified as ‘methicillin resistant’ via susceptibility are mecA positive.  
A full list of target mutations and resistance determinants are summarized in Table 5. 
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Table 5 Molecular Mechanisms of Antibiotic Resistance for Clinical Isolates 
 Resistance Mechanism 
MIC Range 
(ug/mL) 
Strains 
Trimethoprim 
dfrA 250 UCH115, HH1144 
dfrG >1000 
UCH 1, UCH121, UCH127, 
HH714, UCH MSSA1 
dfrK >1000 HH1184 
Sulfamethoxazole 
folB(F17L, V30I, T31N, M37I, 
I58V, T59S, V60L, L64M, 
I110M, V117I, V126I, E208K, 
F226L) 
>500 UCH 1 
folB(F17L, T28S, T59S, L64M, 
E205K) 
>500 
UCH 115, UCH 121, UCH127, 
HH714, HH1144, UCH MSSA1 
folB (V30I, I58V, T59S,V60L, 
L64M, I100M, V117I, V126I, 
F226L) 
32 HH1184 
Tetracycline TetM >16 UCH115, HH1144 
Gentamicin aac(2’)-apc(6”) >16 UCH115, HH1144 
Erythromycin 
mphC 8-32 UCH121, UCH127, HH1184 
ermC >64 UCH 1, HH 1144, UCH 1 
Clindamycin ermC >64 UCH 1, HH 1144, UCH 1 
Levofloxacin/ 
Ciproflxacin/ 
Gatifloxacin 
gryA(S84R ,S85P), 
grlA(S80F), grlB(E471K) 
64/ >64/>8 UCH 1 
gryA(S84L, S85P), grlA(S90K, 
E84K) 
>64/>64/ >8 UCH115 
gryA(S84R ,S85P), 
grlA(S80F), grlB(D432V) 
>64/64/>8 UCH121, HH714 
gyrA (S84L) and grlA (S80F), 
grlB(D432V, E596D*) 
8/32/4 UCH127 
gyrA (S84L) and grlA (S80F) 8/64/4 HH1144 
Levofloxacin/ 
Ciproflxacin 
gyrA(S84L) 8/64 UCH 1 
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5.4 Propargyl-linked Antifolates Potently Inhibit Clinical Isolates 
Whole genome sequencing of the clinical strains showed notable variation in the 
molecular basis of TMP resistance as well as several common antibiotics. This provided a 
useful panel of clinically relevant strains that can be used as an important tool for lead 
optimization. Therefore, we screened a variety of previously developed PLA lead 
compounds against the panel of TMP-resistant strains to identify candidates with broad 
activity. Excitingly, several of the compounds (UCP1039, UCP1164, UCP1172, UCP1173 
and UCP1175; Table 5, Figure 3) showed very potent activity against these highly TMP-
resistant strains. Although we observed activity with earlier generation inhibitors that 
contained a pyridyl C-ring (eg. UCP1039) the most potent activity was observed with a 
recently disclosed charged/zwitterionic series possessing an ionizable carboxylic acid on 
the distal C-ring (UCP1164, UCP1172, UCP1173 and UCP1175). Overall, the PLAs were 
most potent against strains carrying dfrG and dfrK with MIC values as low as 0.1563 
µg/mL, two-fold lower than the MIC for TMP against wild-type S. aureus. Compound 
UCP1173 showed the most potent activity against strains possessing dfrA with MIC 
values of 1.25 and 2.5 µg/mL. Interestingly, compound UCP1172 is the antipode of 
UCP1173 but does not significantly inhibit dfrA-possessing strains.   
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Figure 3 Structure of TMP and PLAs Described in this Chapter 
 
Table 6 PLA Antibacterial Activity against Clinical Isolates (MICs in µg/mL)  
Inhibitor UCH 1 
(dfrG) 
UCH  
115 
(dfrA) 
UCH 
121 
(dfrG) 
UCH 
127 
(dfrG) 
HH  
714 
(dfrG) 
HH 
1144 
(dfrA) 
HH 
1184 
(dfrK) 
UCH 
MSSA 
1 
(dfrG) 
 
ATCC 
43300 
UCP1039 1.25 >20 0.625 0.3125 1.25 >10 1.25 0.625 0.0391 
UCP1164 2.5 10 5 2.5 5 5 0.625 5 0.0391 
UCP1172 0.625 5 0.625 0.3125 0.625 5 0.3125 0.3125 0.0098 
UCP1173 5 2.5 5 2.5 5 1.25 2.5 2.5 0.0098 
UCP1175 2.5 >20 10 5 10 >20 5 10 0.0195 
UCP1191 0.625 20 0.625 0.1563 0.625 10 0.1563 0.3125 0.0195 
UCP1205 0.625 >10 0.625 0.3125 0.625 >10 0.3125 0.3125 0.0195 
UCP1206 2.5 >10 2.5 1.25 2.5 >10 1.25 1.25 0.0098 
UCP1191 
+SMXa 
0.0391 00.625 0.0781 0.3125 0.0391 0.625 <0.0048 0.0098 <0.0048 
aMIC values with 100 µg/mL Sulfamethoxazole (SMX), ATCC 43300 and UCH 127 at 1 
µg/mL SMX 
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It was noted that C3’, C4’ dioxygenation with a pyridyl C-ring (UCP1039) afforded some of 
the strongest activity in this series and as such, we investigated combining this pattern of 
functionality with the preference for a C-ring carboxylic acid. To explore this design, a 
dioxalane ring was chosen as a convenient isostere as it afforded antibacterial activity 
against strains that possessed a DHFR with the F98Y mutation25. The racemic inhibitor 
UCP1191 and the individual enantiomers, UCP1205 and UCP1206, were therefore 
synthesized and evaluated. We were delighted to see a significant increase in activity 
against both dfrG- and dfrK-possessing strains with MIC values of 0.1563-0.625 µg/mL. 
Interestingly, despite these strains also being SMX-resistant, an apparently strong 
synergistic interaction between the PLAs and SMX was observed (Tables 6 and 7). 
 
 Table 7 Minimum Inhibitory Concentrations with 100 µg/mL Sulfamethoxazole (µg/mL) 
Strain  UCP1039 UCP1164 UCP1172 UCP1173 UCP1191 UCP1205 UCP1206 
UCHC 115 dfrA 1.25 0.3125 1.25 0.1563 0.625 2.5 0.625 
HH 714 dfrG 0.0391 0.3125 0.3125 0.3125 0.0391 0.0391 0.1563 
HH 1184 dfrK <0.0048 <0.0048 <0.0048 <0.0048 <0.0048 <0.0048 <0.0048 
 
Cloning, expressing, purifying and evaluating enzyme inhibition provided further validation 
that antibacterial activity of the PLAs in these resistant organisms was directly related to 
their ability to inhibit the resistance-conferring enzymes. The three genes, dfrA, dfrG and 
dfrK were cloned into expression vectors and the resulting proteins purified to 
homogeneity.  The PLAs were evaluated for enzyme inhibition using standard assays that 
measure the oxidation of the NAPDH cofactor (Table 7)25,26. As expected, TMP exhibits 
high inhibition concentration 50 % (IC50) values for all three TMP-resistant DHFRs.  
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Despite the fact that there has been no directed optimization of the PLAs against these 
TMP-resistant proteins, the PLAs showed relatively potent inhibition with the majority of 
IC50 values less than 100 nM, highlighting the value of our approach to use structure-
based targeting of common resistance mechanisms in DHFRs25,27.  Remarkably, this is 
an approximately 4400-, 55-, or 2000-fold increase in potency over TMP for the DfrG, 
DfrA and DfrK proteins, respectively. Although a variety of factors beyond target inhibition 
contribute to the overall antibacterial activity, there is a correlation between PLA activity 
against the TMP-resistant enzymes and the MICs against the corresponding strains. 
Additional validation that the PLAs exert their antibiotic effect through blockade of the 
folate pathway was provided by rescue experiments, where the culture media was 
supplemented with thymidine and MIC values rose by at least 8-fold (data not shown).  
 
Table 8 Enzyme Inhibition (IC50 values shown in µM) 
Inhibitor DfrB DfrG DfrA DfrK 
TMP 0.023 + 0.002 380 + 12 15.1 + 0.7 43 + 2 
UCP1039 0.014 + 0.001 0.45 + 0.02 0.36 + 0.02 0.022 + 0.003 
UCP1164 0.037 + 0.002 1.4 + 0.1 8.8 + 0.9 0.073 + 0.002 
UCP1172 0.0089 + 0.0007 0.22 + 0.02 0.41 + 0.01 0.030 + 0.001 
UCP1173 0.014 + 0.001 0.19 + 0.01 0.27 + 0.02 0.091 + 0.008 
UCP1175 0.0110 + 0.0006 1.4 + 0.2 0.98 + 0.008 0.17 + 0.01 
UCP1191 0.010 + 0.0002 0.087 + 0.005 0.32 + 0.03 0.041 + 0.006 
UCP1205 0.018 + 0.003 0.159 + 0.007 0.34 + 0.01 0.10 + 0.01 
UCP1206 0.017 + 0.002 0.19 + 0.01 0.18 + 0.03 0.054 + 0.005 
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5.5 Structural Basis of Activity of PLAs in Clinical Isolates 
Analysis of the crystal structures of the potent inhibitors, UCP1175 and UCP1191, 
complexed with DfrB and NADPH reveal a structural basis for activity of these inhibitors.  
It appears that the binding position of the inhibitors, influenced on substitutions at both the 
propargyl positions and the B-ring, is critical for achieving potent activity. The carboxylate 
moiety of UCP1191 forms one direct ionic bond to Arg 57 and one water-mediated 
hydrogen bond to Arg 57 and Lys 32, wherase UCP1175, which lacks the methyl 
substitution at the propargly position, forms an extensive water network with Arg 57 and 
carboxylate28. Furthermore, the structure of UCP1106, which retains no activity in these 
resistant enzyme shows a water mediated interaction between the PLA and the enzyme. 
In this structure, however, the water is more closely associated with the PLA and does 
not form a proper interaction with Arg 57.  
 
It appears that the propargyl methyl of UCP1191 pushes the biphenyl system further into 
the active site and within bonding distance to Arg 57 and the lack of substitution at the 
propargyl position and 2’ B-ring positions allows for the formation of an evenly dispersed 
water network, as there is a greater distance between Arg 57 and the carboxylate. 
UCP1106, which binds in an intermediate position, dictated by the 2-OMe B-ring 
substitution, does not allow for the even water formation and therefore forms a less stable 
complex with the enzyme (Figure 4). Arg 57 is conserved in all of the TMP-resistant 
enzymes (Figure 5) and forms a similar key contact with dihydrofolate, suggesting that 
this contact is less likely to mutate to cause resistance to the PLAs. 
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Figure 4 a) Water mediated binding interactions of UCP1175 (green) compared to the 
binding of UCP1191 (blue). b) Binding interactions of UCP1106 (magenta) compared to 
the binding of UCP1191 (blue). All inhibitors are co-crystallized with DfrB and NADPH. 
 
The TMP-resistant enzymes tend to conserve their mechanisms of reducing TMP affinity 
(Figure 5).  Leu 5 is an isoleucine in the TMP-resistant enzymes; this mutation would 
disturb Phe 92, which is critical both for hydrogen bonding to 4- amino group of the 
diaminopyrimidine as well as hydrophobic interactions with the linker. Leu 28 is a tyrosine 
in DfrG and DfrK and Val 31 is Ile in DfrA; these mutations also perturb Phe 92 (38). The 
Val 31 Ile mutation was predicted by K* in the OSPREY suite to cause resistance to an 
earlier PLA, and in fact reduced affinity by 60-fold29. Crystal structures of the double 
mutant enzyme, F98Y/V31I, show the perturbation of Phe 92. His 30 mutations have 
been observed clinically and studied extensively in the dfrB gene3. While the mutation His 
30 Asn has been shown to disrupt the water network stabilizing the pyrimidine ring27, 30, 
the TMP-resistant enzymes DfrK and DfrG carry a tyrosine at this position, which may 
achieve the same goal.  Finally, all three TMP-resistant enzymes maintain a tyrosine at 
position 98 (wt Phe). The tyrosine has been shown to perturb NADPH binding25,26 and to 
decrease synergistic binding between TMP and NADPH31. Previous design efforts 
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focused on achieving inhibitor potency against the mutations observed in the 
chromosomal copy, dfrB, such as the Phe98Tyr-mutated DHFR enzyme25,27,31,32. 
 
Figure 5 Protein sequence alignment of the dfr isoforms. Interesting amino acids are 
highlighted in red. 
 
These efforts may prove valuable as the TMP-resistant enzymes DfrG, DfrK and DfrA all 
possess a tyrosine residue at position 98.  As shown here, designing inhibitors against 
the F98Y chromosomal mutant provided a significant advantage in achieving superior 
potency against these resistant enzymes, as they appear to rely on common 
mechanisms.  Recently, we described potent activity of the COOH-PLA series, 
specifically UCP1164, UCP1172, UCP1173 and UCP1175 against strains containing 
these clinically relevant point mutations in dfrB. Including F98Y, H30N/F98Y and 
F98Y/H149R. While the COOH-PLAs are more potent against the single F98Y mutant 
strain than the acquired dfr isoforms, UCP1164 and UCP1172 maintain superior activity 
against the acquired resistance elements over the double mutants27. The remaining 
compounds display similar inhibitory activity in the acquired and mutant DHFR enzymes. 
As the mutations that confer TMP resistance appear to belong to a conserved and 
relatively manageable group, future design efforts can capitalize on this group to optimize 
ligands that inhibit the majority of clinically observed TMP-resistant species. 
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5.6 Conclusions 
By investigating the contemporary mechanisms of TMP resistance, we are able to show, 
within a small collection of clinical TMPR S. aureus isolates, the surprising preponderance 
of TMPR elements that have never been identified domestically. Genomic analysis of the 
strains indicates an even wider diversity of mechanisms and susceptibilities to commonly 
used antibiotics. This genetic analysis of the strains is representative of the extensive 
spread of antibiotic resistances and supports the thoughts that these elements are easily 
transferred between bacteria, suggesting that occurrence of these genes may be much 
wider than reported. 
 
 Only by understanding the structural mechanisms of TMP resistance are we able to 
continue design of propargyl-linked antifolates that potently inhibit both TMP-resistant 
enzymes and the strains harboring these elements. Here, the identification of the dfrA, 
dfrG and dfrK genes in clinical isolates has validated the efforts to design robust inhibitors 
that can overcome mutational changes in the enzyme. These efforts have yielded a class 
of carboxylate substituted PLAs that exhibit unprecedented activity directly against these 
highly resistant elements, resensitizing these antifolate resistant strains to PLAs. 
Furthermore, the clinical relevancy of the compounds remains acute as timely clinical 
data drive compound design. 
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Chapter 6 
Final Analysis and Future Directions 
 
 
6.1 Continued Development of Propargyl-linked Antifolates 
 
Through the process of structure based drug design, a class of novel antifolates has been 
optimized against S. aureus DHFR enzymes. Adding an acetylene linker and building the 
compounds from simple trimethoprim derivatives and exploiting crucial enzymatic 
interactions through rational inhibitor modifications has lead to a diverse library of 
propargyl-linked antifolates. It is shown that combination of RP, B-ring and C-ring 
substitutions can lead to highly favorable interactions that translate into increased cellular 
and enzymatic potency. Specifically, compounds with R1-OMe substitutions on the 
carboxylate PLA scaffold results in reduced potency compared to the R2 and R2/R3 
positions when a RP methyl is present. Crystal structures indicate that the RP methyl 
dictates the binding position when no R1 substituent is present and provides an optimal 
orientation for direct ionic interactions with Arg 57.  Currently, the most potent compounds 
in this class make one direct and one water mediated interaction with Arg 57. Additional 
modifications to the compounds, including exploring C-ring substituents and B-/C-ring 
linkers can optimize the interaction between the carboxylate and Arg 57 guanidinium to 
better mimic DHF. Overall, these compounds are selective for the pathogenic enzymes 
over the human isoform and maintain activity regardless in S. aureus associated DHFR 
enzymes regardless of their identity. 
 
A single crystal structure of UPC1191, a RP-methyl substituted p-COOH indicates the 
important role of the propargylic methyl in the carboxylate series of PLAs. Comparisons of 
this structure with structures co-crystallized with UCP1106 and UCP1175 (hydrogen-
substituted RP) indicates that this substituent is crucial for optimized interactions with the 
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enzyme. Additional crystal structures of an enantiomer pair, for example UCP1172 and 
UCP1173 or UCP1205 and UCP1206, would elucidate differences in the pyridine and 
carboxylate substituted enantiomers. It is believed that the presence of the carboxylate 
and its hydrogen bonding abilities will dictate the binding position of the biaryl system as 
opposed to the distinct binding of the pyridine enantiomers. In this case, enantiomerically 
pure compounds would not be necessary for optimized potency, reducing both costs and 
time during PLA development.  
 
In addition to being potential therapeutic candidates, these small molecule inhibitors can 
also be used as probes into the structure and function of the DHFR enzymes. Specifically, 
stereospecific modifications to the propargylic position can influence both the cofactor 
and biphenyl system binding. Through investigations with these compounds, it has been 
discovered that the cofactor-binding site can accommodate an alternative configuration, 
indicating plasticity and flexibility of the protein. Continued investigations to the 
mechanism by which this alternate cofactor is generated and its biological relevance 
should be pursued. The β- to α-NADPH anomerization requires a ring opening and ring 
closing mechanism, which occurs at an equilibrium that heavily biases the β-anomer. 
However, the tautomerization of the α-NADPH to the closed-ring tricyclic NADPH 
analogue does not occur under typical thermodynamic and chemical environments.   
 
It is believed that the extended α-NADPH binds the tertiary PLA/ enzyme complex and 
PLA binding induces the reorientation of the internals NAPDH phosphates stabilizing the 
tricyclic NADPH intermediate. Once stabilized, the enzyme can facilitate the cyclization 
reaction if oriented correctly with charged side chains1. Conversely, t-NADPH might be 
generated in solution under crystallization conditions and recruited to the active site, 
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however due to variances in the crystallography conditions this option is less likely. 
Crystal structures indicate that shifts in the acetylene linker binding position correlates 
with identity of NADPH recruited to the active site. Understanding whether or not the PLA 
binding positions and alternative NADPH is an artifact in crystallography or a product of 
PLA binding should be investigated. Experiments that quantitatively look for the 
conversion of β-NADPH to t-NADPH in solution with the enzymes and PLA can be 
designed, following standard biotransformation protocols and measured using analytical 
methods2.  
 
6.2 Understanding Antifolate Resistance 
A comprehensive evaluation of resistance during the development of PLAs against 
trimethoprim resistant S. aureus lead to a better understanding of antifolate resistance. 
These efforts include prediction and prospective mutational resistance and determination 
of the contemporary mechanisms of clinical TMP resistance. During these studies we 
identified a series of mutations the enzyme can make to evade inhibition to a lead PLA 
and determined that these mutations are common among endogenous and acquired TMP 
resistance mechanisms. These studies also allowed us to understand the molecular 
mechanisms of resistance and not only design inhibitors that show potent activity across 
TMPR enzymes but that are also less susceptible to developing mutational resistance. 
 
The discovery of the DfrG and DfrK enzymes in clinical MRSA isolates from Connecticut 
hospitals and lack of point mutations resulted in the reevaluation of clinical antifolate 
resistance.  Until this point, compounds were designed with the understanding that DfrA 
and mutations in DfrB were responsible for clinical resistance. However, just because 
point mutations weren’t identified in the TMPR enzymes, doesn’t mean that they can’t 
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arise in response to antibiotic pressure and later confer resistance. This study indicated 
large diversity in the molecular mechanisms of resistance, even among clonal isolates, for 
trimethoprim as well as other common and important antibiotics. In fact, no two strains 
shared the same resistances for the antibiotics evaluated. Importantly, the design of PLAs 
inhibitors to overcome point mutations resulted a series of compounds that are show 
superior potency against these resistant strains, despite their diversity.  
 
It is important to determine the prevalence of these TMP resistance elements. While 
unlikely, it is possible that they are contained within these two Connecticut hospitals. By 
acquiring TMPR S. aureus isolates from around the country, we can evaluate the 
distribution and relevance of these genes. A more comprehensive, nation-wide 
epidemiological study would allow for more accurate overall TMPR and specific TMPR 
gene clinical frequencies. Due to the ease and accessibility of whole genome sequencing, 
it is plausible to sequence and evaluate a sample of isolates for antifolate and other 
antibiotic resistances. Additionally, the PLA susceptibiliites can be screened against a 
much larger bank of TMPR S. aureus isolates. 
 
The development of the enantio-pure COOH-PLAs, specifically UCP1172, UCP1173, 
UCP1205 and UCP1206, showed high potency against TMPR mutants and acquired 
DHFR enzymes and are promising lead compounds for continued pre-clinical evaluations. 
Prospective mutational resistance of this class should be evaluated against the 
endogenous DHFR as well as the plasmid acquired dfrA, dfrG, and dfrK genes. Because 
activity of these PLAs largely relies on the ionic interaction between the carboxylate and 
Arg57, mutations at this position would likely result in decreased potency of the inhibitor. 
However, Arg 57 is crucial for the binding of DHF and mutation of this position would 
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likely result in a significant loss in enzymatic fitness. Experiments generating mutations to 
these inhibitors against the panel of dfr isoforms would further elucidate their potential 
evolution. Additionally, the frequency at which resistance develops in-vitro to these 
inhibitors would confirm or reject the design principles of exploiting non-mutational 
interactions to avoid resistance generation, especially when compared to their pyridine 
counterparts.  In these studies, the over expression of DHFR should also be evaluated as 
the continued accumulation of mutations would likely result in unfit enzymes; a second 
resistance mechanisms would likely arise in this case. 
 
Of the top 25 mutations predicted by K*, the acquired DHFR enzymes contain five of the 
predicted resistance conferring amino acids for DfrA, DfrG and DfrK. These mutations 
include L5I and V30I for DfrA and L5I, L28W, L20I and V6A for DfrG and DfrK.  
Interestingly, the resistance associated amino acids identified by K* in DfrA are both in 
top three ranked mutations and the PLAs are much less active against this enzyme. Not 
only does this indicate that there are only few modifications that the enzyme can make to 
confer resistance, but it also validates the use of these algorithms in early stage drug 
discovery efforts.  
 
Unlike DfrA, little is known about DfrK and DfrG. Until these studies, only the crude KM  
and TMP IC50 values were previously described3,4. Efforts into determining the structures 
of these enzymes in complex with TMP and potent PLAs can be used to elucidate both 
the mechanism of resistance for the enzymes against TMP and the mechanism of action 
of PLAs. DfrA is less susceptible to TMP (although it confers high levels of resistance) 
and less affected by the PLAs, compared to DfrG and DfrK. A biochemical and structural 
understanding of these enzymes would greatly aid in the development of antifolates and 
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elucidate DfrA’s unique mechanism of PLA resistance allowing for the generation of 
inhibitors with potent activity against this stubborn enzyme. 
 
6.3 Conclusions 
Structure based drug design efforts for a novel class of antifolates resulted in a series of 
potent inhibitors that exhibit selectively potency against antifolate resistant and 
susceptible S. aureus.  These efforts required understanding of the enzymatic and 
cellular structure activity relationship of the PLAs with the including the importance of 
enantio-pure inhibitors. Designing the inhibitors to overcome known clinical DfrB 
mutations resulted in a class of compounds that restore antifolate susceptibility to highly 
TMPR S. aureus strains. In doing this, we discovered that plasticity in the cofactor-binding 
site and identified a novel NADPH configuration believed to exist in response to PLA 
binding.  
 
In order to develop PLAs to overcome TMPR, a comprehensive of understanding of 
clinical antifolates was required. In doing this, we isolated a panel of strains containing 
mutations common to both PLAs and TMP. Investigations into these strains resulted in a 
molecular understanding in their mechanisms of resistance as well as the mechanism of 
action of a potent PLA. Until this point, point mutations and the acquisition of a single 
innately resistant DHFR enzyme were believed to confer clinical resistance. However, our 
investigations indicate that a novel gene, dfrG, never previously reported in the United 
States, is responsible for the majority of clinical TMP resistance; we were also able to 
identify dfrK for the first time as well as the previously described dfrA gene, both of which 
occurred as minor determinants. PLAs designed to overcome the point mutations showed 
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potent activity against both the resistant enzymes and S. aureus strains, resulting in a 
promising class of inhibitors.  
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Appendix B Materials and Methods 
B.1 Construction, Expression and Purification of Dihydrofolate Reductase 
B.1a Generation of Staphylococcus aureus and Mutant Expression Vectors 
The generation, expression and purification of DfrB (wild-type S. aureus DHFR), 
DfrB(F98Y), DfrB (H30N) and DfrB (F98Y, H30N) DHFR enzymes have been previously 
reported1-3. DfrA in pET-41a(+), DfrG in pET-41a(+) and DfrK in pET-24a(+) were 
purchased from Genscript. DfrB(WT) and DfrB(F98Y) in pET-41a(+) constructs were used 
for the generation of DfrB(H149R) and DfrB(F98Y, H149R) DHFR plasmids via 
QuikChange Lightening Site-Directed Mutagenesis Kit (Stratagene) using sense primer 
5’- CTAGATGAGAAAAATACAATTCCACGTAC-3’ and anti-sense primer 5’- 
CGAATTAAATGTAGAAAGGTACGTGGAAT-3’ following the manufacturer’s instructions. 
Mutagenesis was confirmed via Sanger sequencing using primers specific to the T7 
promoter. 
 
B.1b Expression and Purification of Dihydrofolate Reductase  
The expression and purification of DfrB, DfrB(F98Y), DfrB(H30N), DfrB (F98Y, H30N) in 
pET-41a(+) has been previously described1-3.  
Expression and Purification of DfrB (H149R) and DfrB (F98Y, H149R) 
BL21 (DE3) cells (Invitrogen) were transformed with DfrB (mutants) in pET-41a(+). The 
cells were grown to mid-log phase (OD600=0.8-1.0) at 37oC, induced with 1 mM IPTG and 
were allowed to grow for an additional 8 hours at 30oC. One liter cell pellets were lysed 
using 1x BugBuster (Novagen) and DNase A (ThermoFisher Scientific). Protein was 
purified using Ni-NTA agarose using a wash buffer containing 25 mM Tris, pH 8.0, 0.4 M 
KCl, 5 mM Imidazole, 5 mM beta-mercaptoethanol and 5% glycerol and protein was 
eluted using a buffer containing 25 mM Tris pH 8.0, 0.3 M KCl, 20% glycerol, 0.1 mM 
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EDTA, 250 mM imidazole and 5 mM beta-mercaptoethanol.  Clean protein was pooled 
and desalted using PD-10 columns (GE Healthcare) into a buffer containing 20 mM Tris 
pH 8.0, 20% glycerol, 0.1 mM EDTA and 2 mM DTT.  Protein was flash frozen and stored 
at -80oC. 
 
Expression and Purification of DfrA 
BL21 (DE3) cells (Invitrogen) were transformed with dfrA in pET-41a(+). The cells were 
grown to mid-log phase (OD600=0.8-1.0) at 37oC, induced with 1 mM IPTG and were 
allowed to grow for an additional 18 hours at 20oC. Cells were pelleted and resuspended 
to 30 mL using a buffer containing 0.4 M KCl, 25 mM Tris, pH 8.0, 5 mM beta-
mercaptoethanol, 5% glycerol, 100 µg/mL lysozyme, 5 mM imidazole and DNase (Fisher 
Scientific) and lysed via sonication. Protein was purified using Ni-NTA agarose using a 
wash buffer containing 25 mM Tris, pH 8.0, 0.4 M KCl, 5 mM Imidazole, 5 mM beta-
mercaptoethanol and 5% glycerol and protein was eluted using a buffer containing 25 mM 
Tris pH 8.0, 0.3 M KCl , 20% glycerol, 0.1 mM EDTA, 250 mM imidazole and 5 mM beta-
mercaptoethanol.  Clean protein was pooled and desalted into a buffer containing 25 mM 
Tris pH 8.0, 0.1 mM KCl, 15% glycerol, 0.1 mM EDTA and 2 mM DTT.  Protein was flash 
frozen and stored at -80oC. 
 
Expression and Purification of DfrG 
DfrG in pET-41a(+), synthesized by Genscript, was transformed into BL21 (DE3) cells 
(Invitrogen). The cells were grown to mid-log phase (OD600= 0.8-1.0), induced with 1 mM 
IPTG and were allowed to grow for an additional 18 hours at 20oC. Cells were pelleted 
and resuspended to 30 mL using a buffer containing 0.5 M KCl, 50 mM Tris, pH 8.0, 5 
mM beta-mercaptoethanol, 5% glycerol, 0.8 mg/mL lysozyme, 5 mM imidazole and a 
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protease inhibitor tablet (Life Technologies) and lysed with two passes through a French 
Press.  After lysis, the lysate was incubated with DNase and RNase. Protein was purified 
using Ni-NTA agarose using a wash buffer containing 25 mM Tris, pH 8.0, 0.4 M KCl, 5 
mM Imidazole, 5 mM beta-mercaptoethanol and 5% glycerol and protein was eluted using 
a buffer containing 25 mM Tris pH 8.0, 0.3 M KCl, 20% glycerol, 0.1 mM EDTA, 250 mM 
imidazole and 5 mM beta-mercaptoethanol.  Clean protein was pooled and desalted into 
a buffer containing 20 mM Tris pH 8.0, 20% glycerol, 0.1 mM EDTA and 2 mM DTT.  
Protein was flash frozen and stored at -80oC. 
 
Expression and Purification of DfrK 
dfrK in pET-24-a(+) was transformed in BL21 (DE3) cells (Invitrogen). The cells were 
grown to mid-log phase (OD600=0.8-1.0) at 37oC, induced with 1 mM IPTG and were 
allowed to grow for an additional 18 hours at 20oC. Cells were pelleted and resuspended 
to 30 mL using a buffer containing 0.4 M KCl, 25 mM Tris, pH 8.0, 5 mM beta-
mercaptoethanol, 5% glycerol, 100 µg/mL lysozyme, 5 mM imidazole and DNase (Fisher 
Scientific) and lysed via sonication. Protein was purified using Ni-NTA agarose using a 
wash buffer containing 25 mM Tris, pH 8.0, 0.4 M KCl, 5 mM Imidazole, 5 mM beta-
mercaptoethanol and 5% glycerol and protein was eluted using a buffer containing 25 mM 
Tris pH 8.0, 0.3 M KCl , 20% glycerol, 0.1 mM EDTA, 250 mM imidazole and 5 mM beta-
mercaptoethanol.  Clean protein was pooled and desalted into a buffer containing 25 mM 
Tris pH 8.0, 0.1 mM KCl, 15% glycerol, 0.1 mM EDTA and 2 mM DTT.  Protein was flash 
frozen and stored at -80oC. 
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B.2 Biochemical and Inhibitory Evaluation of DHFR Enzymes 
B.2a Michaelis-Mentin Kinetics 
The Michaelis-Mentin constant (KM) and Vmax values for DHF and NADPH were 
determined by Lineweaver- Burke plots generated by the monitoring the rate of NADPH 
oxidation by DHFR via absorbance at 340 nm. The reaction was performed at room 
temperature in buffer containing 20 mM TES pH 7.0, 50 mM KCl, 0.5 mM EDTA, 10 mM 
beta-mercaptoethanol and 1 mg/mL BSA, and 2 µg/mL enzyme. For DHF, the enzymatic 
activities were measured using 12.5-100 µM DHF with 20 µM NADPH and for NADPH, 
the reactions were run with12.5-100 µM NADPH and a constant 50 µM DHF. KM and Vmax 
values were determined by non-linear regression analysis using GraphPad. Kcat was 
determined from Vmax using Equation 1.  
Kcat=Vmax/[Et]                                                        (1) 
[Et]= total enzyme concentration 
 
B.2b IC50 Value Determination  
IC50 values were determined by enzyme inhibition assays via the monitoring the rate of 
NADPH oxidation by DHFR via absorbance at 340 nm. The reaction was performed at 
room temperature in buffer containing 20 mM TES pH 7.0, 50 mM KCl, 0.5 mM EDTA, 10 
mM beta-mercaptoethanol and 1 mg/mL BSA, 0.1 mM NADPH and 2 µg/mL enzyme. 
Inhibitor in DMSO was added to the enzyme/NADPH mixture and incubated for 5 minutes 
prior to the addition of 0.1 mM DHF in 50 mM TES inhibitor volume and concentration is 
based on conditions at which activity is reduced by 50%. Alternate IC50s (Chapter 2, 
Table 1) were determined using the same procedure however the 5 minute protein: 
NADPH: inhibitor incubation was removed. The IC50s were determined using Equations 2 
-4.  
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Enzyme Activity (µM/min)= (∆A340 *0.041)/ (∆t (sec)/60)                     (2) 
IC50 (µM)= (inh vol. (µL)/ % Inhibition)*50/550)*inh conc. (mM) *1000           (3) 
% inhibition = 1-(Activityinh/ActvityEnz)*100                              (4) 
IC50s were converted to KI through use of Equation 5.  
Ki= IC50/ (100/KM +1)                                                (5) 
 
B.2c Dissociation Experiments 
Steady-state NADPH turnover rate was determined by performing enzyme inhibition 
assays following 18h of 4oC incubation with 2 µg/mL purified enzyme, 100 µM NADPH 
and 50 µM inhibitor in buffer containing 20 mM TES, 50 mM KCl, 0.5 mM EDTA, 10 mM 
beta-mercaptoethanol and 1 mg/mL BSA. The reaction was initiated with 0.1 mM DHF 
and monitored at an absorbance of 340 nm. The steady-state NADPH rate was 
extrapolated from data by converting the slope of A340 vs time to change in NADPH 
concentration using a molar extinction coefficient of 6.2x103 Lmol-1cm-1.  
 
B.3 Antibacterial Evaluation of Antifolates and Antibiotics 
B.3a Minimum Inhibitory Concentration Determination 
Minimum Inhibitory Concentrations (MICs) were determined according to the Clinical and 
Laboratory Standards Institute Guideline’s Standard4 micro-dilution broth assay using a 
final inoculum of 5 × 105 cfu/mL in Isosensitest Broth (Oxoid) using half-area 96-well 
plates. The 96-well plate was set-up so that the highest inhibitor, 20µg/mL inhibitor in 
Isosensitest broth, was loaded into the first column and then a series of 2-fold dilutions 
were preformed. The final volume of compound in the 96-well plate is 50µL. The inoculum 
prepared was by diluting the bacteria to an A600 =0.130 followed by a 1:100 dilution into 
sterile isosensitest broth. 50µL of the diluted inoculum was added to each well and the 
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plate was covered and placed in the incubator for 37oC for 18 hours. MICs were defined 
as the lowest concentration to visually inhibit bacterial growth and are confirmed by use of 
Alamar Blue (Life Technologies). UCP compounds (PLAs), trimethoprim, 
sulfamethoxazole, levofloxacin and linezolid are kept in DMSO, whereas erythromycin 
was dissolved in ethanol and ciprofloxacin in 0.1N HCl. 
 
B.3b Thymidine Rescue Minimum Inhibitory Concentration Determination 
Minimum Inhibitory Concentrations (MICs) were determined according to the Clinical and 
Laboratory Standards Institute Guideline’s Standard micro-dilution broth assay using a 
final inoculum of 5 × 105 cfu/mL in Isosensitest Broth (Oxoid) using half-area 96-well 
plates. The 96-well plate was set-up so that the highest inhibitor, 20 µg/mL inhibitor in 
Isosensitest broth, was loaded into the first column and then a series of 2-fold dilutions 
were preformed. The final volume of compound in the 96-well plate is 50µL. The inoculum 
was prepared by diluting the bacteria to an A600 =0.130 followed by a 1:100 dilution into 
sterile isosensitest broth containing 20µg/mL of thymidine (Sigma Aldrich, in water). 50µL 
of the diluted inoculum was added to each well so that the final thymidine concentration is 
10µg/mL and the plate was covered and placed in the incubator for 37oC for 18 hours. 
MICs were defined as the lowest concentration to visually inhibit bacterial growth and are 
confirmed by use of Alamar Blue (Life Technologies) 
 
B.3c Sulfamethoxazole Synergy Minimum Inhibitory Concentration Determination 
Minimum Inhibitory Concentrations (MICs) were determined according to the Clinical and 
Laboratory Standards Institute Guideline’s Standard micro-dilution broth assay using a 
final inoculum of 5 × 105 cfu/mL in Isosensitest Broth (Oxoid) using half-area 96-well 
plates. The 96-well plate was set-up so that the highest inhibitor, 20 µg/mL inhibitor in 
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Isosensitest broth, was loaded into the first column and then a series of 2-fold dilutions 
were preformed. The final volume of compound in the 96-well plate is 50µL. The inoculum 
was prepared by diluting the bacteria to an A600 =0.130 followed by a 1:100 dilution into 
sterile isosensitest broth containing 200 µg/mL or 2 µg/mL of sulfamethoxazole (SMX) for 
SMX resistant and susceptible strains, respectively (Sigma Aldrich, in DMSO). 50µL of 
the diluted inoculum was added to each well so that the final thymidine concentration is 
100 µg/mL or 1 µg/mL and the plate was covered and placed in the incubator for 37oC for 
18 hours. MICs were defined as the lowest concentration to visually inhibit bacterial 
growth and are confirmed by use of Alamar Blue (Life Technologies) 
 
B.4 UCP1006 Resistance Mutant Generation and Characterization  
B.4a Resistance Generation and Selection 
Resistant strains were selected by plating 100 µL of overnight culture (approx. 1012 
CFU/mL) of progenitor strain on Isosensitest (Oxoid) agar plates containing 6x MIC of 
UCP1006 (MIC=0.0781) and incubated at 37 °C for 18 hours. Single colonies were 
isolated and the dfrB gene was identified by directly sequencing the colony PCR product. 
 
B.4b Direct Colony PCR 
The colony was isolated via inoculating loop and lysed using a solution of 1 mg/mL 
lysostaphin (Sigma Aldrich, in water) and 20 µg/mL proteinase K (Sigma Aldrich, in 0.1 M 
Tris, pH 7.5). The gene was amplified using: 
Forward primer (5’-ATGACTTTATCCATTCTAGTTGC-3’)  
Reverse: primer (5’-TTATTTTTTACGAATTAAATGTAG-3’) 
 and rTaq Polymerase (Takara) using the following PCR procedure: 2 min denaturation at 
95oC, 30 cycles of 95oC denaturation for 30 sec, 55oC annealing for 30 sec, 1 min 72oC 
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extension followed by a final 10 minute extension at 72oC. PCR products were purified 
using Promega Wizard SV Gel and PCR Clean Up system, following manufacturers 
protocol, confirmed on a 1.2% w/v agarose gel visualized with ethidium bromide and 
sequenced using the sense primer. 
 
B.4c Mutational Frequency Determination 
The mutational frequency of UCP1006 was determined by the number of resulting 
colonies divided by the total inoculum (1x1011 CFU/mL) for each progenitor strain. The 
frequency of the specific mutations was determined by multiplying the mutational 
frequency for the inhibitor-strain pair by the frequency of sequenced colonies containing 
the specific mutation. 
 
B.4d Pair-wise Fitness Assay 
Relative strain fitness was determined by pair-wise competition assays5 with trimethoprim 
as the selective agent. Cell growth was monitored every 20 minutes via A600 and the 
doubling time of the strains was determined by monitoring cell growth in the log phase at 
an absorbance of 600 nm every 15 minutes for a total of 180 minutes.  Fitness was 
calculated using the following Equation 6.  
Fitness =
ln R(24)R(0)( )
ln S(24)S(0)( )                                                       (6)
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B.4e Doubling-time Growth Curves 
1 mL of overnight culture was used to inoculate 50 mL of LB media. Culture was grown at 
37oC at 225 RPM and growth was monitored at A600 every 30 minutes. The doubling time 
was determined from the linear portion of the growth curve using Equation 7. 𝐷𝑜𝑢𝑏𝑙𝑖𝑛𝑔 𝑇𝑖𝑚𝑒 = ∆!"#$∗!"#!!"# !"#$% !"#$. !!"# (!"#$%& !"#$.)                                           (7) 
 
B.5 Clinical Strain Characterization 
B.5a Clonal Analysis 
SpaA-typing was performed by Charles River using Accugenix’s AccuGENX-ST service 
to identify clonality among isolates. 
 
B.5b Genomic DNA Extraction and Next Generation Genomic Sequencing 
Genomic DNA was isolated using Promega Wizard Genomic DNA Isolation kit. DNA 
extracts were quantified using the Quant-iT PicoGreen kit (invitrogen, ThermoFisher 
Scientific).  One ng of genomic DNA was fragmented, adapter sequences attached, size 
selected and cleaned using the Nextera XT Library Preparation kit (Illumina, Inc.) 
according to the manufacturer’s protocol. Libraries were validated and mean insert length 
was calculated using a Bioanalyzer High Sensitivity chip (Agilent Technologies). The 
libraries were sequenced on the MiSeq using v2 2x250 base pair kit (Illumina, Inc).  The 
genome was assembled using CLC Workbench and annotated using the Rast Server6-8.  
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B.5c PCR Identification and Sequencing 
PCR on gel purified genomic and plasmid DNA was performed to detect the presence of 
dfrB, dfrA, dfrG and dfrK genes.  
Table 1 TMPS and TMPR DHFR PCR Primers9 
Enzyme Primer (5’-3’) Annealing Temp (oC) 
DfrB- Forward ATGACTTTATCCATTCTAGTTGC 55 DfrB- Reverse TTATTTTTTACGAATTAAATGTAG 
DfrA-Forward ACTGACCACTGGGAATACACT 52 DfrA-Reverse CGACTTCCCAGTTTTCGAATGT 
DfrG-Forward TTTCTTTGATTGCTGCGATG 55 DfrG-Reverse CCCTTTTTGGGCAAATACCT 
DfrK-Forward GAGAATCCCAGAGGATTGGG 55 DfrK-Reverse CAAGAAGCTTTTCGCTCATAAA 
 
PCR was performed using rTaq Polymerase (Takara), following standard PCR 
procedures. PCR product was purified using Promega SV Gel and PCR Clean-Up 
System, following manufacturers procedures. Purified PCR reactions were run on 1.2% 
agarose gels and visualized with ethidium bromide using 2-Log Ladder as a size 
comparator (Thermo Scientific). The sequences were confirmed via Sanger Sequencing 
using the corresponding forward primer as the sequencing primer. 
 
B.5d Clinical Antibiotic Susceptibility Determination  
Susceptibilities were determined using Sensititre Gram Positive plates (Remel, 
ThermoFisher Scientific) using Mueller-Hinton Broth and an inoculum of 1x105 CFU/mL. 
The plates were incubated for 18 hours at 37oC and MICs were colorimetrically 
determined using Alamar Blue (ThermoFisher Scientific). 
Susceptible/Intermediate/Resistant designations were made based on CLSI breakpoint 
standards. 
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B.6 Crystal Growth Conditions and Protein Crystallography 
B.6a Wild-type DHFR Crystal Structures 
DfrB: NADPH: UCP1061 
Purified SaDHFR at 17 mg/mL was co-crystallized with 2mM NADPH and 1mM UCP1061 
in DMSO via hanging drop method. The protein, cofactor and inhibitor mix was incubated 
on ice for 2 hours. Equal volumes of protein solution were added to an optimized buffer 
solution containing 0.1M MES, pH 6.5, 0.1M sodium acetate, 13% PEG 10,000 and 
12.5% gamma-butrylactone. When stored at 4oC, crystals typically formed within 7 days. 
Crystals were harvested and frozen in cryo-protectant buffer containing 25% glycerol. 
Data were collected remotely on beamline X25A at Brookhaven National Laboratories. 
Data were indexed and scaled using HKL2000. Phaser was used to identify molecular 
replacement solutions using PDB ID: 3F0Q10 as a probe. Coot11 and Phenix12 were used 
for structure refinement until acceptable RWork and RFree were achieved. 
 
DfrB: NADPH: UCP1062 
Purified SaDHFR at 21 mg/mL was co-crystallized with 2mM NADPH and 1mM UCP1062 
in DMSO via hanging drop method. The protein, cofactor and inhibitor mix was incubated 
on ice for 2 hours. Equal volumes of protein solution were added to an optimized buffer 
solution containing 0.1M MES, pH 6.0, 0.1M sodium acetate, 13% PEG 10,000 and 
12.5% gamma-butrylactone. When stored at 4oC, crystals typically formed within 7 days. 
Crystals were harvested and frozen in cryo-protectant buffer containing 25% glycerol. 
Data were collected at the Rigaku HighFlux HomeLab Protein Crystallography X-Ray 
system at the University of Connecticut.  Data was indexed and scaled using d*TREK.  
Phaser was used to identify molecular replacement solutions for the structures of 
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Sa(F98Y):NADPH using PDB: 3F0Q as a probe.  The programs Coot and Phenix were 
used for structure refinement until acceptable Rwork and Rfree were achieved.  
 
DfrB: NADPH: UCP1070 
Purified SaDHFR at 21 mg/mL was co-crystallized with 2mM NADPH and 1mM UCP1070 
in DMSO via hanging drop method. The protein, cofactor and inhibitor mix was incubated 
on ice for 2 hours. Equal volumes of protein solution were added to an optimized buffer 
solution containing 0.1M MES, pH 6.0, 0.3M sodium acetate, 13% PEG 10,000 and 
12.5% gamma-butrylactone. When stored at 4oC, crystals typically formed within 7 days. 
Crystals were harvested and frozen in cryo-protectant buffer containing 25% glycerol. 
Data were collected at the Rigaku HighFlux HomeLab Protein Crystallography X-Ray 
system at the University of Connecticut.  Data was indexed and scaled using d*TREK.  
Phaser was used to identify molecular replacement solutions for the structures of 
Sa(F98Y):NADPH using PDB: 3F0Q as a probe.  The programs Coot and Phenix were 
used for structure refinement until acceptable Rwork and Rfree were achieved.  
 
DfrB: NADPH: UCP1106 
Purified SaDHFR at 18 mg/mL was co-crystallized with 2mM NADPH and 1mM UCP1106 
in DMSO via hanging drop method. The protein, cofactor and inhibitor mix was incubated 
on ice for 3 hours. Equal volumes of protein solution were added to an optimized buffer 
solution containing 0.1M MES, pH 5.5, 0.2M sodium acetate, 17% PEG 10,000 and 
12.5% gamma-butrylactone. When stored at 4oC, crystals typically formed within 7 days. 
Crystals were harvested and frozen in cryo-protectant buffer containing 25% glycerol. 
Data were collected remotely on beamline 7-1 at Stanford Synchrotron Radiation 
Lightsource, SLAC National Accelerator Laboratory. Data were indexed and scaled using 
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HKL2000. Phaser was used to identify molecular replacement solutions using PDB ID: 
3F0Q as a probe. Coot and Phenix were used for structure refinement until acceptable 
RWork and RFree were achieved. 
 
DfrB: NADPH: UCP1175 
Purified SaDHFR at 18mg/mL was co-crystallized with 2mM NADPH and 1mM UCP1175 
in DMSO via hanging drop method. The protein, cofactor and inhibitor  mix was incubated 
on ice for 3 hours. Equal volumes of protein solution were added to an optimized buffer 
solution containing 0.1M MES, pH 5.5, 0.2M sodium acetate, 17% PEG 10,000 and 
12.5% gamma-butrylactone. When stored at 4oC, crystals typically formed within 7 days. 
Crystals were harvested and frozen in cryo-protectant buffer containing 25% glycerol. 
Data were collected remotely on beamline 7-1 at Stanford Synchrotron Radiation 
Lightsource, SLAC National Accelerator Laboratory. Data were indexed and scaled using 
HKL2000. Phaser was used to identify molecular replacement solutions using PDB ID: 
3F0Q as a probe. Coot and Phenix were used for structure refinement until acceptable 
RWork and RFree were achieved. 
 
DfrB: NADPH: UCP1191 
Purified SaDHFR at 13 mg/mL protein was co-crystallized with 2 mM NADPH and 1 mM 
UCP1191 in DMSO via the hanging drop method. The mixture of protein and cofactor was 
incubated on ice for 3 hours. Equal volumes of protein solution were added to an 
optimized buffer solution containing 0.1 M MES, pH 5.0, 0.3 M sodium acetate, 17% PEG 
10,000 and 12.5% gamma-butyrolactone. Crystals were harvested and frozen in cryo-
protectant buffer containing 25% glycerol. Data were collected remotely on beamline 14-1 
at Stanford Synchrotron Radiation Lightsource, SLAC National Accelerator Laboratory. 
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Data were indexed and scaled using HKL2000. Phaser was used to identify molecular 
replacement solutions using PDB ID: 3F0Q as a probe. Coot and Phenix were used for 
structure refinement until acceptable RWork and RFree were achieved. 
 
B.6b S. aureus F98Y Mutant DHFR Crystal Structures 
DfrB (F98Y): NADPH Apo 
Sa(F98Y)DHFR was co-crystallized with NADPH using the hanging drop vaporization 
method. Purified protein (20 mg/mL) was incubated with 2 mM NADPH (Sigma-Aldrich) 
and for 2h on ice. Equal volumes of the protein: cofactor solution were mixed with an 
optimized crystallization solution containing 13 % PEG 10,000, 0.1 M sodium acetate, 
0.1-0.2 M MES pH 6.0 and 5% gamma-butyrolactone. When stored at 4oC, conditions 
typically yielded crystals within 7 days. Crystals were frozen in cyro-protectant buffer 
containing 25 % glycerol. Data were collected at the Rigaku HighFlux HomeLab Protein 
Crystallography X-Ray system at the University of Connecticut.  Data was indexed and 
scaled using d*TREK.  Phaser was used to identify molecular replacement solutions for 
the structures of Sa(F98Y):NADPH using PDB: 3FQO as a probe.  The programs Coot 
and Phenix were used for structure refinement until acceptable Rwork and Rfree were 
achieved.  
 
DfrB (F98Y): NADPH: UCP1106 
DfrB (F98Y) DHFR was co- crystallized with NADPH and UCP1106 using the hanging 
drop vaporization method. Potein at 14.25 mg/mL was incubated with 1 mM UCP1106 
and 2 mM NADPH (Sigma Aldrich) for three hours. It was crystallized in a solution 
containing 0.1 M MES pH 6.0, 0.2 M Sodium acetate, 13% PEG 10,000 and 20% gamma-
butyrolactone. Crystals were frozen with well solution containing 25% glycerol. Data were 
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collected remotely at Stanford Synchrotron Radiation Lightsource on beamline 7-1. Data 
was indexed and scaled using HKL2000.  Phaser was used to identify molecular 
replacement solutions for the structures of Sa(F98Y):NADPH:UCP1106 using PDB: 3F0Q 
as a probe.  The programs Coot and Phenix were used for structure refinement until 
acceptable Rwork and Rfree were achieved.  
 
B.6c S. aureus H30N Mutant DHFR Crystal Structures 
DfrB (H30N): NADPH: UCP1106 
DfrB(H30N) DHFR at 14.25 mg/mL was incubated with 1 mM UCP1106 and 2 mM 
NADPH for three hours. It was crystallized using the hanging drop method in solution 
containing 0.1 M MES pH 5.75, 0.3M Sodium acetate, 17% PEG 10,000 and 20% 
gamma-butyrolactone. Crystals were frozen with well solution containing 25% glycerol.. 
Data were collected remotely at Stanford Synchrotron Radiation Lightsource on beamline 
7-1. Data was indexed and scaled using HKL2000.  Phaser was used to identify 
molecular replacement solutions for the structures of Sa(H30N):NADPH:UCP1106 using 
PDB: 3F0Q as a probe.  The programs Coot and Phenix were used for structure 
refinement until acceptable Rwork and Rfree were achieved.  
 
B.6d S. aureus H30N, F98Y Mutant DHFR Crystal Structures 
DfrB (H30N, F98Y): NADPH: UCP1106 
Sa(F98Y/H30N) DHFR at 21 mg/mL was incubated with 1 mM UCP1106 and 2 mM 
NADPH for three hours. It was crystallized using the hanging drop vaporization method in 
a solution containing 0.1 M MES, pH 6.0, 0.2 M Sodium acetate and 13% PEG 10,000 
and 20% gamma-butyrolactone. Crystals were frozen using well solution containing  25% 
glycerol. Data were collected remotely at Stanford Synchrotron Radiation Lightsource on 
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beamline 7-1 and indexed and scaled using HKL2000.  Phaser was used to identify 
molecular replacement solutions for the structures of Sa(H30N, F98Y):NADPH:UCP1106 
using PDB: 3F0Q as a probe.  The programs Coot and Phenix were used for structure 
refinement until acceptable Rwork and Rfree were achieved.  
 
B.6e S. aureus V31L, F98Y Mutant DHFR Crystal Structures 
DfrB (V31L, F98Y):NADPH: UCP1021 
Sa(V31L, F98Y)DHFR was co-crystallized with NADPH and UCP1021 using the hanging 
drop vaporization method. Purified protein (20 mg/mL) was incubated with 2 mM NADPH 
(Sigma-Aldrich) and 1 mM inhibitor in DMSO for 2h on ice. Equal volumes of the protein: 
cofactor: inhibitor solution were mixed with an optimized crystallization solution containing 
13 % PEG 10,000, 0.1 M sodium acetate, 0.1-0.2 M MES pH 6.0 and 5% gamma-
butyrolactone Crystals were frozen in cyro-protectant buffer containing 25 % glycerol. 
High-resolution data were collected on the X4A Beamline at Brookhaven National 
Laboratories. Data for Sa(V31L, F98Y)DHFR:NADPH were indexed and scaled using 
HKL2000. Phaserwas used to identify molecular replacement solutions for the structures 
of Sa(V31L, F98Y)DHFR:NADPH and Sa(F98Y):NADPH using PDB: 3F0U The programs 
Coot and Phenix were used for structure refinement until acceptable Rwork and Rfree were 
achieved. 
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Appendix C Crystallographic Data Collection and Refinement Statistics  
 
C.1 Structures Presented in Chapter 2 
 
Table C1 Data Collection and Refinement Statistics for Pyridine PLAs 
 Sa(WT):NADPH: 
UCP1061 
Sa(WT):NADPH: 
UCP1062 
Sa(WT):NADPH: 
UCP1070 
PDB ID  4XEC 4TU5 N/A 
Space group  P6122 P6122 P6122 
No. monomers in 
asymmetric unit  
1 1 1 
Unit cell (a, b, c in Å)  78.90, 78.90, 
108.12 
79.14, 79.14, 
108.99 
79.048, 079.048, 
109.04 
Resolution (Å)  31.89-2.69 58.02-2.16 50-1.66 
Completeness % (last 
shell, %)  
99.97 (98.6) 99.8 (100) 99.08 
Unique reflections  5,929 11,493 34, 438 
Redundancy (last 
shell)  
18.2 (17.4) 12.94 (13.26) 14.3 (14.1) 
Rsym, (last shell)  0.160 (0.428) 0.154 (0.437) 0.109(0.699) 
<I/σ> (last shell)  38.6 (9.0) 8.8 (3.6) 35.1 (4.5) 
R-factor/Rfree  0.1564, 0.2327 0.1990 , 0.2495 0.2241, 0.2384 
No. of atoms (protein, 
ligands, solvent)  
1,398 1,496 1,517 
Rms deviation bond 
lengths (Å), angles 
(deg)  
0.008, 1.343 0.008, 1.248 0.011, 1.980 
Average B factor for 
protein (Å2)  
30.22 30.75 24.17 
Average B factor for 
ligand (Å2)  
26.89 (NADPH) 
33.49 (DRG) 
25.64 (NADPH) 
35.86 (DRG) 
16.92 (NADPH) 
23.89 (DRG) 
Average B factor for 
solvent molecules (Å2)  
28.17 39.06 27.13 
Residues in most 
favored regions (%)a  
96.79 97.44 98.75 
Residues in additional 
allowed regions (%)a  
3.21 2.56 1.25 
Residues in 
disallowed regions 
(%)a  
0 0 0 
Collection Location  Brookhaven 
National Lab 
NSLS X25 
Beamline 
Rigaku HighFlux 
HomeLab 
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Table C2 Data Collection and Refinement Statistics for Carboxylate PLAs 
 Sa(WT):NADPH: 
UCP1006 
Sa(WT):NADPH: 
UCP1175 
Sa(WT):NADPH: 
UCP1191 
PDB ID  5HF0 5HF2 5JG0 
Space group  P6122 P6122 P6122 
No. monomers in 
asymmetric unit  1 1 1 
Unit cell (a, b, c in Å)  79.09, 79.09, 
107.93 
90.0, 90.0, 120.0 
79.02, 79.02, 
108.25 
90.0, 90.0, 120.0 
78.86, 78.86, 106.43 
90.0, 90.0, 120.0 
Resolution (Å)  32.65-2.24 (2.28-
2.24) 
25.15-1.81 (1.87-
1.81) 
39.44-1.88 (1.91-
1.88) 
Completeness % (last 
shell, %)  100 (99.9) 99.8 (100) 99.75 (97.0) 
Unique reflections  10,059 18,798 16, 498 
Redundancy (last 
shell)  14 (14.2) 12.32 (12.03) 16.7 (17.4) 
Rsym, (last shell)  0.055 (0.144) 0.110 (0.644) 0.107 (0.483) 
<I/σ> (last shell)  68.5 (31.9) 11.7 (2.3) 41.2 (5.52) 
R-factor/Rfree  0.1703/ 0.2167 0.1991/0.2322 0.1765/ 0.2172 
No. of atoms (protein, 
ligands, solvent)  1,499 1,489 1,458 
Rms deviation bond 
lengths (Å), angles 
(deg)  
0.008, 1.912 0.009. 1.810 0.007, 1.238 
Average B factor for 
protein (Å2)  22.34 28.01 29.54 
Average B factor for 
ligand (Å2)  
17.46 α-NADPH 
16.91 β-NADPH 
31.29  Inhibitor 
24.65 α-NADPH 
24.93 Inhibitor 
25.34 β-NADPH 
34.66 Inhibitor 
Average B factor for 
solvent molecules (Å2)  25.25 35.10 35.74 
Residues in most 
favored regions (%)a  96.86 98.73 98.12 
Residues in additional 
allowed regions (%)a  3.14 1.27 1.88 
Residues in disallowed 
regions (%)a  0 0 0 
Collection Location  SSRL Beamline 7-
1 
Rigaku HighFlux-
007 
SSRL Beamline 7-1 
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C.2 Structures Presented in Chapter 3 
 
Table C3 Data Collection and Refinement Statistics for K* Predicted Mutants  
 Sa(V31L,F98Y) Apo Sa (F98Y) Apo 
PDB ID    
Space group  P6122 P6122 
No. monomers in 
asymmetric unit  
1 1 
Unit cell (a, b, c in Å)  79.335, 79.335, 
107.553 
79.26, 79.26, 107.42 
Resolution (Å)  68.706- 1.559 42.30-2.04 (2.51-2.04) 
Completeness % 
(last shell, %)  
99.8 (98.6) 98.7 (98.5) 
Unique reflections  29,153 13,132 
Redundancy (last 
shell)  
13.7 (13.5) 10.22 (10.44) 
Rsym, (last shell)   0.070 (0.340) 
<I/σ> (last shell)  31.7 (20.0) 16.9 (5.6) 
R-factor/Rfree  0.1993/ 0.2221 0.1752/ 0.2330 
No. of atoms 
(protein, ligands, 
solvent)  
1,524 1,446 
Rms deviation bond 
lengths (Å), angles 
(deg)  
0.007, 1.275 0.007, 1.205 
Average B factor for 
protein (Å2)  
20.68 28.75 
Average B factor for 
ligand (Å2)  
13.14 (NADPH) 21.11 (NADPH) 
Average B factor for 
solvent molecules 
(Å2)  
32.08 35.18 
Residues in most 
favored regions (%)a  
98.15 98.10 
Residues in 
additional allowed 
regions (%)a  
1.85 1.90 
Residues in 
disallowed regions 
(%)a  
0 0 
Collection Location  BNL X4A Rigaku MicroMax 
HomeFlux 
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C.3 Structures Presented in Chapter 4 
 
Table C4 Data Collection and Refinement Statistics for Mutant DHFR with UCP1106  
 Sa(F98Y):NADPH:UCP1106 
Sa(H30N):NADPH: 
UCP1106 
Sa(H30N, F98Y): 
NADPH: 
UCP1106 
PDB ID 5ISP 5IST 5ISQ 
Space group P6122 P6122 P6122 
No. monomers in 
asymmetric unit 1 1 1 
Unit cell (a, b, c in Å) 79.13, 79.13, 107.41 
79.07, 79.07, 
108.42 
78.99, 78.99, 
108.69 
Resolution (Å) 28.85-1.84 31.96-1.72 28.95-1.90 
Completeness % (last 
shell, %) 99.9 (100) 99.05 99.95 
Unique reflections 17,979 21,572 16,379 
Redundancy (last 
shell) 8.2 (8.3) 9.3 (9.1) 9.1 (9.1) 
Rsym, (last shell) 0.105 (0.516) 0.108 (0.590) 0.095 (0.400) 
<I/σ> (last shell) 48.4 (5.16) 36.0 (4.36) 44.6 (7.82) 
R-factor/Rfree 0.1803/ 0.2096 0.1872/ 0.2305 0.1798/ 0.2219 
No. of atoms (protein, 
ligands, solvent) 1508 1576 1478 
Rms deviation bond 
lengths (Å), angles 
(deg) 
0.08, 1.251 0.07, 1.872 0.008, 1.239 
Average B factor for 
protein (Å2) 29.39 20.62 25.64 
Average B factor for 
ligand (Å2) 
21.64 NADPH 
39.87 Inhibitor 
14.89 tNADPH 
14.38 β-NADPH 
26.46 Inhibitor 
18.97 NADPH 
31.28 Inhibitor 
Average B factor for 
solvent molecules (Å2) 36.36 29.22 31.72 
Residues in most 
favored regions (%)a 97.56 98.15 98.10 
Residues in additional 
allowed regions (%)a 2.44 1.85 1.90 
Residues in 
disallowed regions 
(%)a 
0 0 0 
Collection Location SSRL 7-1 SSRL 7-1 SSRL 7-1 
 
 
 
